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Lantibiotics are a powerful class of antimicrobials but their success in clinical settings has 
been limited. Stability and solubility issues in combination with the significant synthetic 
challenge posed by the characteristic thioether ring structures have hampered our ability 
to exploit this class of natural products. 
 
A well-studied lantibiotic, nisin, is of interest due to its broad-spectrum activity and novel 
mode of action. It has been shown that rings A and B of nisin bind tightly to lipid II, a 
precursor for bacterial cell wall biosynthesis. The C terminus can then insert itself into the 
bacterial membrane to form stable pores causing cell lysis. 
 
This thesis investigates the synthesis of analogues of nisin with simplified structures that 
maintain good biological activity whilst improving stability, solubility and also giving easier 
synthetic access to compounds with nisin’s unique mode of action. Orthogonally protected 
lanthionine was synthesised and used in SPPS to produce novel analogues of rings A and B 
with improved stability. Rings A and B of wild type nisin were also obtained through 
digestion of a commercially available preparation. To maintain the pore forming abilities of 
nisin but simplify the synthetic route we have replaced the lanthionine containing C 
terminus with simpler, linear pore forming peptides and a peptoid and connected these to 
rings A and B using click chemistry. These hybrid peptides were assessed for their biological 
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The rise and spread of resistance to antibiotics and other antimicrobials is well established 
as one of the greatest threats to modern health. In 2014 a UK government commissioned 
report estimated that every year 700,000 deaths can be attributed to resistant infections 
from bacteria and other microbes such as HIV, tuberculosis and malaria.1 The report went 
on to estimate that this could rise to 10 million deaths annually by 2050. Whilst the 
accuracy of these estimates has been contested2 the severity of the problem and the 
urgent need for solutions cannot be dismissed. The last few years have seen a rise in 
bacterial infections that are resistant to even last line of defence antibiotics such as 
vancomycin and carbapenems. Data collected from US hospitals from 1995 to 2002 showed 
an increasing proportion of hospital acquired bloodstream infections were due to 
antibiotic-resistant bacteria (Figure 1-1).3 Given this, we now face the bleak prospect of the 
occurrence of bacterial infections that are resistant to every available therapeutic and 
reports of resistance to every available therapeutic.  
 
It is important to note that this is a global problem that requires a globally coordinated 
response. There is limited data on the extent of antimicrobial resistance in developing 
countries but it is largely understood that they have the highest rates of mortality due to 
antimicrobial resistance. This is attributed to several factors including: high rates of 
infectious disease; weak healthcare systems; limited access to new or expensive drugs; and 
lack of diagnostic resources for recognising and containing resistant infections. Even when 
comparing developed countries, high income inequality has been linked to higher rates of 
antimicrobial resistance.4 
  
Current outbreaks of resistance need to be mitigated through global health policy and 
funding that facilitates: stringent clinical hygiene standards; a cut down of the misuse of 
antibiotics in humans and livestock; standardization of resistance diagnostics and data 
collection. Another of the tools essential to tackling resistance is the discovery and 
development of new antimicrobials with, importantly, novel mechanisms of action. Several 
drug discovery initiatives have been launched for  the development of antibiotics, on both a 
national and international level,5 but we are sadly still seeing a decrease in the number of 









Figure 1-1: Rates of antimicrobial resistance rates over time among Gram positive isolates; 
methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-
negative staphylococci, vancomycin-resistant Enterococcus faecium (VRE), ampicillin-
resistant Escherichia coli (E. coli), and ceftazidime-resistant Pseudomonas 
aeruginosa recovered in a series of 24,179 cases of hospital; acquired bloodstream 
infection;3 Figure reprinted with permission, copyright Oxford University Press  
 
Antimicrobial peptides (AMPs) are one class of natural products that are seeing an increase 
in interest from pharmaceutical research and development. Many peptides are found to 
have potent antibacterial activity and a low propensity to select for resistance but they are 
held back from clinical use by their poor drug-like properties. New developments in peptide 
chemistry and design are enabling a new generation of peptide therapeutics that can be 
selective and non-toxic, orally bioavailable,8 even multifunctional9 or compatible in 
combination therapies.9 
 
1.1 Antimicrobial Peptides 
 
A huge wealth of AMPs exist in nature; they are produced by virtually all classes of 
organism, occurring as part of innate and adaptive immune systems of prokaryotes 
(bacteriocins) and eukaryotes. In multicellular organisms, they are largely found in 





in more complex, self defence mechanisms to protect against invading pathogens. Ganz 
defined AMPs as “polypeptide antimicrobial substances, encoded by genes and synthesized 
by ribosomes, with fewer than 100 amino acid residues”.10 
 
AMPs are commonly found to have broad spectrum activities, inhibiting or killing a large 
number of Gram positive and Gram negative bacteria as well as a whole host of other 
activities such as antileishmanial,11 antitumour,11 antifungal12 and antiendotoxin.13 The 
majority of peptides reported tend to have net cationic charges but there are a number of 
anionic AMPs14 and neutral peptides reported.15 Many AMPs have been found to target 
bacterial membranes and whilst some are found to have disordered solution structures it is 
well established that on contact with cell or model membranes they form amphipathic 
secondary structures, commonly alpha helices or beta sheets, where charged and 
hydrophobic residues line up on opposite sides of the structure allowing the peptides to 
interact with membranes through both electrostatic and hydrophobic interactions. This 
forms the basis of their mechanism of action which is largely thought to be disruption of 
cell membranes through pore formation but it is increasingly understood that many also, or 
only, have intracellular targets.16 Many also have immunomodulatory effects and for host 
defence peptides this can be their main biological activity.17  
 
Peptide Family Origin Reported Biological Activities 
Magainins18 Frog Antibacterial, antitumour19 
Mastoparans20 Wasp 
Antibacterial,21 mast cell degranulation,20 
stimulation of insulin release22 
β-Defensins23 Mammal Antibacterial,23 immune modulatory activity,23 
Protegrins24 Mammal Antibacterial,24 immune modulatory activity24 
Thionins23 Plant 
Antibacterial,23 antifungal,23 toxicity towards 
mammalian cells23 
 
Table 1-1: Examples of different families of AMPs and some of their reported activities 
 
AMPs are found to have a very low propensity to select for resistance but there are some 
reported mechanisms: the production of proteases,9 increased number of exporter 
pumps25 and altering the cell membrane to reduce the net negative charge.26  
 
Selectivity among AMPs is usually determined in vitro by comparing haemolysis assays with 
minimum inhibitory concentration (MIC) assays and is found to vary widely. The 
mechanisms by which it is exerted are not fully understood but, where it is present, 





cell membrane and the presence of cholesterol in mammalian cells contributing stability to 
the cell membrane.27 Haemolysis assays can be poor indicators of in vivo toxicity and this is 
particularly true for AMPs which can have immunomodulatory activity. The toxicity of 
AMPs for systemic application is also poorly understood which is reflected in the lack of in 
vivo studies in the literature. Most AMPs currently in clinical or pre-clinical development 
are topical creams or gels for the treatment of skin infections,28–30 inhalational formulations 
to treat respiratory tract infections31 or intended for the treatment of infections of the 
gastrointestinal tract.32,33 
 
1.1.1 Mode of Action for Membrane Active AMPs 
 
Peptides that target bacterial cell membranes must initially pass through the cell wall. It is 
well established that they then bind parallel to the lipid bilayer and, at low concentrations, 
embed into the lipid head group region, this is known as the surface state. Although this is 
largely referred to as an inactive state, thinning of the membrane is observed as the 
peptides increase the surface area of the head group region, this is often reversed on 
formation of pores.34 As the concentration of bound peptide increases, the peptides will be 
increasingly observed as perpendicular to the bilayer as they insert into the membrane. 
Insertion and the extent of membrane disruption is dependent on both the properties of 
the peptide and the lipid content of the membrane. There are three main models to 
explain how membrane disruption is believed to work: ‘barrel-stave’, ‘carpet’ and 
‘toroidal-pore’ (Figure 1-2 to Figure 1-4) 
 
 
Figure 1-2: Barrel-stave pore formation in a lipid bilayer 
 
The barrel-stave model was the first model developed for membrane disruption when it 
was used to describe the ion channels alamethicin formed in lipid bilayers35 and it is still 
believed to be unique to alamethicin. A variety of studies have shown that alamethicin 





peptide regions aligning to face the internal lipid core of the membrane and the hydrophilic 
peptide regions facing inwards forming the interior of the pore.36,37  
 
 
Figure 1-3: Toroidal-pore mechanism in a lipid bilayer 
 
The toroidal pore mechanism (Figure 1-3) occurs when peptide helices insert into the 
bilayer and cause curvature in the lipid monolayers so that the interior of the pore is lined 
by the peptide and the head group of the lipid.  
 
Unlike the other two models, the carpet model (Figure 1-4) proposes that peptides do not 
insert themselves into the lipid core of the membrane.38 It is also understood that this 
mechanism does not require peptides to adopt a specific secondary structure on 
interaction with the membrane or to aggregate with one another.39 Once a high local 
concentration of peptide is reached toroidal pores are formed and the membrane is 
disrupted in a detergent like manner and can eventually disintegrate completely.40 Some 








Figure 1-4: Carpet model in a lipid bilayer 
 
AMPs are fairly easy to synthesise and there has been a wealth of structure activity 
relationship studies carried out looking at the effect of charge,41 length of peptide,42 and 
amphipathicity.43 These are not straightforward to study as changing one parameter will 
usually impact the others. For more in depth discussion of these studies see reviews by 




Pexiganan was developed through structure activity relationship studies from magainin, a 
well-studied model AMP. Magainins were first isolated from the skin of an African claw frog 
by M. Zasloff who noticed that after non sterile surgery the frogs rarely suffered from 
bacterial infections.18 Extracts from the skin were tested for antimicrobial activity against 
E. coli and the fractions that showed activity were further purified. Reverse phase HPLC 
showed there were five main components with antibacterial activity. The best two of these 
were then sequenced and further screened for antimicrobial activity and they showed good 
activity against both Gram-negative and Gram-positive bacteria, fungi, and protozoa (1 and 
2, Figure 1-5). They were named "magainins" which was derived from the Hebrew word 







Figure 1-5: Magainin 1 (1) and 2 (2) isolated by Zasloff, differences highlighted in blue 
 
It was thought that the magainin peptides could be membrane disrupting peptides due to 
the structural similarity to other peptides already shown to disrupt membranes such as 
mellitin. To probe their activity further, Zasloff went on to use to synthesise the 
characterised peptides (1), (2) and, in addition, a C-terminus truncated analogue of (2) that 
had also been identified as one of the five main components of skin extracts (3, Figure 




Figure 1-6: Truncated analogues of magainin synthesised by Zasloff et al.46 
 
Magainin 1 (1), 2 (2) and the C-terminus truncated analogue (3) were tested against a range 
of Gram positive and Gram negative bacteria for antibacterial activity and were shown to 
have broad spectrum activity (Table 1-2). MIC data was not obtained for the N-terminus 
truncated analogues but solutions of peptide (50 µg in 10 µl water) were spotted on 
agarose plates spread with E. coli. The first two truncations (4-5) were well tolerated, 
showing large “halos” of growth inhibition of E. coli but removing four or more amino acids 
(6 and 7) showed little inhibition of growth. Peptides with truncations of five or six (8 and 
9) amino acids showed no activity against E. coli using this assay.  It was suggested that the 
decrease in activity was due to the peptides no longer being able to span the bacterial 
membrane as an α-helical structure. In the same study, a protozoan, Paramacium 
caudatum, was treated with magainin 2 and it was observed that this caused osmotic 





encapsulating fluorescent markers47 and the disruption of electrochemical ion gradients 
across cell membranes48 had also been observed. 
 MIC µg/mL 







Escherichia coli D31 1-7 1-7 1-7 
Streptococcus pyogenes (19615) 7-35 1-7 7-35 
Enterobacter cloacae (23355) 7-35 1-7 7-35 
Staphylococcus epidermidis (12228) >100 7-35 35-70 
Staphylococcus aureus (25923) >100 35-70 >100 
 
Table 1-2: Selection of MIC values obtained by Zasloff et al.46 
 
Solid state 15N NMR on model membranes of phospholipids showed magainin 2 (2) existed 
as a helical peptide in membrane environments and lay parallel to the plane of the 
membrane.49 This was supported by earlier work involving fluorescence quenching 
experiments carried out with phenylalanine containing analogues of magainin50 and also 
Monte Carlo simulations.51 Wade et al.52 showed that the all D-enantiomer of the natural 
L-magainin had equivalent antibacterial activity and produced the same current in 
conductivity measurements in model membranes, which indicated the target was not a 
protein or enzymatic target. These experiments only accounted for interactions with the 
head groups of the membrane and did not show any significant interaction with the alkyl 
chain region.   
 
Ludtke and co-workers were the first to publish evidence that suggested at high 
concentrations (around a 1:30 peptide to lipid molar ratio) magainin inserts itself into 
model membranes.53 Using oriented circular dichroism (OCD) measurements (a technique 
used to assess orientation of a peptide with respect to a lipid bilayer as well as its 
secondary structure)54 they saw changes in OCD spectra that indicated a shift in orientation 
of magainin from parallel to perpendicular to the plane of the lipid membrane. The 
concentration at which the shift occurred corresponded well with the concentration 
required for lysis in liposome leakage experiments, also around 1:30.55 
 
Magainin peptides were later shown to have anti-cancer activity, causing lysis of tumour 
cells at concentrations non-toxic to peripheral blood cells.56 Cancer cell membranes are 
more fluid and more negatively charged than mammalian cells making them a prime target 







Figure 1-7: Sequence of pexiganan (10); differences to magainin 2 (2) highlighted in blue 
 
Several structure activity relationship studies were carried out on magainin but it was 
Zasloff and co-workers who founded a small biotech company, Magainin Pharmaceuticals, 
and developed the most successful analogue, pexiganan (10, Figure 1-7). This analogue was 
amidated at the C-terminus and contained more basic lysine residues than either magainin 
1 (1) or 2 (2). Extensive in vitro screenings showed pexiganan  to have broad spectrum 
activity against both Gram positive and Gram negative bacteria57 including a  number of 
antibiotic resistant strains, showing no signs of cross resistance and also no signs of 
selecting for resistance. Pexiganan (10) was also shown to have equivalent in vitro 
bactericidal activity to ofloxacin,58 a commonly used antibiotic. In 1999 it underwent clinical 
trials as a 1% cream formulation for the topical treatment for diabetic foot ulcers.59 The 
trials determined pexiganan was no more effective than already approved treatments for 
diabetic foot ulcers and so failed to obtain approval by the US Food and Drug 
Administration (FDA). Now owned by Dipexium Pharmaceuticals Inc., pexiganan has 
recently gone through a second round of clinical trials but was again deemed no more 
effective than existing treatments. 
 
Similar to magainin, solid state NMR has shown pexiganan exists in a disordered structure 
in solution but on binding to both lipid bilayers and detergent micelles it forms a defined 
secondary structure, a dimeric antiparallel α-helical coiled-coil.60,61 NMR studies have also 
shown that pexiganan is most likely to form pores in a toroidal like mechanism.62 This has 
been supported by a number of other studies including the use of differential scanning 
calorimetry to show the induction of positive curvature strain on the lipid bilayer when 




Mastoparan (11, Figure 1-8) was first isolated in 1979 by Y. Hirai whilst analysing the 
complex mixture of bioactive compounds in wasp venom and it was shown to cause 
degranulation of mast cells.20 It was later shown to have anti-microbial activity and 





Gram positive bacteria.63 Haemolytic activity was also observed but required much higher 
concentrations of peptide. Since 1979 many more analogues of mastoparan have been 
isolated from different species of wasps64,65,66 and many more generated through synthetic 
manipulation of the peptides.67 Mastoparan has been found to have a number of other 
biological activities including stimulating insulin production in pancreatic islet cells22 and 
myotoxic effects in mice skeletal muscle.68   
 
 
Figure 1-8: Sequence of the first mastoparan peptide isolated (11) 
 
Mastoparans are generally found to be tetradecapeptide amides and are now 
characterised by their ability to cause mast cell degranulation. Mast cells are leukocytes 
that are part of the immune and neuroimmune systems, playing a key role in participating 
in early recognition of pathogens and inflammation.69 They contain granules rich in immune 
response mediators such as histamine, heparin and proteases. It is thought mastoparans 
trigger exocytosis of these granules through interaction with G-protein receptors.70 Once 
released these go on to modulate the host immune response in a variety of ways for 
example by releasing their own AMPs and the release of mediators that go on to promote 
neutrophil recruitment. 
 
Experiments by Katsu et al.71 suggested there was a correlation between the ability of 
mastoparan peptides to release histamine, cell permeability and their antimicrobial 
activity. As well as interacting with G-protein receptors mastoparans were also membrane 
active towards mast cells; this was attributed to the increase in negative charge of the 
cytoplasmic membrane arising from histamine release. This study again confirmed that 
much higher concentrations of peptide (> 80 µM) were required for a haemolytic effect.  
 
Eliciting an immune response is generally considered to be an unwanted side effect of 
AMPs as the response is hard to study and predict in vitro and in vivo and can result in 
adverse effects in clinical trials. However, a situation in which an AMP such as mastoparan 
could also elicit a controlled immune response would result in a very effective therapeutic 
therapy against bacterial infections. Much more work on understanding the immune 





For now, the promiscuity of mastoparan for other biological targets limits its therapeutic 
potential especially if considering its use as a systemic drug. 
 
One analogue of mastoparan that shows promising therapeutic potential and greater 
selectivity than other analogues is Polybia-MP1 (12). It was first isolated by B. Souza et al.21 
in 2005 from the venom of the wasp Polybia paulista alongside another less potent 
analogue, Polybia-CP (13).  
 
 
Figure 1-9: Sequences of Polybia-MP1 (12) and Polybia-CP (13) 
 
Polybia-MP1 (12) was shown to have antimicrobial activity against both Gram positive and 
Gram negative bacteria but did not cause haemolysis to rat erythrocytes and whilst mast 
cell degranulation activity was recorded it required significantly higher concentrations of 
peptide than relevant for physiological concentrations.21 
 
Further studies involving molecular dynamics simulations, circular dichroism and dye 
leakage assays using both anionic and zwitterionic vesicles were carried out to investigate 
the selectivity of Polybia-MP1 (12).72 It was suggested that the selectivity was a result of 
the distribution of the charged and polar residues along the peptide helix and the resulting 
orientation of solvent molecules. The presence and position of aspartic acid residues 
appeared to be especially important, a single substitution of Asp2 residue for Asn2, led to a 
haemolytic analogue. It was suggested that the partial neutralisation of the cationic 
residues that aspartic acid provides causes a smaller disturbance of the head group region 





Peptoids were developed as a tool for drug discovery; they provided a way to rapidly and 
cheaply generate vast libraries of small molecules for screening for biological activity. A 





way nature uses a finite selection of small building blocks to create diverse collections of 
biopolymers.73 This approach was also attractive as a limited number of building blocks 
would only need a limited number of reactions to put them together. Once that 
methodology was in place a small team of chemists could generate vast libraries of 
compounds. The researchers at Chiron Corp. proposed the five most desirable attributes of 
these systems: 
 
“(i) the monomers should be straightforward to synthesize in large amounts, (ii) the 
monomers should have a wide variety of functional groups presented as side chains off of 
the oligomeric backbone, (iii) the linking chemistry should be high yielding and amenable to 
automation, (iv) the linkage should be resistant to hydrolytic enzymes, and (v) the 
monomers should be achiral.”74 
 
With these criteria in mind, the team developed a set of peptide mimics with oligomeric 
N-substituted glycines where the alpha carbon side chain of an amino acid was shifted onto 
the amide nitrogen. In comparison to peptides these oligomers lacked an amide hydrogen 
bond donor and chirality at the alpha carbon. The biggest advantage over peptides was 
that these oligomers, or peptoids, were no longer susceptible to proteases as they no 
longer contain a peptide amide bond. In order to avoid having to prepare a set of 
N-substituted glycine monomers (the peptoid equivalent of amino acids) Zuckermann and 
co-workers developed a  sub monomer approach whereby the peptoid chain can be built 
up with alternating condensation of copolymers of a haloacetic acid and a primary amine 
(Scheme 1-1).75  
 
Scheme 1-1: Peptoid synthesis for a sub-monomer approach 
 
Peptoids have now been shown to be adequate peptide mimics and have wide range of 





mimics of peptide lung surfactants,78 mimicking protein secondary structures,79 inhibiting 
protein-protein interactions,80 and cell penetrating abilities.81 
 
Alongside the development of pure peptoid structures, peptoid building blocks can be 
incorporated easily in a peptide sequence82 to give peptoid-peptide hybrids or 
“peptomers”. AMPs are ideal candidates for peptoid substitutions as one of their main 
disadvantages is their susceptibility to degradation in vivo by proteases and this can be 
minimised with increasing peptoid character. As previously discussed, the amphipathic 
nature of AMPs is what drives their activity, this is determined by the distribution of 
hydrophobic and cationic residues and this distribution can be relatively easily replicated 
with the relevant peptoid monomers.  
 
Building on work that had shown that both monomers with bulky alpha-chiral aromatic side 
chains83 and those with bulky alpha-chiral aliphatic side chains84 give rise to peptoids with 
stable helical structures, Patch and Barron synthesised a set of peptoids with helices that 
were predicted to be similar to that of magainin 2 (Figure 1-10).85 The mimics were of 12 
and 17 monomers in length as this gave predicted helix lengths in line with the α-helical 
conformation of magainin-2. The most promising of the mimics (15) and (17) gave potent 
antibacterial activity against both Gram-positive and Gram-negative bacteria with 








Figure 1-10: Peptoid mimics of magainin 2 amide 
 
Peptoid E. coli MIC (µM) B. subtilis MIC (µM) Haemolysis at E. coli MIC (%) 
14 >100 >100 (>200) 0 
16 49 ± 8.3 7.8 ± 1.3 0 
17 9.9 ± 2.5 4.4 ± 0.8 0 
19 19 ± 4.9 1.4 ± 0.2 1.2 
15 5.4 ± 0.9 0.82 ± 0.14 1.4 
18 7.7 ± 1.3 1.2 ± 0.2 51 
20 >75 >75 100a 
 
Table 1-3: Peptoid antibacterial and haemolytic activities obtained by Barron85 
Estimated uncertainties of MIC data indicated; areported at 75 µM85 
 
Further structure activity relationship studies were carried out by the same group with the 
most promising analogue (15). The effects of chirality, length, charge, amphipathicity and 
hydrophobicity on potency and selectivity were investigated.86 The group were able to 
produce 6 variants that had improved selectivity over (NLysNspeNspe)4 (15), determined by 





Table 1-4). The most selective was a reduced hydrophobicity variant, 1-Pro6 (26), where 
Nspe at position 6 was replaced with L-proline. This analogue was shown to have similar 
antibacterial activity to pexiganan (10) but was not quite as selective as the AMP. However, 
in a cytotoxicity assay using lung epithelial cells the peptoid (26) performed 10 x better 
than the AMP with a 10% metabolic inhibitory dose (ID10) of 22.8 µM. The group concluded 
that the activity of peptoids depends on moderate hydrophobicity and net cationic charge 
and their haemolytic activity relies mostly on high hydrophobicity and strong amphipathic 
structure in a very similar fashion to AMPs. 
 
Sequence 






H-(NLys-Nspe-Nspe)4-NH2 (15) 3.5 0.88 6.0 
H-(NLys-Nspe-Nspe)2-NH2 (21) 27 27 >8.1 
H-(NLys-Nspe-Nspe)3-NH2 (22) 9.1 1.2 >16 
H-(NLys-Nsmb-Nspe)4-NH2 (23) 7.4 0.95 >16 
H-(NLys-Nssb-Nspe-NLys-Nssb-Nsna)2-NH2 (24) 7.2 0.93 7.6 
H-(NLys-Nspe-Nspe-NLys-Nspe-NHis)2-NH2 (25) 3.5 6.9 >31 
H-NLys-Nspe-Nspe-NLys-Nspe-L-Pro(NLys-Nspe-
Nspe)2-NH2 (26) 
3.1 1.6 20 
GIGKFLKKAKKFGKAFVKILKK-NH2 (10) 3.1 1.6 24 
 
Table 1-4: Antibacterial and haemolytic activities of peptoids (15, 21-26) and pexiganan (10) 
obtained by Barron86  
aSelectivity ratio, SR = (10% haemolytic dose)/(E. coli MIC) 
 
Acknowledging that haemolytic assays are not always good predictors for in vivo toxicity, 
Bolt et al.87 have recently generated a large peptoid library and tested for toxicity using two 
mammalian cell lines. Like Barron and co-workers, they found that the most toxic peptoids 
tended to have higher hydrophobicity and, interestingly, sequences with reduced 
frequency of chiral monomers, compared to the standard NxNspeNspe motif, showed 
reduced toxicity. They go on to suggest that the selectivity they observe indicates that cell 




Lantibiotics are a subset of AMPs that have seen an increase in attention from 
pharmaceutical research and development over the last decade. They are ribosomally 
synthesised by a wide range of bacteria and form a substantial class of AMPs.88 Their 





modifications they undergo.89 The name originates from the inclusion of one or more of the 
uncommon amino acids, lanthionine (Lan) (29) and methyllanthionine (MeLan) (30). These 
thioether analogues of cystine are the product of enzymatically controlled Michael addition 
to dehydroalanine (Dha) (31) and dehydrobutyrine (Dhb) (32) which are derived from the 
dehydration of serine and threonine respectively. These modifications give rise to peptides 
with multiple, often overlapping, cyclic motifs, some examples of these peptides can be 
seen in Figure 1-11. 
 
Lantibiotics are broadly divided into three classes, Type I, II and III, defined by their mode of 
action and the type of enzymes involved in their biosynthetic pathways. Type I lantibiotics 
such as nisin (27) and epidermin (28), are flexible, elongated molecules whose primary 
mode of action is binding and sequestering a cell wall precursor, lipid II, and forming pores 
in the bacterial plasma membrane. Type II Lantibiotics, such as cinnamycin (33) are more 
rigid and globular in shape and can bind lipid II but are less likely to have pore forming 
abilities. Type III form the smallest class of lantibiotics and are found to have long, 
hydrophobic sequences but little antimicrobial activity. Lantibiotics are also sometimes 
produced as two-component systems where an organism produces two separate peptides 
that work synergistically together such as lacticin 3147 (35 and 36) in which lacticin A1 (35) 
binds to lipid II and lacticin A2 (36) forms pores in membranes, but only in the presence of 
lacticin A1 (35).90 
 
Due to the lipid II dependant nature of their mode of action lantibiotics are primarily active 
against Gram positive bacteria as the thick outer membrane of lipopolysaccharides of Gram 
negative bacteria prevents the peptides from reaching lipid II. High concentrations of 
peptide or the addition of membrane destabilising agents can improve activity against 













A significant number of lantibiotics are reported to have excellent antibacterial activity, 
notably against multi-drug resistant strains of bacteria, but their development as drugs has 
been held back by poor drug-likeness and a lack of synthetic methods available to generate 
or modify their complex structures. 
 
Poor drug-likeness can be attributed to the chemical instability of lantibiotics: 
sulphur-containing lanthionine residues are prone to oxidation and unreacted dehydro 
residues can be easily cleaved in basic conditions, attacked by nucleophiles or undergo 
hydrolysis in strongly acidic conditions.92,93 Solubility can also be a problem, notably, nisin is 
poorly soluble at neutral or high pH94 and whilst the thioether bridges of lantibiotics 
provide some protection to proteolysis and thermal degradation95 they are still prone to 
enzymatic degradation in the gastrointestinal tract and in the bloodstream.96 This means 
lantibiotics are unlikely to be orally bioavailable. 
 
However, as the pressure for new antimicrobials mounts, there are now a small handful of 
lantibiotics undergoing clinical trials. NVB302 (38, Figure 1-12), a C-terminally modified 
derivative of a type II lantibiotic, actagardine,  is currently being developed by Novacta 
Biosytems and has completed Phase I clinical trials for the treatment of Clostridium 
difficile infections.97  
 
 
Figure 1-12: Structure of NVB302 (38) 
 
1.2.1 Nisin  
 
Nisin (27) is the most widely studied member of the lantibiotics. It has broad spectrum 
antimicrobial activity, notably against MRSA and VRE.98 Nisin also happens to have good 
activity against food spoilage bacteria which has been put to use in its role as a food 
preservative in the dairy industry.99 It is produced by lactic acid bacterium Lactococcus 
lactis100 and a modified strain of this  is used industrially in a neutral fermentation process 





considered non-toxic as it is broken down in the acidic conditions of the stomach.96 One of 
the most significant features of nisin is that despite widespread use as a preservative over a 
period of decades no significant incidences of resistance have been reported.  
 
There are now eight natural variants of nisin reported. The first two isolated, and the most 
studied are nisin A and nisin Z. These differ by a single amino acid substitution at position 
27; in nisin A this is histidine and for nisin Z it is asparagine. Antimicrobial activity is not 
affected by the substitution but nisin Z has been found to have better diffusion and 
solubility properties.102 Despite the fact that nisin is the most extensively studied lantibiotic 
its mode of action is not fully understood at a molecular level.  
 
1.2.2 Biosynthesis of Nisin 
 
Biosynthesis begins with the NisA gene which encodes the 57 amino acid straight chain 
“prepeptide” of nisin (39, Scheme 1-2). This is ribosomally synthesised with an N-terminal 
“leader” peptide section which serves two main functions: guiding and activating the 
lanthionine modification enzymes and keeping the core peptide inactive during 
maturation.103 After ribosomal synthesis, the NisB dehydratase enzyme selectively catalyses 
the dehydration of the necessary serine and threonine residues (Scheme 1-3). This is 
followed by the regio- and stereo-specific Michael addition of the cysteine residues to the 
newly formed Dha and Dhb residues catalysed by the NisC cyclase enzyme to give the five 
rings of nisin (41).104 For nisin this reaction produces only DL-lanthionine and 
methyllanthionine which is the most commonly reported stereochemistry for lanthionine 
residues but some exceptions have been found in other lantibiotics.105 
 
After cyclisation NisP protease cleaves the leader peptide to give nisin A. NisT is also 
involved in the biosynthesis as an ATP-binding cassette transporter responsible for the 










Scheme 1-3: Dehydration of serine (R= H) and threonine (R = Me) residues to Dha and Dhb 






The antibacterial activity of nisin means that a system of immunity needs to work alongside 
the biosynthetic pathway to protect the producing strain of bacteria from the effects of its 
own product and in turn, ensure a good rate of production of nisin. Features of immunity 
were first uncovered in work characterising the biosynthetic pathway of nisin107,108 and it 
was further probed by Ra and co-workers who used a “knockout” technique on the genes 
believed to be responsible for immunity.109 Another key study was carried out by Stein and 
co-workers who engineered a nisin-sensitive strain of Bacillus subtilis with different 
combinations of nisin immunity genes and measured the impact on cell viability.110 It is 
understood that immunity is conferred by a combination of two systems: a lipoprotein NisI 
and an ATP binding cassette (ABC) transporter NisFEG. The lipoprotein is believed to be 
transported to the extracellular side of the cytoplasmic membrane where it can interact 
and intercept nisin and disrupt pore formation. The ABC transporter is thought to work by 
expelling nisin molecules from the membrane, before or during pore formation, back into 
the environment.  
 
Some strains of L. lactis that do not produce nisin still confer resistance to it. They have 
been found to produce an enzyme that breaks down nisin and protects the bacteria.111 
Mechanisms of resistance like this are important to study as they could indicate the way in 
which resistance could develop if nisin, or other lantibiotics, were used in a clinical setting. 
 
1.2.3 Nisin Mode of Action- Initial Studies 
 
Several early experiments suggested nisin’s mode of action involved the destabilisation of 
cytoplasmic cell membranes. To investigate the structure-activity relationship, van der 
Hooven et al.112 used NMR spectroscopy and model membranes to study the solution 
structure of the peptide in the presence and absence of model membranes. Both 
zwitterionic dodecylphosphocholine (DPC) and ionic sodium dodecyl sulphate (SDS) 
micelles were used to mimic both mammalian and bacterial membranes respectively. Nisin 
was shown to have two well-defined domains: an N-terminal domain including the A, B and 
C rings and a second domain consisting of rings D and E. Both components were shown to 
be amphipathic where charged and hydrophobic residues line up on opposite sides of the 
structure allowing the peptide to interact with membranes through both electrostatic and 
hydrophobic interactions. This is a characteristic of many membrane active peptides. 
Residues 20-23 were later defined as the hinge region, which was shown to be important 






Alongside membrane destabilising activity, nisin had also been shown to inhibit 
peptidoglycan synthesis in vitro113 but the discrepancy between nisin’s activity in model 
membrane studies which was in the micromolar range, similar to other linear pore forming 
peptides, and the nanomolar concentrations at which it killed bacteria could not be 
accounted for. This was until de Kruijff and co-workers observed that extracting lipid 
content from bacteria and forming model membranes with the resulting lipids also gave 
better activities for nisin.114 They hypothesised that nisin could rely on a peptide-based 
component of the cell wall, lipid II, a cell wall precursor. By using competition assays with 
vancomycin (a known lipid II ligand) they showed that nisin’s activity was indeed likely to 
rely on lipid II. They went on to incorporate lipid II into model membranes that 
encapsulated carboxyfluorescein, a fluorescent dye, and could show a strong correlation 
between lipid II concentration and nisin’s ability to cause leakage of the dye. In comparison, 
magainin a less potent, linear, membrane destabilising peptide showed no dependency on 
lipid II. 
 
1.2.4 Lipid II as a Target for Antibiotics 
 
All bacterial cell walls are made up of cross-linked, polymeric, amino acid sugars that form a 
peptidoglycan matrix which is vital in providing the cell wall with its strength and rigidity. 
The cycle of cell wall synthesis is shown in  
Scheme 1-4115. Lipid II forms a vital intermediate in the cycle enabling the cell wall subunits 
to pass from the cytoplasmic side of the plasma membrane, where they are synthesised, to 
the exterior of the plasma membrane where they are inserted into the growing cell wall. 
Only small amounts of the precursor, bactoprenyl phosphate, are available within the cell 
which means only a small amount of lipid II can be generated at any one time. This is 
compensated for within the cycle by a rapid turnover of around 1-3 cycles per second per 
prenyl chain116 and it is this limited availability of lipid II that makes it a weak link in the cell 
wall synthesis chain and an ideal target for antibiotics. As previously mentioned, lipid II is 
less accessible in Gram negative bacteria and so they are significantly less susceptible to 
lipid II targeting antibiotics.   
 
Alongside nisin, there are several other antibiotics that are known to target lipid II. 
Vancomycin, a glycopeptide, which has been shown to bind to the pentapeptide region of 
lipid II, specifically to the D-Ala-D-Ala residues, is used clinically to treat MRSA and several 





vancomycin has been reported whereby bacteria have mutated the terminal D-Ala to D-Lac 
or D-Ser which significantly reduces the binding affinity of vancomycin.118 Another 
glycopeptide believed to interact with lipid II is ramoplanin which has undergone phase II 
clinical trials to treat C. difficile infections.119 The most recent addition to this group of lipid 
II binding antibiotics is teixobactin which was discovered using novel iChip technology, 
which allowed for the isolation and culture of bacteria from soil, the majority of which do 
not grow under standard laboratory conditions.120 Excitingly, initial studies have suggested 
teixobactin has a very low propensity to select for resistance and it is believed to form 
stoichiometric complexes with both lipid II and lipid III. For a more in depth discussion of 
lipid II binding antibiotics see reviews by Breukink and de Kruijff115 and more recently by Ng 





Scheme 1-4: Cell wall synthesis (a) synthesis begins intracellularly with a 
MurNAc-pentapeptide precursor coupling to bactoprenyl-phosphate, a membrane carrier, 
to give Lipid I. A second sugar GlcNAc is coupled to lipid I to produce lipid II, which now 
contains the complete peptidoglycan subunit linked via a pyrophosphate to the membrane-
embedded bactoprenol lipid anchor. Lipid II is then translocated to the exterior side of the 
plasma membrane by an unknown mechanism where it can be incorporated into a 
polymeric peptidoglycan chain and form the cell wall. (b) Chemical structure of lipid II; red 
bars indicate the minimal binding sites in Lipid II of glycopeptide antibiotics (1), nisin (2), 







1.2.5 Nisin Mode of Action- a Complete Picture? 
 
Although nisin’s dependence on lipid II for achieving its maximum potency had been 
established, the mechanism for the increased activity was still unclear. Using tryptophan 
mutants of nisin and fluorescence measurements Heusden et al.122 were able to show that 
lipid II was able to induce a transmembrane configuration of nisin. They suggested that 
because it would be energetically unfavourable for one molecule of nisin to insert into the 
hydrophobic membrane it was likely that a pore formed with several nisin molecules 
creating a water-filled channel in the membrane which the charged residues of nisin would 
face. The same group went on to show that lipid II acted not just as a recruiting or docking 
molecule for nisin but actually played a structural role in the pore.123 Using labelled lipid II 
molecules and fluorescence measurements they were able to estimate the distance 
between two lipid II molecules, believed to be situated within a pore, as 18 Å. From this 
data they proposed a model of the pore that had a possible stoichiometry of five to eight 
nisin molecules and an identical number of lipid II molecules. This report also suggested 
that interaction of nisin with lipid II was likely to occur at the 
pyrophosphate-MurNAc(pentapeptide)-GlcNAc head group of lipid II. Previous using 15N 
labelled nisin has also suggested that the amide protons of the N-terminus of nisin formed 
hydrogen bonds with lipid II.124 
 
 
Figure 1-13: Functional regions of nisin (27) 
 
Hsu et al.125 were able to produce an NMR structure of a 1:1 complex of nisin with a 
truncated analogue of lipid II (left, Figure 1-14). A shorter isoprene tail was used to 
minimise non-diagnostic signals and to increase water solubility but still provided enough 
surface for anchoring lipid II into the membrane. Rings AB of nisin were shown to form a 
cage like structure around the pyrophosphate moiety with hydrogen bonds between the 
amide groups of the nisin backbone and the pyrophosphate moiety. This was a novel lipid II 





resistant strains of bacteria as vancomycin binds to the pentapeptide region and resistance 
arises out of a point mutation of an amino acid. This work provides a much clearer 
understanding of how nisin binds to lipid II and it also indicates why nisin has such a low 




Figure 1-14: Solution structure of the nisin-lipid II complex; backbone of nisin rings AB form 
a cage-like structure around the pyrophosphate (spheres); hydrogen bonds from the 
backbone amides that hold the pyrophosphate in place are depicted in yellow; sulphur 
atoms of the thioether bonds are shown in orange (left);125 figure reprinted with permission, 
copyright Nature Publishing Group; fluorescently labelled lipid II (right, 42) used by 
Breukink126 
 
Further work by Breukink and co-workers using fluorescently labelled lipid II molecules 
(right, 42, Figure 1-14) confirmed that the pores in model membranes consist of 8 nisin and 
4 lipid II molecules.126 The stability of these pores was also confirmed as the pores were 
shown to remain intact even after addition of detergents that solubilized the membranes.  
 
This provides a reasonable model for nisin’s pore formation (Scheme 1-5) but there are still 
significant gaps in the current mechanism. It is not known how multiple nisin and lipid II 
complexes come together and what the forces of attraction and recognition that facilitate 
this are. The order in which pore formation occurs is not well understood, whether 
insertion occurs before or after aggregation and the specific role of the hinge region, other 
than requiring flexibility, is still unclear- is it essential to stable pore formation? Certainly, 
there is still much more work to be done to complete our understanding of nisin’s pore 
formation. A more robust understanding would facilitate the synthesis of optimal lipid II 







Scheme 1-5: Mechanism of nisin pore formation: (a) nisin reaches the membrane (b) the 
N-terminus of nisin binds to lipid II forming a 1:1 nisin-lipid II complex (c) these complexes 
then aggregate and insertion into the membrane takes place whereby several nisin 
molecules have adopted a trans-membrane orientation with lipid II molecules to form a 
stable pore structure;115 figure reprinted with permission, copyright Nature Publishing 
Group 
 
1.3 Synthesising Lantibiotics 
 
There are several synthetic and biosynthetic methods that have been developed over the 
last few decades to produce meaningful amounts of both wild type and modified analogues 
of lantibiotics. Each method has its own advantages and disadvantages and to meet the 
significant challenges of the structural complexity of lantibiotics it’s likely that a wide 
spectrum of tools will be required. 
 
Chemical methods of synthesising lantibiotics largely rely on the synthesis of lanthionine 
residues which can be incorporated by SPPS into linear peptides and enable cyclisation to 
give the characteristic lanthionine rings (Scheme 1-6). Several different approaches for the 
synthesis of lanthionine, methyllanthionine and orthogonally protected analogues have 
been investigated by many different groups and a select few are highlighted below. For a 







Scheme 1-6: Incorporation of bis-amino acids into peptides by SPPS  
Reagents and conditions: (i) standard Fmoc SPPS protocol to build up chain (Fmoc 
deprotection using 40% piperidine, followed by amino acid addition using HBTU and DIPEA) 
followed by incorporation of lanthionine and further chain extension (ii) deprotection of 
both lanthionine protecting groups and Fmoc group (iii) cyclisation to form thioether bridge 
(iv) further chain extension or cleavage from resin 
 
1.3.1 Desulfurisation to Synthesise Lanthionine and Lantibiotics 
 
One approach towards the synthesis of lanthionine, that has been attempted by a number 
of groups, utilised the desulfurisation of cystine derivatives.128,129 This approach involved 
the use of aminophosphines to desulfurise various cystine derivatives to give lanthionine 
compounds in modest yields (Scheme 1-7). These methods were incompatible with base 
sensitive protecting groups and several other difficulties, including purification, meant this 
approach was not pursued.   
 
Scheme 1-7: General method for synthesis of lanthionine by desulfurisation  
 
However, the desulfurisation methodology of Harpp and Gleeson was more successful 
when used to install the lanthionine bridge in a preformed peptide. This approach enabled 
the first total synthesis of nisin.130 Fukase and co-workers synthesised fragments of the 
peptide chain with Cys-Cys bridged rings and then used desulfurisation to reduce the 
disulphide bonds to the thioether bonds of nisin (Scheme 1-8). Dehydro residues were then 
installed and the resulting fragments were coupled together using solution phase synthesis 






Scheme 1-8: Synthesis of nisin ring A 
Reagents and conditions: (i) P(NEt2)3, DMF, (ii) 1. H2, Pd, 2. HCHO, NaBH3CN, 3. CH3I, KHCO3 
 
1.3.2 Lanthionine Synthesis via β-Haloalanines  
 
Several groups have investigated the synthesis of lanthionines via a coupling reaction 
between β-haloalanines and cysteine residues under basic conditions.131,132,133 Problems 
were encountered with competing elimination reactions that gave dehydroalanine which 
could then undergo Michael addition with cysteine to give a mixture of diastereomers. To 
overcome this problem, derivatives with a trityl protected amine were developed where 
the trityl group sterically hinders α-proton abstraction.134  
 
Tabor and co-workers showed that a trityl protected iodoalanine derivative (50) could 
undergo coupling with Fmoc-Cys-OtBu in the presence of Cs2CO3 to afford a protected 
lanthionine (51) in good yield (Scheme 1-9). Replacement of the trityl group with an alloc 
group and removal of the tert-butyl group gave orthogonally protected lanthionine (52) 
that could be readily incorporated in SPPS using the methodology described in Scheme 1-6. 
 
 
Scheme 1-9: Synthesis of orthogonally protected lanthionine 
 
1.3.3 Incorporation of Lanthionine into Nisin Ring Analogues by SPPS 
 
Tabor and co-workers went on to synthesise an analogue of ring C of nisin (58) using this 





build up linear chain (54) and then the simultaneous allyl and Alloc deprotection of 
incorporated lanthionine (52) was carried out using a palladium catalyst to give (55). An 
intramolecular coupling could then be carried out to form the C ring. 
 
Scheme 1-10: SPPS of an analogue of ring C nisin 
Reagents and conditions: (i) standard Fmoc SPPS protocol to build up chain followed by 
incorporation of lanthionine (52) with HOAt, PyAOP, DIPEA (ii) standard Fmoc SPPS protocol 
to build up chain (iii) 40% piperidine in DMF, then Pd(PPh3)4, 1,3-dimethylbarbituric acid (iv) 
HOAt, PyAOP, DIPEA (v) Fmoc-Lys-OH, HBTU, DIPEA (vi) 40% piperidine in DMF (vii) TFA, 
ethanedithiol, TIPS, water 
 
Using this methodology, Vederas and co-workers were able to form multiple lanthionine 
rings on resin to give the first SPPS of a lantibiotic, lactocin S.135 
 
Taking this methodology, a step further, A. Tabor and co-workers synthesised the 
overlapping ring system of nisin rings D and E (63, Scheme 1-11). This required the 
synthesis of a second orthogonally protected lanthionine residue with silyl based protecting 






Scheme 1-11: SPPS of nisin rings D and E 
Reagents and conditions: (i) 1. incorporation of lanthionine (52) with HOAt, PyAOP, DIPEA, 
DMF 2. Fmoc-His(Trt)-OH, HBTU, DIPEA (ii) 1. incorporation of lanthionine (60) with HOAt, 
PyAOP, DIPEA (iii) 1. 40% piperidine in DMF 2. Pd(PPh3)4, 1,3-dimethylbarbituic acid, 3. 
HOAt, PyAOP, DIPEA (iv) 1. TBAF 2. HOAt, PyAOP, DIPEA 3. Fmoc-Lys(Boc)-OH, HBTU, DIPEA 
followed by Fmoc deprotection and cleavage from resin 
 
Linear peptide (61) was synthesised using standard Fmoc SPPS methodology. The allyl ester 
and Alloc protecting groups were then selectively removed and the peptide cyclized to give 
the ring E analogue (62). This was followed by chain extension and selective removal of the 
orthogonal Teoc and TMSE groups of incorporated (60), allowing a second on-resin 
cyclisation to take place to form ring D. Further chain extension and resin cleavage afforded 
(63). 
 
1.3.4 Biomimetic Michael Additions 
 
An early attempt at a biomimetic route to lanthionine used the Michael addition of 
cysteine residues to dehydroamino acids, but this proved unsuccessful with poor stereo 
control of the addition.136 More recently, Avenoza and co-workers reported the first 
asymmetric Michael addition route to lanthionine and methyllanthionine (Scheme 1-12).137 
They used chiral dehydroamino acid derivatives (64) that acted like chiral auxiliaries 





S) as well as the required (S, R) and (S, S) optically active isomers of methyllanthionine. The 
strongly acidic conditions for the removal of the chiral group means this route is not 
suitable for incorporating acid labile protecting groups. 
 
Scheme 1-12: Asymmetric Michael addition route to lanthionine  
 
Biomimetic Michael additions have proven more successful when performed with a 
dehydro and a cysteine residue that are already installed in a linear precursor peptide. By 
using this strategy single rings of nisin,138 subtilin139,140 and an analogue of ring B of 
epidermin141 have all been synthesised, notably, with the correct stereochemistry at the 
newly formed chiral centre. The excellent diastereoselectivity of these Michael additions 
suggests the linear sequence is pre-organised in a way that aids the regio and 
diastereoselectivity of these reactions. However, when cyclisation was attempted on more 
complex peptides, either with multiple dehydro residues,140 when cyclising more than one 
ring142 or with non-lantibiotic sequences,143 the selectivity was lost suggesting a cyclase 
enzyme is still required for longer sequences. 
 
1.3.5 Ring Opening Methods to Synthesise Lanthionine 
 
The Vederas group successfully synthesised lanthionine and methyllanthionine derivatives 
using a synthetic route that relies on the ring opening of aziridine derivatives (69, 71, 







Scheme 1-13: Ring opening of aziridine derivatives 
Reagents and conditions: (i) allyl chloride, NaHCO3 (ii) MsCl, Et3N, 0 °C (iii) 3:3:1 
TFA/DCM/MeOH, 0 °C. (iv) DNs-Cl, Na2CO3 (v) Fmoc-Cys-OH, BF3.Et2O, 0 °C (vi) thioglycolic 
acid, DIPEA (vii) alloc chloride, DIPEA (viii) p-NBOH, p-TsOH (ix) TrtCl, Et3N (x) MsCl, Et3N, 
reflux (xi) 3:3:1 TFA/DCM/MeOH, 0 °C, p-NZCl, Na2CO3, (xii) Fmoc-Cys-OH, BF3.Et2O 
 
Using this methodology, with a cysteine nucleophile, the Vederas group were able to 
synthesise the naturally occurring methyllanthionine diastereoisomer with both allyl/Alloc 
protecting groups and p-nitrobenzyloxycarbonyl (p-NZ)/p-nitrobenzyl (p-NB) protecting 
groups from two differentially protected aziridines both derived from D-Thr.144  
 
1.3.6 Synthesis of Lacticin 3147 
 
With the two methyllanthionine and lanthionine derivatives in hand, the group went on to 
synthesise both components of lacticin 3147 by SPPS.  The synthesis of lacticin 3147 A1 (35) 
is described below ( 
Scheme 1-14).  
 
Standard Fmoc methodology was used to synthesise linear peptide (74) with both 
methyllanthionine residues incorporated. The first ring was synthesised by deprotection of 
the allyl/Alloc protecting groups using Pd(PPh3)4 followed by Fmoc deprotection and 
cyclisation using PyBOP and HOBt. Fmoc-Leu-OH was then installed and the second ring 
was formed by removing both NZ and NB groups with 6M SnCl2 in HCl and followed by 
cyclisation using the same conditions as before. Lanthionine (52) was then installed using 
standard Fmoc methodology and the chain was again extended to give (77). Repeating the 
cyclisation conditions for the first ring enabled the formation of the third and the chain was 
again extended by another three residues to give (79). The N-terminus pentapeptide (80) 





a short thioether bridge. The two final fragments (80) and (79) were then coupled using 
fluoro-N,N,N’,N’-tetramethyl formamidinium hexafluorophosphate (TFFH) and the final 
sequence was cleaved from the resin to give lacticin 3147 A1 (35).  
 
The Vederas group also synthesised a ring-expanded, carbocyclic analogue of lacticin 3147 
A2 (36), replacing the three thioether bridges with alkene bonds using on-resin ring-closing 
olefin metathesis.145 The resulting carbocyclic peptide showed no biological activity. The 
oxa-analogue of this peptide has also been synthesised using protected oxa-lanthionines 








Scheme 1-14: SPPS of lacticin 3147 A1 
Reagents and conditions: (i) 1. Pd(PPh3)4, PhSiH3, 2. 20% piperidine 3. PyBOP, HOBt, 
NMM 4. PyBOP, HOBt, Fmoc-Leu-OH (ii) 1. SnCl2, HCl 2. 20% piperidine 3. PyBOP, HOBt, 







1.3.7 In vitro Engineering  
 
Biotransformations provide yet another tool for synthesising lantibiotics. This approach 
involves the isolation of the cyclase and dehydration enzymes from bacteria which can then 
be used on linear peptides in vitro. The advances in genome sequencing over the past 
decade have greatly improved the feasibility of this method, making it relatively easy to 
search genomes for the biological machinery we need such as conserved elements of 
dehydratase enzymes. This approach of ‘genome mining’ has also been successfully used to 
discover new lantibiotics such as Lichenicidin.147 For a more in depth discussion of both in 
vivo and in vitro engineering see reviews by Ross and Vederas,148 Field149 and more recently 
Kuipers and co-workers.150 These methods are also discussed in wider reviews by van der 
Donk and Paul151 and Tabor.127,152  
 
Van der Donk and co-workers were able to use this method to produce lacticin 481 and 
analogues by feeding in linear sequences such as (81) to an isolated LctM enzyme which 
carried out both dehydration of Ser and Thr residues and cyclisation reactions (Scheme 
1-15).153,154 Recognition of the non-natural sequences by LctM was dependant on 
recognition of the leader peptide which was attached by click chemistry. They were also 
able to feed in non-proteinogenic amino acids to generate slightly more potent analogues 
of lacticin 481 (34, Scheme 1-15).155 Similar studies have been carried out with the 
modification enzymes of nisin with both the dehydration process156 and the cyclisation 
process157 being reconstituted in vitro. More recently van der Donk and Yang were able to 







Scheme 1-15: In vitro mutasynthesis of lacticin 481 (34) and analogues indicated by arrows 
 
1.3.8 In vivo Engineering    
 
The genetically encoded nature of lantibiotics means they are easily amenable to genetic 
engineering compared to other classes of antimicrobials. Mutagenesis studies via site 
directed or random mutagenesis can be used to generate analogues of wild type 
lantibiotics with improved physiochemical properties and improved activities. This 
approach has been fairly successful for nisin for which mutants with improved activity 
against both Gram negative bacteria159 and Gram positive bacteria160 have been generated. 
Some notable studies featuring hinge region mutants of nisin are highlighted below but for 
a recent review of nisin bioengineering see Field et al.161  
  
There are several difficulties encountered with this approach which include mutations that 
impact the bacteria’s biosynthetic pathway, where mutant intermediates are no longer 
recognised, decreasing production levels of lantibiotic. In some cases, mutants can be 
produced that are toxic towards bacteria expressing the lantibiotic. 
 
The hinge region of nisin (residues 20-22; NMK) has been subjected to a significant number 
of mutation studies. Huan and co-workers used site directed mutagenesis to produce nisin 
Z mutants with slightly improved activity against Gram negative bacteria (left, Figure 





mutants to have good activity against S. dysenteriae, Salmonella, P. aeruginosa and other 
Gram negative bacteria whilst wild type nisin Z showed no growth inhibition. Field and 
co-workers used saturation mutagenesis to generate a large bank of nisin A hinge mutants 
several of which were found to have increased activity against specific Gram positive 
pathogens.160 Three of these are pictured in Figure 1-15 (centre) and these were shown to 
have 100% increased activity, compared to nisin A, against S. aureus ST528 as assessed by 
well-diffusion assays. 
 
A mutant, M21V (centre, Figure 1-15), subsequently renamed, nisin V, showed increased 
activity against several significant pathogens and was taken on for further study. Nisin V 
was shown to be two-fold more potent, compared to nisin A, against several MRSA and 
VRE indicator strains as evaluation by broth micro-dilution assays.162 The same group went 
on to carry out site-saturation mutagenesis of all three hinge residues to generate a further 
library of novel mutants.163 Screening of this library indicated that small, chiral amino acids 
were preferential and building on this, two mutants, AAA and SAA, were rationally 
designed (right, Figure 1-15). These two mutants were shown to have improved activity, 
relative to nisin A, against all four strains of Gram positive bacteria used in agar diffusion 
assays but the effect was less pronounced in broth diffusion assays.  
 
Zhou et al.164 engineered an L. lactis strain to produce hinge region mutants of nisin to 
investigate how length of the hinge region affects activity. Shorter hinge region mutants 
showed greatly reduced activity against a range of Gram positive bacteria with their 
residual activity, in comparison to nisin A, dropped below 25%. Mutants with two extra 
amino acids were better tolerated with residual activity in the range of 25-50% compared 
to nisin A, apart from activity against S. aureus which dropped to 6%. Previous work in this 
group had shown that flexibility is important; mutants with proline-proline substitutions 
have greatly reduced activity165 which correlates well with the understanding of the mode 






Figure 1-15: Hinge region mutants of nisin with improved activity; mutants with improved 
activity against Gram negative bacteria (left);159 mutants with improved activity against 
specific Gram positive strains (centre);160 triple mutants showing improved activity against 
Gram positive bacteria in agar diffusion assays (right)163 
 
Using the same expression system in L. lactis, Zhou et al.,166 have recently looked at 
improving the ability of nisin to cross the outer membrane of Gram negative bacteria and 
hence improve nisin’s antibacterial activity against Gram negative bacteria. Ten different 
peptides known to be active against Gram negative bacteria, or sections of them, were 
fused onto the C-terminus of nisin or truncated versions (Figure 1-16). They were classed 
into 4 groups distinguished by their architecture: group 1 peptides consisted of Gram 
negative active peptides fused onto rings ABC, incorporating the hinge region of nisin; 
group 2 peptides consisted of Gram negative active peptides fused onto full length nisin; 
group 3 consisted of Gram negative active peptides fused onto full length nisin but with the 
last Dha residue left undehydrated as serine; group 4 consisted of peptides fused onto rings 
ABCDE of nisin with an additional serine-glycine linker. For group 3 peptides it was unclear 
whether the undehydrated Dha residue was intentional or as a result of a disrupted 
biosynthetic pathway. Many of the peptides synthesised were expressed poorly or 
degraded after expression which made obtaining meaningful amounts of the fused 
peptides challenging. Seven fused peptides were scaled up, purified and used in biological 







Figure 1-16: Nisin fragments fused with Gram negative active linear peptides 
 
The best result obtained (GNT16, 85) was from group two, with a truncated tail peptide of 
apidaecin 1b,167 an anti-Gram negative peptide with a mode of action dependant on 
translocation into the cytoplasm, fused onto the C-terminus of full length nisin. The fused 
nisin was over twice as effective at killing E. coli but the modification had a detrimental 
effect on the activity against the Gram positive indicator strain used (L. lactis) indicating 
pore formation was probably reduced. This reduction could also have been occurring with 
the E. coli strain but was counteracted by improved ability to cross the outer membrane. 
GNT1 (83), GNT16SG (86), GNT7 (85) from groups 1 and group 4 did not have improved 
activity against E. coli but did retain some activity against L. lactis.  
In addition to the naturally occurring analogues, the analogues produced from 
bioengineering provide us with good substrates for structure activity relationship studies 
though there is still much work to be done on deciphering how these structural changes 





1.4 Modification of Peptides using Click Chemistry  
 
The development of lantibiotics as clinically relevant compounds entails specific synthetic 
challenges but alongside this there are several wider barriers to the study and manipulation 
of peptides and proteins that all peptide chemists face. Peptides contain a variety of 
functional groups including amines, amides, alcohols, thiols and carboxylic acids. This 
means selectivity is a problem when modifying a peptide and with so many functional 
groups present several competing reactions can occur. A number of different tools have 
been developed in order to carry out regio- and chemoselective modifications of peptides 
both in vitro and in vivo168 and one of the most significant and successful methods of these 
has been click chemistry. 
 
Click chemistry was first reported in 2002 by Sharpless169 and by Meldal170 as the use of 
copper (I) to catalyse a 1,3-dipolar-cycloaddition between an azide and an alkyne; a 
reaction that had previously required high temperatures and pressures.171 Meldal also 
showed it was a reaction suitable to be performed on peptides still attached to solid 
supports with alkynes at the N-terminus. Click chemistry was later defined with a wider 
scope by Kolb, Finn and Sharpless as a reaction that “must be modular, wide in scope, give 
very high yields, generate only inoffensive by-products that can be removed by non-
chromatographic methods, and be stereospecific (but not necessarily enantioselective). 
The required process characteristics include simple reaction conditions (ideally, the process 
should be insensitive to oxygen and water), readily available starting materials and 
reagents, the use of no solvent or a solvent that is benign (such as water) or easily 
removed, and simple product isolation.”172 
 
 
Scheme 1-16: Huisgen 1,3-dipolar-cycloaddition 
 
Click chemistry has been widely employed throughout biomedical173 and materials 
science174 research and although click chemistry is now used as a broader term, the 
Huisgen 1,3-dipolar-cycloaddition is still considered to be the defining reaction. 
Modification of the reaction has included the use of different catalysts, copper free 





been used for protein modification, labelling peptides and proteins, identifying enzyme 
inhibitors, drug discovery and molecular probes. Bio-orthogonal, copper free click reactions 
are now enabling selective click reactions to be carried out within living systems.175 These 
tend to rely on strain-promoted alkyne-azide cycloadditions (Scheme 1-17). Nikic et al.176 
developed a procedure using click chemistry that enabled the labelling of cell-surface 
proteins in living mammalian cells. They used genetic code expansion technology177 to 
incorporate ring-strained alkynes or alkenes into the sequences of the protein of interest 
and then carried out click reactions at physiological conditions with dyes containing azide 
or tetrazine groups respectively.  
 
 
Scheme 1-17: Copper free click reaction with a strained cyclooctyne 
 
The success of click chemistry in peptide and protein modification can be attributed to mild 
reaction conditions and the inertness of the resulting triazole moiety which mimics an 
amide bond well (Figure 1-17) and increases stability and resistance to proteases. In 2013  
Valverde et al.178 showed that the systematic replacement of residues with triazoles or 
“triazole scanning” can be an effective way to identify novel therapeutic peptidomimetics 
with improved stability.  
 
 
Figure 1-17: Cis amide bond (left) mimicked by a 1,4-disubstituted triazole and a trans 








1.4.1 Click Chemistry for Manipulating Lantibiotics 
 
Slootweg et al.179 developed a useful method for functionalising WT nisin via click chemistry 
and were able to conjugate two different fluorescent reporter molecules, 
carboxyfluorescein and dansyl to the C-terminus of full length WT nisin with short PEG 
spacers (Scheme 1-18). Nisin contains only one carboxylic acid at the C-terminus and so 
regioselective modification is relatively straightforward; previous groups have also carried 
out fluorescent labelling at the C-terminus. However, amide coupling is not ideal; an excess 
of amine is required to prevent self-condensation with the side chain of one of nisin’s three 
lysine residues and when the desired amine is a fluorescent molecule or other biologically 
relevant compound this can be expensive. An excess of amine can also make purification 
more difficult. Slootweg and co-workers reasoned that an inexpensive amine with a 
terminal alkyne could be used in excess to install a more reactive bio-orthogonal ‘handle’. 
This allows for stoichiometric coupling with a large number of functionalised azides in this 
case, fluorescent reporter molecules.  
 
Commercial sources of nisin typically contain only 2.5% nisin, 22.5% dairy proteins and 75% 
NaCl and so it was first necessary for Slootweg and co-workers to purify WT nisin using a 
previously published protocol of theirs.180 With purified full length WT nisin in hand they 
coupled an inexpensive alkyne handle, propargylamine, onto the C terminus to give (87) 
and then carried out a click reaction with a dansyl fluorescent label modified with a short 
PEG linker and an azide (88). Using this method Slootweg and co-workers were also able to 
prepare a nisin dimer using a bis-azide with a short PEG linker. The resulting conjugates 







Scheme 1-18: Using click chemistry to attach a fluorescent label to nisin 
 
With the aim of producing more stable ring systems of lantibiotics, Slootweg et al.181 have 
also investigated dicarba analogues of nisin and have shown that replacing lanthionine with 
dicarba bridge in ring AB analogues has minimal impact on binding to lipid II. Prior to this 
they also synthesised dicarba analogues of the overlapping ring system DE where alkene 
bridges replaced lanthionine (77, Scheme 1-19).182 These analogues of the C-terminus did 
not show any biological activity on their own but Slootweg and co-workers also conjugated 
the DE C-terminus mimic to a lipid II binding motif to see if this would facilitate pore 
forming or antibacterial activity (Scheme 1-19).183 Rings ABC of nisin were first obtained 
from a chymotrypsin digest of a commercial preparation of WT nisin (Figure 1-18) and using 
the same conditions as before they coupled propargylamine on to the C-terminus of the 
fragment to give (90). 
 
 
Figure 1-18: Cleavage sites of nisin for chymotrypsin (orange), trypsin (pink), and CNBr (red) 






Click chemistry was again used to conjugate (90) the previously synthesised DE carba 
analogue (91). The conjugate did not show pore forming activity in experiments with large 
unilamellar vesicles (LUVs) encapsulating carboxyfluorescein (CF) but it did retain lipid II 
binding capabilities and performed similarly to nisin 1-20 in antimicrobial assays. This 
suggested the modified C-terminus, whilst not being biologically active itself, did not 
disrupt the activity of the nisin fragment.  
 
 
Scheme 1-19: Click chemistry used to synthesise nisin hybrids with dicarba analogue tails 
 
Koopmans et al.98  have also looked at the production of more stable nisin analogues by 
replacing the entire C-terminus and hinge region with lipid tails (Scheme 1-20). By scaling 
up the enrichment and trypsin digest protocol as previously published by Slootweg, they 
obtained good amounts of WT AB rings of nisin (27). They then used a huge excess of 
amine lipids and otherwise standard amine coupling conditions to attach the smaller lipid 
amines directly onto the C-terminal lysine. If less than 50 equivalents were used, they 
found that the side chain amine of lysine would couple with the lysine carboxylic acid to 
give an unwanted cyclised side product. With larger, bulkier lipids they encountered 
solubility/miscibility problems and were unable to use such a large excess of reagents. They 
circumvented this problem by coupling a small azide “handle” to AB rings (100) and then 







Scheme 1-20: Lipid analogues of nisin 
 
Compounds (96-98) and (104) were found to have antibacterial activity comparable to that 
of nisin against clinically relevant, VRE and MRSA strains of bacteria (Table 1-5) and in 
serum stability assays were found to remain intact at a much higher rate than nisin. The 
analogues did not cause fluorescence leakage in lipid II spiked LUV assays suggesting they 
do not form pores like nisin but it was shown that lipid II binding was conserved as they 
antagonised pore formation by nisin in competition assays. Haemolysis assays suggested 
there was a small increase in lytic activity towards human blood cells compared to nisin. 
 
 
Table 1-5: Antibacterial activity of nisin analogues obtained by Koopmans et al.98 
 
One considerable drawback of incorporating large alkyl groups is that aqueous solubility of 
these hybrids is greatly reduced. This could cause significant problems for these 
  MIC (µg/mL)  
Compound MRSA USA300 MRSA WKZ2 VRE E155 
96 16 16 8 
97 64 32 4 
98 16 16 8 
104 8 8 8 





compounds if used in a clinical setting; poor aqueous solubility is often associated with 
slow drug absorption and inadequate bioavailability. It will be interesting to see how these 
compounds are further optimised and their mode of action deciphered. 
 
Breukink and co-workers used the lipid II binding action of nisin 1-12 conjugates to revive 
activity of vancomycin against VRE.184 Vancomycin resistance has been shown to be 
conferred through the substitution D-Lac for the terminal D-Ala residue in lipid II resulting 
in a decreased level of vancomycin binding.185 It was thought that this could be 
compensated for by conjugating another lipid II binding moiety, simultaneously binding 
two separate sites of the target to increase overall binding affinity. Computer modelling 
was used to predict the optimal binding points and connectivity lengths between nisin 1-12 
and vancomycin. Click chemistry was used to produce a set of three conjugates. In MIC 
assays the best conjugate was shown to be about 40 times more active than either of its 
components.  
 
Breukink went on to use the most successful vancomycin-alkyne adduct (105, Scheme 1-21)  
in a different study to investigate whether conjugating vancomycin to a linear, cationic 
AMP could increase the selectivity and potency.186 As discussed previously, linear AMPs 
disrupt bacterial membranes and form pores similar to nisin but via different mechanisms, 
notably, without binding lipid II. This tends to result in lower potency and less selectivity 
which both contribute towards toxicity for mammalian cells. Vancomycin adduct (105) was 
conjugated using click chemistry with magainin 2 modified with an N-terminus lysine 
bearing an azide side chain (106). A previously optimised analogue of magainin 2 was also 








Scheme 1-21: Using vancomycin to improve selectivity and potency of magainin 
 
The conjugates (108, 109) showed improved activity compared to that of magainin 2 and its 
analogue alone but did not perform better than vancomycin against Gram positive bacteria 
(Table 1-6). However, against VRE the conjugates did perform better than vancomycin. 
Additionally, the group also synthesised a nisin 1-12 conjugate with the optimised magainin 
2 analogue (111, Scheme 1-22) which did not perform as well as the best vancomycin 
conjugate (109) and this was attributed to the weaker binding of nisin 1-12 to lipid II 








Scheme 1-22: Nisin 1-12 conjugated with the optimised magainin 2 analogue 
 
 MIC (µg/mL) 
Compound MRSA (15A763) VRE (15A799) VSEa (15A797) 
vancomycin 0.4 128 0.5 
106 >256 256 256 
107 256 64 128 
108 32 256 16 
109 2 16 4 
111 - 32 64 
 
Table 1-6: Antibacterial activity of vancomycin and nisin conjugates obtained by Breukink186 
aVSE: vancomycin susceptible Enterococci 
 
 
1.5 Aims and Objectives 
 
AMPs have significant potential as therapeutics but are held back from clinical application 
by poor pharmacokinetics, poor drug-like properties and an incomplete understanding of 
their mechanisms of action and selectivity. Various strategies have been employed to 
improve their drug like properties with varying success. Lantibiotics have the additional 
synthetic challenge of their thioether bridges which has been tackled using several 
synthetic and biosynthetic approaches.  
 
The aim of this project was to prepare simplified mimics of nisin with improved solubility 
and stability with an accessible synthetic route. The design of simplified analogues centred 
around the removal or replacement of synthetically challenging lanthionine residues and 





to design mimics with conserved AB ring moieties. The C-terminus, however, was replaced 
with simpler, linear pore forming peptides which were designed with a non-peptide hinge 




Figure 1-19: Design of simplified analogues of nisin 
 
It was proposed that rings AB could be obtained from a digestion of WT commercially 
available nisin as reported by Slootweg et al.180 and, in addition, this moiety could also be 
simplified further by using SPPS methodology developed with the Tabor group.133,187,188 
Using this methodology, via the synthesis of an orthogonally protected lanthionine residue, 
the methyllanthionine of WT nisin could be replaced with lanthionine and the unstable 
dehydro residues could be replaced with more stable analogues such as their biosynthetic 
precursors, serine and threonine. Analogues of rings AB produced this way will be valuable 
in their contribution towards hybrid lantibiotics but also in studies examining the molecular 
basis of lipid II binding.  
 
Modifications to the structure of nisin may have a negative impact on biological activity, 
however, this could be balanced by the improvement in pharmacokinetic properties of the 
















2 Lanthionine Synthesis 
 
This chapter describes the synthesis of orthogonally protected, target lanthionine (60, 
Figure 2-1) that will be incorporated into analogues of rings AB of nisin via SPPS using the 
procedure as outlined in Chapter 1.3, Scheme 1-6. This analogue had previously been 
synthesised within the Tabor group by Mothia to enable the synthesis of an analogue of the 
overlapping ring system of nisin rings DE (Scheme 1-11).189 The S,R diastereomer was 
synthesised in accordance with WT nisin which contains only S,R methyllanthionine and 
lanthionine. Alongside the transient Fmoc protecting group, another set of protecting 
groups is required to enable the on-resin cyclisation that forms the characteristic thioether 
bridge. In this case, silyl-based protecting groups were chosen for the protection of the 
amino and carboxylic acid moieties, (trimethylsilyl)ethoxycarbonyl (Teoc) and 
trimethylsilylethyl (TMSE) respectively, as they could be easily removed under mild 
conditions and at a neutral pH using a source of fluoride ions such as TBAF (Figure 2-1).  
 
 
Figure 2-1: Orthogonally protected (Teoc, TMSE/Fmoc) lanthionine 
 
2.1 Published Procedure 
 
The route designed by Mothia and Tabor used Boc-D-Ser(Bn)-OH (112) and L-cystine (117) 
as starting materials (Scheme 2-1). This had been previously carried out on a small scale to 






Scheme 2-1: Synthesis of (Teoc, TMSE/Fmoc) lanthionine (60); route and yields by Mothia189 
Reagents and conditions: (i) 2-(trimethylsilyl)ethanol, DMAP, DCC (ii) 1. Pd/C 2. TFA (50%) 
(iii) Ph3MeCl, NEt3 (iv) PPh3, DEAD, MeI, -2 °C (v) HClO4, t-butyl acetate (vi) FmocCl, NMM 
(vii) 50% TFA, 50% CH2Cl2 (viii) p-TSA, TceOH, 100 °C, (ix) βME, PPh3, H2O (x) Cs2CO3, 0 °C (xi) 
1. 10% TFA, 5% TES, 2. NaHCO3, Teoc-ONSu, (xii) NH4OAc, Zn dust 
 
This route was initially repeated on a small scale (2 g) and was later adapted to suit a larger 
scale (25 g). Reagents and purification methods were modified to ease the difficulties 
associated with handling large scale reactions (Chapters 2.1.1-2.1.3). To optimise the 






2.1.1 Synthesis of β-Iodoalanine (116) 
 
Synthesis of protected β-Iodoalanine (116) was first attempted using the Mothia and Tabor 
route. This began with the esterification of commercially available Boc-D-Ser(Bn) (112) with 
2-(trimethylsilyl)ethanol (TMSEOH) using DMAP and DCC to give Boc-D-Ser(Bn)-OTMSE 
(113) in good yield (83%). This was followed by a two-step deprotection procedure. The 
benzyl group was removed by hydrogenation using a palladium on carbon catalyst (10% 
loading) and the crude product was then treated with TFA, removing the Boc group, to give 
H-D-Ser-OTMSE (114) in good yield (86%). Tritylation of the amine was then carried out 
using basic conditions and trityl chloride. As previously mentioned, the trityl group is an 
important transient protecting group, conserving the stereochemistry at the alpha carbon. 
Trt-D-Ser-OTMSE (115) was then converted to protected β-iodoalanine (116) using a 
Mitsunobu type reaction.  
 
 
Scheme 2-2: Synthesis of protected β-Iodoalanine (116) 
Regaents and conditions: (i) 2-(trimethylsilyl)ethanol, DMAP, DCC (ii) 1. Pd/C 2. TFA (50%) 
(iii) Ph3MeCl, NEt3 (iv) PPh3, DEAD, MeI, -5 °C 
 
Low yields of around 20-30% were initially obtained in the Mitsunobu reaction which was 
partly attributed to the reaction not going to completion. Analysis by TLC showed starting 
material (115) was still present in the reaction mixture after 6 h. Longer reaction times 
were not feasible as the product needed to be synthesised and purified in the same day to 
avoid decomposition of the product and so the reaction was instead carried out at a higher 
concentration using a smaller volume of solvent. Changing the initial concentration of 
Trt-D-Ser-OTMSE (115) from 0.47 M to 0.94 M was shown to push the reaction to 
completion as visible by TLC analysis. Formation of aziridine (125) was also identified as a 
reason for low yields and it was believed this was being formed both during the reaction 
and during purification (Scheme 2-3). This unwanted side product had previously been 
identified within the group it had been shown that the aziridine can be attacked by iodide 





identify as it gave a bright pink colour to the solution (presumably attributed to an 
iodo- species not the aziridine) and the structure was confirmed by NMR analysis. To 
minimise this problem, the reaction mixture was kept below -2 °C throughout the course of 
the reaction using a salt and ice bath and care was taken to carry out the purification 
process as quickly as possible using reduced pressure at room temperature to concentrate 
the column fractions in vacuo. By using more concentrated reaction conditions and carrying 




Scheme 2-3: Aziridine formation and possible ring opening 
 
When the scale of this reaction was increased (1 g to 10 g), care was taken to add DEAD 
and MeI slowly as monitoring the reaction temperature showed addition of these reagents 
increased the temperature inside the reaction vessel by 10 °C. This was important to avoid 
due to formation of the aziridine and due to safety concerns as DEAD is known to be 
explosive at high temperatures.   
 
2.1.2 Synthesis of Protected Cysteine (122) 
 
Concurrently, protected cysteine (122) was synthesised from a stock of (Fmoc-Cys-OtBu)2 
(119) (custom synthesis by Oxygen Healthcare, Cambridge, UK). A solution of 50% TFA in 
CH2Cl2 was used to remove the tert-butyl groups which was followed by esterification of the 
disulfide (120) with trichloroethanol and p-toluenesulfonic acid (p-TSA). This was carried 
out under reflux, overnight using a Dean Stark trap to remove the water produced by the 
reaction. To avoid using the carcinogenic solvent benzene, as previously used by Mothia, 
the reaction was attempted using toluene but this significantly decreased the yield (45% 
from around 60%) and so benzene was used for all further reactions. The first step of the 
work up procedure required cooling of the reaction mixture to 0 °C and filtration to remove 





using two different solvent systems and the product was found to elute slowly over many 
column fractions. When the scale was increased to multigram amounts, this purification 
became impractical as it used many litres of mobile phase and required about 5-6 h. It was 
thought the difficulty was due to poor solubility of the product and so to take advantage of 
this, the product was instead added to an excess of MeOH and left in the fridge overnight. 
In the morning, the mixture could be filtered and washed with further portions of cold 
MeOH to give pure (121), as assessed by NMR, and column chromatography was avoided. 
This method of purification saved significant time and improved the yield to 87%. Care had 
to be taken to ensure all the acid had been removed otherwise the methyl ester was 




Scheme 2-4: Synthesis of protected cysteine (122) 
Reagents and conditions: (i) 50% TFA, 50% CH2Cl2 (ii) p-TSA, TceOH, 100 °C, (iii) βME, PPh3, 
H2O 
 
(Fmoc-Cys-OTce)2 (121) was then reduced using 2-mercaptoethanol (βME) to the thiol 
(122). Again, when the scale of this reaction was increased, purification using column 
chromatography was unsuccessful and the product (122) co-eluted with impurities as 
analysed by TLC and NMR. The conditions of Wright were then employed which used 
dithiothreitol (DTT) as the reducing agent (Scheme 2-5).190 Excess DTT, the oxidised 
by-product and excess base could be removed during the workup and column 
chromatography was again avoided. This procedure improved the yield from 76% to 92% 
and significantly decreased the time taken for this step. 
 
 







2.1.3 Coupling of Cysteine (122) and β-Iodoalanine (116) 
 
Coupling of the β-iodoalanine (116) and cysteine (122) was carried out in mild base at 
around 0 °C. Initially poor yields were obtained (30-40%) which were accounted for by the 
re-oxidation of thiol (122) to the unreactive disulphide (121), though this could be 
recovered during purification, and the decomposition of β-iodoalanine (116) to the 
aziridine as identified by a visible pink colour in the solution. Previously it has been shown 
that the ring opened regioisomer (126) of iodoalanine (116) can react with cysteine and 
form an unwanted regioisomer of lanthionine, norlanthionine.133,187 However, at low 
temperatures ring opening is believed not to occur and no nor-lanthionine was observed 
during NMR analysis of the impurities. The presence of water in basic conditions was also 
enough to remove the Fmoc group and the resulting product was also observed by LCMS in 
trace amounts. Yields were thus improved (to 56%) by lowering the temperature of the 
reaction to -5 °C to discourage aziridine formation and care was taken to ensure the 
reaction was kept as dry as possible with the use of molecular sieves. Caesium carbonate 
was also dried overnight, prior to use, in a desiccator under reduced pressure. 
 
 
Scheme 2-6: Coupling of the β-iodoalanine (116) and cysteine (122) followed by protection 
group manipulation to give protected lanthionine (60) 
Reagents and conditions: (i) Cs2CO3, -5 °C (ii) 1. 10% TFA, 5% TES, 2. NaHCO3, Teoc-ONSu (iii) 
NH4OAc, Zn dust 
 
A two-step reaction was used to remove the trityl group of coupled intermediate (123) 
under mild acidic conditions, necessary to avoid removing the silyl groups. The acid was 
removed during a workup step with sodium bicarbonate. The crude residue was 
re-dissolved in 1,4-dioxane and the Teoc group was added using Teoc-ONSu to give (124). 
Small amounts of TMSEOH were found to have eluted with lanthionine (124) during 
purification as identified by NMR and this was removed in vacuo. Deprotection of the Tce 
group was carried out with zinc to give the orthogonally protected lanthionine (60) that 





2.2 Optimisation of Synthetic Route 
 
It was then investigated if it was possible to synthesise the desired lanthionine analogue 
with cheaper starting materials and a fewer number of steps. The overall scheme for the 
adapted route can be seen in Scheme 2-10. 
 
 
Scheme 2-7: Route to Trt-D-Ser-OTMSE using unprotected D-Serine as a starting material 
Reagents and conditions: (i) 1. TMSCl, NEt3, 2. MeOH, 3. Ph3MeCl, NEt3 (ii) EDCI, DMAP, 
TMSEOH 
 
Previously within the group there had been success using a “one-pot” procedure that used 
trimethylsilyl chloride to temporarily protect the alcohol and acid group of D-serine (127) 
ensuring tritylation only occurred at the amine.191 However, it had also been noted that this 
was not a reliable reaction and Trt-D-Ser (128) was recovered with 38% yield using this 
method.  
 
With Trt-D-Ser (128) in hand, the next step was to esterify the acid with TMSEOH. Amino 
acids can be esterified using standard Fischer conditions192 (eg H2SO4, reflux) or converting 
first to the acid chloride with thionyl chloride. In this case, acidic conditions needed to be 
avoided due to the acid lability of the trityl group. Steglich conditions193 (DCC, DMAP) could 
also be employed but without protection of the hydroxyl group a large excess of alcohol 
would be required to avoid self-condensation and polymerisation. Taking this into account, 
an excess of TMSEOH (>10 equivalents) was used to esterify Trt-D-Ser (128), forming the 
TMSE ester (115) in good yield (69%). Excess TMSEOH was collected during purification and 
reused.  
 
This route to Trt-D-Ser-OTMSE (115) had an overall yield of 26% over two steps which was 
lower than the original route by Mothia of 35% over three steps. However, this is balanced 
by a shorter, quicker, route and considerably cheaper starting material of D-serine; £28.70 
for 5g from Sigma Aldrich compared to £150 for Boc-D-Ser(Bn). There is also potential to 






Limited availability of Fmoc-Cys-OtBu (119) meant that the route to thiol (122) needed to 
be reassessed. Previously Fmoc-cystine (120) had been synthesised via tert-butyl 
protection of cystine (117) using perchloric acid and tert-butyl acetate (Scheme 2-8). 
 
 
Scheme 2-8: Previously used route to Fmoc-cystine (106)189 
Reagents and conditions: (i) HClO4, tert-butyl acetate (ii) FmocCl, NMM (iii) 50% TFA, 50% 
CH2Cl2 
 
Wright improved the yields of tert-butyl protection to 93% and used Fmoc succinimide to 
give a higher yield of 61% for Fmoc protection190 but it remained undesirable to use 
perchloric acid on a medium to large scale given its toxicity and potential for explosion. A 




Scheme 2-9: Fmoc protection of L-cystine (117) 
 
A handful of groups had reported the Fmoc protection of cystine. The conditions of 
Kirichenko et al.194 were first employed which used sodium carbonate and Fmoc-Cl at -10 
°C. Whilst the reaction appeared to go to completion as shown by TLC analysis, problems 
were encountered during the workup. Despite reporting to require only a simple filtration 
step, a 5% yield was obtained. Boger et al.195 had previously protected cystine using sodium 
hydroxide and Fmoc-Cl in THF and water and here the procedure was employed 
successfully (Scheme 2-9). After TLC analysis indicated the reaction had gone to completion 
THF was removed in vacuo and the reaction mixture was acidified using 1.0M HCl. The 





and left in the fridge overnight. This mixture was again filtered and washed with further 
portions of cold ethyl acetate to give clean Fmoc protected cystine (120) as analysed by 
NMR. 
 
Tce protection and coupling and replacement of the trityl group was carried out as before. 
When the final deprotection was carried out on a larger scale it was thought that the final 
product (60) could be purified by recrystallization and several conditions were attempted 




Scheme 2-10: Optimised route for the medium scale synthesis of lanthionine 
Reagents and conditions: (i) 1. Trimethylsilyl chloride, 2. MeOH 3. NEt3, Ph3CCl (ii) TMSEOH, 
DMAP, DCC (iii) PPh3, DEAD, MeI, -10 °C (iv) NaOH, Fmoc-Cl (v) pTSA, TceOH, 100 °C, 
(vi) DTT, NEt3 (vii) Cs2CO3, 0 °C (viii) 1. 10% TFA, 5% TES, 2. NaHCO3, Teoc-ONSu, (ix) 
NH4OAc, Zn dust 
 
This route was carried out on scales up to 190 mmol, 25 g of starting materials, with an 




Orthogonally protected lanthionine (60) was initially synthesised using a previously 





incorporation into ring AB analogues of nisin with an overall yield of 5% from Boc-D-Ser(Bn) 
(112) and 10% from (Fmoc-Cys-OtBu)2 (119). To enable large scale synthesis, adjustments to 
the reactions conditions and purification procedures were required. Flash column 
chromatography was avoided in two steps which made the route to intermediate cysteine 
(122) more viable for medium and large scale synthesis and increased the overall yield from 
(Fmoc-Cys-OtBu)2 (119) to 17%. This was carried out on 20-25 g of starting materials to give 
about ~250 mg of lanthionine (60). 
 
Investigations into the use of cheaper starting materials proved successful. The number of 
steps to protected lanthionine were significantly reduced, decreasing the time required for 
synthesis and avoiding the potentially hazardous steps of large scale hydrogenation and 
use of perchloric acid whilst also using significantly cheaper starting materials. This route 
was also carried out using 20-25 g of starting materials to give 350 mg of lanthionine (60) 
with an overall yield of 9% from cystine (117) and 4% from D-serine (127) with room for 
further optimisation. This is a significant improvement from the previously used route of 
























3 Synthesis and Preparation of WT Rings AB of Nisin and 
Analogues  
 
This chapter describes the SPPS of simplified analogues of rings AB (residues 1-12) and the 
preparation and purification of WT rings AB from a commercial preparation of nisin. These 
are intended for use in lipid II binding studies and in hybrid lantibiotics with simpler, linear, 
pore forming peptides. 
 
3.1 Target Analogues 
 
To simplify the structure of rings AB, all analogues (129-131, Figure 3-1) were designed to 
contain only lanthionine in comparison to WT rings AB (93) which contains both lanthionine 
and methyllanthionine. It was anticipated that this modification would be well tolerated 
due to the nature interaction between lipid II and rings AB as it has been shown to rely on 
hydrogen bonding of the backbone amides.125 In addition, mutacin I, a structurally related 
analogue of nisin contains only lanthionine in its AB ring system and shows good binding to 
lipid II suggesting methyllanthionine is not essential for activity.196  
 
The analogues were simplified further by replacing the dehydro residues of WT rings AB 
with more stable residues. There is good literature precedence to suggest these 
substitutions would have minimal impact on the binding of rings AB to lipid II: random 
mutagenesis studies of rings AB suggested modifications of ring A are well tolerated;197 
Chan et al.93 were able to isolate a mutant of nisin with Dha5 substituted with alanine 
which had little impact on the activity inhibiting growth of Lactococcus lactis and 
Micrococcus luteus; Dhb2 of nisin z was replaced with Ser, Ala and Val and the mutations 
were found to have little impact on the MIC (all remained under 5 nM compared to nisin, 
3.3 nM) with only slightly reduced activity against lipid II-containing liposomes.198  
 
The first target analogue (129) was designed using the biosynthetic precursors, serine and 
threonine, as mimics for dehydroalanine and dehydrobutyrine respectively. Serine and 
threonine offer some improvement in stability and, as commercially available residues, are 
significantly easier to incorporate by SPPS into nisin ring analogues than their dehydrated 
counterparts. As polar amino acids replacing hydrophobic amino acids it is likely they would 
also increase the aqueous solubility of rings AB and any hybrid peptides the fragment is 






The second analogue (130) was designed with the saturated counterparts, alanine and 
aminobutyric acid (Abu), replacing dehydroalanine and dehydrobutyrine which are again, 
much easier to incorporate and would significantly improve the stability of rings AB. 
 
Target analogue (131) was designed to incorporate α-Aminoisobutyric acid (Aib), a known 
α-helix inducer and stabiliser199 which is found in several membrane active peptides such as 
alamethicin.200 Increased helicity is attributed to the restriction in the range of accessible 
backbone conformations of the peptide and it would be interesting to see what effect this 
residue would have on the conformation of rings AB and the impact on binding to lipid II. 
 
Finally, it was necessary to obtain WT rings AB (93) from the enrichment of crude nisin and 
trypsin digestion as described by Slootweg et al.180 This will be required as a control for 













3.2 Peptide Synthesis 
 
Standard Fmoc based SPPS protocol was used throughout peptide synthesis with Nα-Fmoc 
protected amino acids and permanent Boc/tBu protecting groups. Fmoc deprotection was 
carried out with 40% piperidine, and uronium based HOAt and PyAOP were used as 
coupling reagents with DIPEA as a base as they have been reported to ensure high yielding 
reactions and reduce racemisation during coupling and cyclisation.201,202  
 
A low loading resin, Fmoc-Lys(Boc)-NovaSyn, 0.20 mmol g-1 was used to avoid cross-linking 
between two complementary functional groups of different peptides on the same resin 
during the cyclisation, effectively reducing the local concentration. The low loading also 
helps prevents aggregation of the peptide during the synthesis. Reverse phase high 
performance liquid chromatography (HPLC) was used for purification of all peptides.  
 
3.3 Ring B Analogue (138) 
 
Before attempting synthesis of the double ring analogues (129-131) the synthesis of ring B 
was first attempted to check the SPPS protocol (Scheme 3-1). 
 
Synthesis began by first deprotecting the pre-loaded, Fmoc protected residue (132) using a 
solution of 40% piperidine in DMF. After every Fmoc deprotection the resin was manually 
washed with 6 fresh aliquots of DMF. Washing was followed by coupling orthogonally 
protected lanthionine residue (60) which had been “pre activated” by dissolving in a 
solution of DIPEA, HOAt and PyOAP in DMF and left for 5 min before addition to the resin. 
Couplings were left for two hours to ensure the reaction had gone to completion after 
which the syringe was evacuated and the resin was washed with 4 fresh aliquots of DMF. 
Fmoc deprotection of (134) was carried out as before and this was followed by coupling 
Fmoc-Gly-OH. Sequential Fmoc deprotection and proline coupling gave linear peptide 
(135). The resin bound intermediate (135) was then treated with TBAF to remove the silyl 
groups of the lanthionine residue. The Fmoc group was likely to be removed by TBAF but 
Fmoc removal was also carried out to ensure complete deprotection. Cyclisation to form 
resin bound ring B (137) was carried out using the standard coupling conditions of DIPEA, 
HOAt and PyAOP. The peptide was then cleaved from the resin using a standard TFA 
cleavage procedure to give (138). The crude peptide was purified using reverse phase HPLC 





purification on a small scale as the crude HPLC chromatogram looked reasonable at this 
stage (Figure 3-2). 
 
 
Scheme 3-1: Synthesis of ring B of nisin (138) 
Reagents and conditions: (i) 40% piperidine in DMF (ii) incorporation of lanthionine (60) 
with HOAt, PyAOP, DIPEA (iii) standard Fmoc SPPS protocol using HOAt, PyAOP as 
activators to build up chain (iv) TBAF followed by 40% piperidine (v) HOAt, PyAOP, DIPEA (vi) 










Figure 3-2: Crude HPLC chromatogram of ring B (Rt = 5.83 min); (top) 
Purified ring B HPLC chromatogram (Rt = 7.06) (bottom) 
 
3.4 Thr/Ser Analogue (129) 
 
With ring B analogue (138) in hand, the synthesis of the Thr/Ser analogue (129) was 
attempted (Scheme 3-2). Synthesis began by repeating the protocol used for ring B, 
however, instead of cleaving resin bound intermediate (137) the peptide chain was 





of leucine, serine and isoleucine were carried out and then followed by a TBAF 
deprotection of TMSE/Teoc and an Fmoc deprotection of intermediate (139). A second 
intramolecular cyclisation was carried out and then the last two residues threonine and 
isoleucine were coupled (140). The peptide was cleaved from the resin using a standard 
TFA cleavage procedure. 
 
Scheme 3-2: Synthesis of Thr/Ser analogue (129) 
Reagents and conditions: (i) standard Fmoc SPPS protocol using HOAt, PyAOP as activators 
to build up chain (ii) TBAF followed by 40% piperidine and then HOAt, PyAOP, DIPEA (iii) 
standard Fmoc SPPS protocol to incorporate lanthionine (60) and to build up chain (iv) TBAF 
followed by 40% piperidine and then HOAt, PyAOP, DIPEA (v) standard Fmoc SPPS to extend 
chain followed by standard TFA cleavage procedure 
 
Using this protocol, product (129) was visible by LCMS but a significant number of 
impurities were also present and it was not possible to isolate the product via reverse 
phase HPLC due to large amounts of impurities.  
 
To assess where impurities were being introduced the synthesis was repeated. Periodically, 
small batches of resin (around 2 mg) were taken from the syringe and were treated with 
cleavage solution (Scheme 3-3). This was then filtered, diluted with water and used directly 
for crude MS analysis to record the progression of the peptide synthesis. Although this 





sometimes none of the expected masses could be observed. This was possibly due to ion 
suppression caused by a high concentration of TFA in the sample which, in future, could be 
avoided by precipitating the cleaved peptide in ether and analysing the resulting 
precipitate to avoid excess amounts of TFA.203 Alongside the identified impurities, 
significant amounts of unidentified impurities could be seen on the LCMS mass spectra 
although some of this could be attributed to background noise due to the very low 
concentration of the samples. 
 
 
Scheme 3-3: Results of the mini-cleave experiments 
 
Synthesis was shown to proceed successfully until the addition of the second lanthionine 
residue. A peak for cyclised ring B (138) (m/z = 473.2) was visible in the proceeding 
cleavages whereby lanthionine or any of the proceeding residues had failed to couple to 
the N-terminus of the ring. This suggested that the terminal amine of ring B was likely to be 





Preliminary NMR work carried out by Dickman on (138) and WT nisin ring B has supported 
this idea, showing that the proline amide bond sits in a cis conformation which can cause 
the terminal amine to point towards the middle of the ring.204 The additional steric bulk of 
lanthionine could have also contributed to poor rates of reaction for this step. 
 
The second significant problem encountered was the cyclisation of ring A. Here the MS 
analysis showed a peak for both cyclised (140) and uncyclised peptide (142) (m/z = 976.8) 
suggesting cyclisation had not gone to completion (Figure 3-3). This was likely to be due to 
the failure of the uncyclized intermediate to pre-organise in such a way that the amine of 
Ile was near to the carboxylic group of lanthionine. Following incomplete cyclisation, a 
significant number of different products could be produced in the proceeding coupling 
steps through inter- and intra-molecular coupling. Poor rates of coupling and ring closure 
are problematic in producing impurities and low yields and they will also increase the 
chances of C-terminal epimerisation. 
  
 
Figure 3-3: LRMS mass spectrum of mini cleave experiment taken after cyclisation
 
Previously within the group, Wright, had shown microwave conditions improved the 
coupling of lanthionine to a linear peptide chain190 and it was thought that these conditions 












Performed first in a modified kitchen microwave in 1991,205 microwave assisted SPPS is 
now fairly commonplace with purpose built microwave technology incorporated into bench 
top automated peptide synthesisers. Microwave irradiation is beneficial to SPPS in two 
ways: rate of reactions can be increased significantly which improves purity of crude 
peptides and this also cuts the reaction time down, decreasing the need for multiple 
couplings or deprotections. This can be especially useful for the coupling of bulky amino 
acids.206 The elevated temperatures have also been shown to increase racemisation and so 
it is recommended to decrease reaction temperatures to 50 °C for histidine and cysteine.207 
 
Wright reported optimised conditions of 5 minutes and 60 °C with longer reaction times 
and higher temperatures having a detrimental effect on yield. Indeed, when microwave 
conditions were used for every coupling and cyclisation step during the synthesis of rings 
AB (129) no product could be observed in the crude LCMS (Table 3-1). Microwave 
conditions were then limited to installing both lanthionine residues.  
 
To help each coupling step to completion double coupling of every residue apart from 
lanthionine was employed as standard throughout the rest of the ring AB analogues 
syntheses. This is a commonly used technique in SPPS for the synthesis of difficult 
sequences whereby a second solution of the required amino acid and coupling agents are 
added to the syringe after the first solution has been evacuated.208 The limited availability 
of lanthionine meant this was not practical for the lanthionine coupling steps. 
 
Conditions 




Single couplings of all residues, no 
microwave, 5 equivalents of lanthionine 
 
Yes No 
Single couplings of all residues with 
microwave conditions for every step, 5 
equivalents of lanthionine 
 
No - 
Double couplings of all residues apart from 
lanthionine, coupled with 3 equivalents 
and microwave conditions 
Yes No 
 
Table 3-1: Conditions used for the attempted synthesis of ring AB analogue (129) 
 
Unfortunately, in this case, double coupling and microwave conditions did not improve the 





compound. However, microwave conditions did allow a decrease in the equivalents of 
lanthionine required for coupling and so further synthesis was carried out using 3 
equivalents of lanthionine instead of 5. 
 
3.4.1 Use of Hmb-Protected Amino Acids 
 
Again, looking back to previous work carried out by Wright, Hmb-protected amino acids 
were used to aid the synthesis of large lanthionine-containing rings where it was suspected 
that aggregation was disrupting coupling of amino acids within the ring system. Whilst 
Hmb-protected amino acids are widely used for this purpose as they disrupt hydrogen 
bonding of the backbone, it was thought that in the smaller ring systems of AB where 
aggregation is unlikely to be occurring, the addition of N-alkylated residues may alter the 
uncyclised solution structure in such a way that cyclisation is favoured. On searching the 
literature, it was found that N-alkylation does have an impact on the conformation of small 
peptide rings209 and both N-methylation and Hmb protected amino acids had been used to 
improve cyclisation of pentapeptides.210 
 
Scheme 3-4: Mechanism of acetyl transfer of Hmb residues 
 
The bulky nature of the Hmb group means that coupling of the proceeding residue can be 
disturbed and it is understood that the residue reacts first with the aryl alcohol of the Hmb 
group (Scheme 3-4). This enables acyl capture to form intermediate (146), followed by 
intramolecular acyl transfer to give the desired product (147). Peptide synthesis can then 
continue using the standard Fmoc SPPS protocol to build up the chain and the Hmb group is 
removed during the standard acidic conditions used to cleave the resin. Literature 
protocols suggest the most successful way to couple the proceeding amino acid is to use 







Scheme 3-5: Synthesis of the symmetrical anhydride of serine 
 
Hmb-Leu was used at position 7 in ring A to see if this would help cyclisation (Scheme 3-6). 
The symmetrical anhydride of serine was synthesised using DCC as a coupling agent (149, 
Scheme 3-5). The reaction mixture was filtered and the product was easily identified by a 
shift of the carbonyl carbon signal in the 13CNMR. The symmetric anhydride of serine was 
carried forward crude and coupled to the peptide chain using literature conditions211 with 
10 equivalents in CH2Cl2. The rest of the synthesis was carried out as before but 










Scheme 3-6: Unsuccessful synthesis of analogue (129) using Hmb-Leu 
Reagents and conditions: (i) standard Fmoc SPPS protocol using HOAt, PyAOP as activators 
to build up chain (ii) TBAF followed by 40% piperidine and then HOAt, PyAOP, DIPEA (iii) 
incorporation of Hmb-Leu using HBTU, DIPEA followed by 40% piperidine in DMF (iv) 
incorporation of serine symmetric anhydride in CH2Cl2 followed by standard Fmoc SPPS 
protocol to build up chain (v) TBAF followed by 40% piperidine and then HOAt, PyAOP, 
DIPEA followed by standard Fmoc SPPS protocol to build up chain (vi) standard TFA 
cleavage procedure 
 
3.4.2 Use of Pseudoprolines 
 
Hmb protected amino acids belong to a group of commercially available, reversibly 
Nα-alkylated amino acids designed to disrupt formation of secondary structures and 
aggregation of growing peptide chains in SPPS. Another approach to this problem is the use 
of pseudoprolines, in which cysteine, threonine and serine derived dipeptides are 
reversibly protected with proline-like thiazolidines or oxazolidines which are returned to 
their respective derivatives on cleavage with standard acid conditions (Figure 3-4).212 These 
are incorporated as dipeptides and are increasingly commercially available. It has also been 
reported that they have aided in the head-to-tail cyclisation of both short213 and longer214 





cisoid conformation about the amide bond adjacent to the modified amino acid, resulting 
in the temporary induction of a β-turn much like proline is found to do. It was thought that 
incorporating a pseudoproline in ring A could help ring closure proceed to completion, 
essentially, pre-organising the peptide for ring closure.  
 
 
Figure 3-4: Serine (153), threonine (154) and cysteine (155) derived pseudoprolines 
 
Fortunately, the combination of ring A containing a serine residue and the commercial 
availability of Fmoc-Ile-Ser[ψ(Me,Me)pro]-OH meant a pseudoproline residue could be easily 
incorporated into ring A of Thr/Ser analogue (129). Pseudoproline residues also provide the 
advantage of incorporating two residues at once, reducing reaction times and the 
introduction of impurities.  
 
Fmoc-Ile-Ser[ψ(Me,Me)pro]-OH was coupled onto intermediate (125) using the same 
conditions as all other residues, double coupling with 5 equivalents of amino acid (Scheme 
3-7). The sequence was completed as before and cleaved from the resin using a standard 






Scheme 3-7: Attempted synthesis of rings AB (129) using pseudoproline 
Reagents and conditions: (i) standard Fmoc SPPS protocol using HOAt, PyAOP as activators 
to build up chain (ii) TBAF followed by 40% piperidine and then HOAt, PyAOP, DIPEA (iii) 
incorporation of Fmoc-Leu-OH and Fmoc-Ile-Ser[ψ(Me,Me)pro]-using standard Fmoc SPPS 
protocol (iv) TBAF followed by 40% piperidine and then HOAt, PyAOP, DIPEA followed by 
standard Fmoc SPPS protocol to extend chain (v) standard TFA cleavage procedure 
 
Crude LCMS analysis looked promising showing one significant product. However, the main 
product observed was not the target product but the protected pseudoproline derivative 






Figure 3-5: Crude mass spectrum of attempted synthesis of (129) showing pseudoproline 
protected (158) 
 
Surprisingly, the acidolysis of the ring had not occurred in aqueous 95% TFA over 40 mins. 
On searching the literature, it was found that several other groups had experienced 
difficulty removing threonine derived pseudoprolines of cyclic peptides and these had 
required long deprotection times up to 4 days.215–217 It is also established that the cysteine 
derivatives are much more stable often requiring long reaction times or very strong acids 
like triflic acid (TFMSA).212 
 
Increasing the reaction time for the deprotection of (158) with TFA did increase the amount 
of desired product (129) as visible by LCMS analysis but also visible were degradation 
products. Different solvent systems using 10% CH2Cl2 and 10% water in TFA were also 
investigated but these did not help the rate of deprotection (Table 3-2). 
 
Returning to the literature, Wong et al.215 had incorporated Cys(ψMe,Mepro) into the 
sequence of cycloglossine B to aid cyclisation and found that the deprotection of the 
thiazolidine required 15 minutes at 0 °C with 100% TFMSA to obtain complete 
deprotection. The product was precipitated using diethyl ether in the same way as is 





shown to go to completion by LCMS analysis. A shorter reaction time of five minutes was 
then trialled and complete deprotection was also observed. An overall yield of 200 µg, 1% 
was obtained for rings AB (129) after reverse phase HPLC.  
 
Conditions Time Results 
96.5% TFA, 2.5% H2O, 1% TIPS 40 mins No deprotection 
90% TFA, 10% H2O 24 hours 
Partial deprotection & 
degradation products 
90% TFA, 10% CH2Cl2 24 hours 
Partial deprotection & 
degradation products 
100% TFMSA, 0 °C 15 mins Complete deprotection 
100% TFMSA, 0 °C 5 mins Complete deprotection 
 
Table 3-2: Summary of conditions used to deprotect (158) 
 
3.5 Abu/Ala Analogue (130) 
 
The alkyl analogue (130) was synthesised using the same procedure as had been used for 
Thr/Ser analogue (129) with double coupling and microwave conditions for the 
incorporation of lanthionine (Scheme 3-8). In this case the product could be purified from 







Scheme 3-8: Synthesis of Abu/Ala Analogue (130) 
Reagents and conditions: (i) standard Fmoc SPPS protocol using HOAt, PyAOP as activators 
to build up chain (ii) TBAF followed by 40% piperidine and then HOAt, PyAOP, DIPEA (iii) 
standard Fmoc SPPS protocol to incorporate lanthionine (60) and to build up chain (iv) TBAF 
followed by 40% piperidine and then HOAt, PyAOP, DIPEA (v) standard Fmoc SPPS protocol 
to extend chain followed by standard TFA cleavage procedure 
 
3.5.1 Use of Hmb-Protected Amino acids 
 
To improve the yield of the Abu/Ala analogue (130) two different commercially available, 
Hmb residues were incorporated into ring A, Hmb-Ala and Hmb-Leu (Figure 3-6). The 
appropriate symmetrical anhydrides were synthesised and incorporated as before after the 
Hmb residues (Scheme 3-9). No product could be seen in the crude LCMS in either case. 
 
 







Scheme 3-9: Synthesis of symmetrical anhydrides of alanine (R=CH3) (165) and isoleucine 
(R=CH(CH3)CH2CH3) (166) 
 
3.6 Aib/Aib Analogue (131) 
 
The synthesis of analogue (131) with Aib residues was also attempted using the same 
procedure as used for the Abu/Ala analogue (130) but unfortunately the product was not 
visible in the crude LCMS. 
 
Figure 3-7: Target Aib/Aib analogue (131) 
 
Two main products were visible in the crude LCMS both visible as [M+H]+ and [M+2H]2+ 
suggesting they were both lysine containing peptides. Tandem mass spectrometry analysis 
was carried out on the two main components but the results were inconclusive. It is likely 
the failure was due to the additional bulkiness at the alpha carbon of Aib compared with 
Ala or Ser. Further work should look at using the established microwave conditions to 
incorporate Aib. Subiros-Funosas et.al.218 successfully used Oxyma-based uronium-type 
coupling reagent, COMU, and microwave conditions to improve the synthesis of an Aib 
containing pentapeptide and these conditions could be worth pursuing for future synthesis.  
 
3.7 Recovering Excess Lanthionine 
 
Standard SPPS amino acid coupling procedures use an excess of amino acid to ensure each 
coupling goes to completion and the excess reagents are easily removed by evacuation 
through the syringe. This is not an ideal protocol for coupling of modified amino acids of 
limited quantity such as lanthionine. The equivalents of lanthionine (90) were reduced to 3 





To remove side products, excess coupling agent and DMF the evacuated coupling solution 
was washed with a large excess of a solution of 5% citric acid and extracted with CH2Cl2. 
The resulting residue was purified by flash column chromatography to give clean 
lanthionine in good yield, 60%. Occasionally small amounts of DIPEA were still present after 
column chromatography and another washing with citric acid was required.  
 
3.8 WT Rings AB (93) 
 
3.8.1 Enrichment of Nisin 
 
WT rings AB of nisin were obtained using a literature procedure outlined by Slootweg et 
al.180 for the trypsin digest of commercially available WT nisin (Scheme 3-10). Typically, 
commercially available preparations of nisin contain 75% NaCl, 22.5% dairy proteins and 
only 2.5% of nisin and so first an extraction was carried out, as outlined by Slootweg, to 
perform the digest on a more enriched sample of nisin. The enrichment was carried out 
using 25g of commercially available preparation purchased from MP Biomedicals and 
would give around 600-700 mg of enriched nisin. 
 
Scheme 3-10: Procedure for obtaining WT rings AB (93) 
Reagent and conditions: (i) water, CH2Cl2 followed by centrifugation and filtration (ii) tris 
acetate buffer, trypsin, 30 °C, 40 h 
 
The commercial preparation of nisin was dissolved in water and then CH2Cl2 was added to 
precipitate out the peptide content which formed a cloudy precipitate in the aqueous 
layer. The solution was then transferred to falcon tubes and centrifuged causing the 





collected and dried under reduced pressure to remove any remaining CH2Cl2. It was then re-
dissolved in deionised H2O and filtered through a small column of celite to remove any 
aggregated peptide material. If the filtrate appeared cloudy this filtration step was 
repeated. The solution was then concentrated in vacuo and lyophilised to give an off-white 




Figure 3-8: HPLC chromatogram of commercially available nisin (bottom trace) and 
enriched nisin (top trace) at 10 mg mL-1 
 
3.8.2 Trypsin Digest 
 
The enriched nisin was then used without further purification in a trypsin digest according 
to the published procedure. After HPLC purification 10 mg of rings AB were obtained with 
estimated 8% yield. Even though the reaction was monitored by HPLC and the digest was 
shown to go to completion this was significantly lower than the yield obtained in the 
literature (93%).180  
 
Differences in yield may be partially accounted for by the varying quality of commercial 
sources. Despite using the same conditions, it could be possible that the digested rings AB 








Figure 3-9: Typical HPLC chromatogram for the purification of digested nisin 
 
More recently Koopmans and co-workers also used a trypsin digest on WT nisin using more 
trypsin and a more concentrated solution of nisin with shorter reaction time.98 Using these 




The previously published methodology used to synthesise rings DE and rings C of nisin was 
adapted to enable the synthesis of two novel analogues of rings AB (129) and (130) and an 
analogue of ring B (138). 
 
Success of SPPS of the ring AB analogues was clearly very sequence dependant with the 
analogue with the least bulky amino acids proving the most straightforward. Increasing the 
bulkiness of alanine and aminobutyrine to serine and threonine required a pseudoproline 
residue to facilitate ring closure which also required an additional deprotection step. The 
synthesis of analogue (131) containing Aib residues was attempted but further work is 






WT rings AB of nisin (93) were obtained by using a literature procedure for the enrichment 
and digestion of commercially available WT nisin. This was intended for use in lipid II 



































4 Hybrid Peptides 
 
With the analogues of nisin rings AB and WT rings AB in hand, the design of the C-terminus 
tail peptides and hinge region linkers was assessed and the synthesis of hybrid peptides 
was carried out. 
 
4.1 Hybrid Peptide Design 
 
To enable click chemistry we aimed to attach an azide or alkyne to rings AB and incorporate 
the corresponding moiety into the hinge region. Coupling an alkyne “handle” to rings AB 
was chosen due to literature precedence for coupling propargylamine to fragments of nisin 
as discussed in Chapter 1.4.1.183,186 The hinge region and tail peptides then needed to 
incorporate an azide (Figure 4-1). 
 
As discussed in Chapter 3.8, multimilligram amounts of WT rings AB were obtained via 
digestion of commercially available nisin. Simplified analogues of rings AB were also 
obtained via SPPS, however, synthesis was complex and low yielding and so hybrids with 
WT rings AB were first synthesised with the intention of using the simplified SPPS 
analogues once the methodology had been developed. 
 
 
Figure 4-1: Design of hybrid peptides 
 
As previously discussed in Chapter 1.3.8, the hinge region of nisin (residues 20-23) is 
essential for activity; truncations or mutations to proline, decreasing flexibility, have a 
negative impact on activity.164,165 The use of a short PEG chain as a linker is a logical choice 
due to the commonplace incorporation of PEG into peptides, and other biomolecules, to 
simplified 
hinge region 










aid solubility, maintain flexibility and, for large PEG chains, reduce the reticuloendothelial 
clearance and recognition by the immune system.219,220 In addition to the requirement for 
an azide, the linkers also needed to be easily coupled to the N-terminus of the tail 
sequences and so they were designed with carboxylic acids to enable easy attachment 
using standard amide coupling conditions which could be carried out whilst still on resin.  
 
Linear pore forming peptides were chosen to mimic the C-terminus of nisin; we envisaged 
that replacing rings D and E with non-lanthionine containing peptides would significantly 
reduce the synthetic challenge of synthesising compounds with nisin’s mode of action. A 
reduction in the number of lanthionine residues also reduces the number of residues prone 
to oxidation. Cationic sequences were chosen to mimic the polarity of nisin and to enhance 
aqueous solubility. Removing the thioether bridges may increase the susceptibility of the 
hybrid peptides to enzymatic degradation and so the use of peptoids as mimics for nisin’s 
tail region was also investigated. These tail segments were synthesised using standard 
Fmoc SPPS protocol and standard peptoid sub monomer synthesis respectively. 
 
4.2 Tail Peptides 
 
Two peptides with established pore forming, antibacterial activity (as discussed in Chapter 
1.1) were chosen for incorporation into the hybrid peptides: a mastoparan analogue, 
Polybia-MP1 (12), and pexiganan (10), developed from magainin.57 The peptoid (15) 








Figure 4-2: Selected "tails" for hybrid peptides 
 
4.2.1 Peptide Synthesis 
 
The tail peptides mastoparan and pexiganan were synthesised using an automated peptide 
synthesiser with standard Fmoc SPPS protocol using HBTU and DIPEA for amino acid 
couplings and a piperidine/DMF solution for Fmoc deprotection. Rink amide resin was used 
for all tail peptides synthesised to give C-terminal amide peptides on cleavage.221 Initially, 
the tail peptides without linkers were synthesised to check the automated synthesis 





Figure 4-3: Resin bound intermediates mastoparan (167) and pexiganan (168) 
 
The crude LCMS mass spectra of pexiganan (10) showed good purity and the peptide was 





LCMS of mastoparan (12) whereby the terminal amino acid did not couple onto the N-
terminus and several unidentified impurities were also present (Figure 4-4). The synthesiser 
was programmed to carry out double coupling of the amino acids and this significantly 















Figure 4-5: Analytical HPLC chromatogram of purified matoparan (12) obtained using the 
standard conditions as described in Chapter 7.3 
 
Figure 4-6: Analytical HPLC chromatogram of purified pexiganan (10) obtained using the 
standard conditions as described in Chapter 7.3 
 
4.2.2 Peptoid Synthesis 
 
Peptoid synthesis was carried out using the procedure previously reported by Barron and 





protected dibutamine (170).85 The synthesis of Boc protected dibutamine (170) was 
attempted but the starting material diamine was toxic and difficult to handle on a medium 
scale and so (170) was instead purchased from Sigma Aldrich. 
 
 
Figure 4-7: Amine monomers used in peptoid synthesis 
 
Rink amide resin was again used to give the C-terminal amide. The automated peptide 
synthesiser was programmed to carry out addition of bromoacetic acid in DMF to the resin 
and then addition of DIC in DMF to activate the acid. After 1 h this was followed by 
washings with DMF and NMP and then subsequent additions of the required amine 






Scheme 4-1: Peptoid synthesis 
Reagents and conditions: (i) bromoacetic acid and DIC added to the reaction syringe, after 1 
h syringe was evacuated and washed with 3 portions of DMF followed by 3 portions of NMP 
(ii) (169) in NMP added to the reaction syringe and after 1 h the syringe was evacuated and 
washed with 3 portions of NMP followed by 3 portions of DMF (iii) repeat of bromoacetic 
acid coupling (iv) repeat of amine coupling with (169) (v) repeat of bromoacetic coupling (vi) 
(170) in NMP added to the reaction syringe and after 1 h syringe was evacuated followed by 
washing with 3 portions of NMP followed by 3 portions of NMP (vii) repeat of steps (i-vi) x 4 
 
The synthesis was successful showing adequate purity in the crude LCMS and peptoid (15) 
was purified by reverse phase HPLC in adequate yield (5%). Due to the lack of backbone 
chirality peptoids exhibit greater flexibility and the increase in conformational freedom 







Figure 4-8: Analytical HPLC chromatogram showing broadened peak of purified peptoid (15) 
using the standard conditions as described in Chapter 7.3 
 
4.3 Hinge Region Linkers 
 
The first set of linkers were chosen from commercially available reagents available within 
the laboratory. As previously mentioned PEG linkers are extremely suitable for this role and 
so Fmoc protected PEG4 amino acid (179) and Fmoc-Lys(N3)-OH (181) were employed as 
this was a straightforward way to incorporate an azide moiety. These were coupled using 
standard amide coupling conditions directly onto the N-terminus of resin bound 
intermediates of mastoparan (167) and pexiganan (168) before being cleaved from resin 







Scheme 4-2: Incorporation of PEG4 and Fmoc-Lys(N3) onto N-terminus of pexiganan 
 
Hinge region mimics produced in this way were significantly longer than the nisin hinge 
region and so shorter linkers were then designed. 
   
Shorter PEG linker, 11-azido-3,6,9-trioxaundecanoic acid (187) was chosen as the next 
target linker. This PEG linker, and longer chain analogues, have been synthesised from 
triethylene glycol, or longer PEG compounds, by a number of groups often as an 
intermediate in the synthesis of PEG amino acids where the azide group is later reduced to 
an amine.222 The azide is commonly installed by substitution of a mono-mesylated PEG 
chain with sodium azide.222,223 The acid can be installed in a number of ways such as 
oxidation of the terminal alcohol224 or installed as an ester and later hydrolysed.223 
 
Here the route of Weong and O’Brien225 was used which installed the acid using a 
substitution reaction with bromoacetic acid (Scheme 4-3). Synthesis began with mono-
tosylation of triethylene glycol (184) and then substitution with sodium azide to give (186). 
Initially the conditions of Jeong225 were used to install the acid moiety, using potassium 
hydroxide as a base, but this was unsuccessful and despite several attempts, the product 
(187) was never obtained with >5% yield. The conditions of Behrens et al.226 were then 







Scheme 4-3: Synthesis of PEG3 linker (170) 
 
Inspired by the good lipid II binding activity of the lipopeptides synthesised by Koopmans et 
al.98 an alkyl hinge region (189) was designed to investigate whether strong binding to lipid 
II could be combined with the pore forming ability of one the tail peptides. However, it 




Scheme 4-4: Synthesis of alkyl linker (172) 
 
The alkyl linker (189) was easily synthesised from commercially available 
11-bromoundecanoic acid (188) by refluxing with sodium azide to obtain (189) in good 
yield.  
 
4.4 Target Tail + Linkers 
 
With the linkers in hand, a set of tail peptides coupled with linkers was synthesised (Figure 
4-9). Linkers were coupled onto the N-terminus of resin bound intermediates (167), (168) 
and (178) using 5 equivalents of linker and standard HBTU and DIPEA coupling conditions. 
Double coupling was used to ensure the reaction went to completion. The tail peptides plus 
linkers were then cleaved from resin and purified to give multi milligram amounts in good 







Figure 4-9: Set of target tails coupled with each linker; the full set of peptoid tails were not 
synthesised due to time constraints 
 
4.5 Model Click Chemistry 
 
Model click reactions were carried out to optimise the conditions required for click 
chemistry, minimising the loss of valuable intermediates already synthesised. To this end, 
model peptides were synthesised to represent the C-terminus of rings AB (196) and the 
N-terminus of a tail peptide, pexiganan (199), terminated with Fmoc-Lys(N3)-OH (181). The 
first step was to check the conditions used for coupling an alkyne moiety onto the model 
rings AB peptide (196). This was carried out using the conditions of Slootweg and 
co-workers who coupled propargylamine onto the C-terminus of full length WT nisin using 
25 equivalents of propargylamine (Scheme 4-5).179   
 
 
Scheme 4-5: Coupling of propargylamine to ring B N-terminus model (198) 
 
Using these conditions, no visible peak for the alkyne product (198) could be observed in 
the crude LCMS. A peak of m/z = 414.4 was observed which was attributed to peptide 
(197), produced by the intermolecular cyclisation of the side chain amine of lysine coupling 





also observed the intramolecular cyclisation of the terminal lysine of rings AB.98 They 
suggested that more than 50 equivalents of amine were required to avoid the cyclisation 
and so the reaction was repeated using 51 equivalents of propargylamine and this gave 
alkyne-peptide (198) in good yield, 55%. 
 
With the truncated AB-alkyne and pexiganan mimics in hand, click chemistry was 
attempted using 0.2 equivalents of CuSO4.H2O and 0.4 equivalents of NaAsc, heating in the 
microwave for 15 min at 80 °C using the smallest microwave vial available at the time, 5 
mL, to give a concentration of 1.65 mM (Scheme 4-6). Product (200) was observed in the 
crude LCMS alongside peaks for both starting materials suggesting the reaction had not 
gone to completion. An extra 0.2 equivalents of CuSO4.H2O and 0.4 equivalents of NaAsc 
was added to the reaction vial and the vial was returned to the microwave for a further 15 
min at 80 °C. The reaction did appear to have progressed further but starting materials 
were still visible. This prompted a short review of literature conditions for click chemistry 





























Slootweg et al.183 1.9 eq CuSO4.H2O 
5.95 eq NaAsc 
20 80 0.737 26-54 
Koopmans et al.98 
0.2 eq CuSO4.H2O 
0.4 eq NaAsc 
0.05 eq TBTA 
20 80 16.2 13-60 
Arnusch et al.184 
2.0 eq CuSO4.H2O 
5.0 NaAsc 
5 80 1.90 39 
Arnusch et al.186 5.1 eq CuSO4.H2O 
10 eq NaAsc 
10 80 1.43 53-79 
 
Table 4-1: Review of literature conditions for click chemistry involving fragments of nisin 
 
Click chemistry was then attempted with increased equivalents of NaAsc and CuSO4, (5.1 
and 10) using the conditions of Arnusch et al.184 with a smaller microwave vial, 2 mL. Peaks 
for starting materials were still visible in the crude LCMS although at a decreased intensity. 
Concentrating the reaction down further by using a 0.5 mL vial, to give a concentration of 
15.7 mM, pushed the reaction to completion with no starting materials visible in the crude 
LCMS. This reaction was repeated following the procedure of Koopmans et al.98 with the 
addition of tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) but no visible 
difference could be seen in the yield of product (200) as assessed by HPLC. 
 
4.6 Click Chemistry  
 
Using the optimised conditions from the model experiment, propargylamine was coupled 
to rings AB in adequate yield (Scheme 4-7). 
 
 






Click chemistry was then performed with each of the tail peptides. The first click reaction 
was attempted using (N3)Lys-PEG4-pexiganan (183) and the optimised conditions of the 
model click reactions without TBTA. This was successful and gave (201) with a yield of 8%. 
The second click reaction was attempted with N3-C11-mastoparan (194) using the same 




Scheme 4-8: Synthesis of the first hybrid peptide 
 
The third click reaction with N3-PEG3-pexiganan (191) was unsuccessful with only starting 
materials collected. The fourth with (N3)Lys-PEG4-mastoparan (190) also failed. After two 
failed click reactions it was decided that TBTA227 would be used as a catalyst, as used by 
Koopmans et al.,98  and so all further click reactions were carried out with 0.05 equivalents 
of TBTA (202). 
 
 






TBTA is a polytriazole ligand designed as a  stabilizing ligand for copper(I) protecting it from 
oxidation and disproportionation and so improving catalytic activity.227 Cu(II) ions have 
been shown to catalyse the oxidative coupling of alkyne substrates to give diynes as 
undesired by-products. Fokin and co-workers, the researchers who designed TBTA, 
proposed that TBTA acts as a tetradentate ligand and blocks all coordination sites at the 
metal centre so that no oxidant can attack at the copper(I) ion.227 The tertiary amine was 
assumed to bind permanently to the metal centre, donating additional electron density to 
the metal centre whilst the triazole ligands would temporarily dissociate from the copper(I) 
ion to allow for the formation of the copper acetylide complex.  
 
Here it was employed with success, the reaction of N3Lys-PEG4-mastoparan (190) with 
alkylated rings AB was repeated with TBTA and the product (203) was obtained with 5% 
yield. Five further click reactions were carried out successfully with only one further failure 
with N3-C11-pexiganan (193). This reaction was not repeated due to time constraints.  
 
Substrate TBTA Product observed 
(N3)Lys-PEG4-pexiganan (183)   
N3-C11-mastoparan (194)   
N3-PEG3-pexiganan (191)   
N3Lys-PEG4-mastoparan (190)   
N3-PEG3-mastoparan (192)   
N3Lys-PEG4-mastoparan (190)  
N3-C11-pexiganan (193)   
N3-C11-peptoid (195)  
(N3)Lys-PEG4-pexiganan (183)  
N3-C11-mastoparan (194)   
 
Table 4-2: Summary of click reactions 
 
The first full set of hybrid peptides obtained were the mastoparan analogues (203-205, 
Figure 4-11) and these underwent initial assessment for antimicrobial activity as discussed 







Figure 4-11: Mastoparan hybrids taken on for biological evaluation 
 
Initial biological testing was promising with all three peptides showing antibacterial activity 
against Micrococcus luteus, an “indicator strain” for activity in Gram positive bacteria. 
Unfortunately, time constraints meant that only four hybrid peptides were obtained in high 








The synthesis of mastoparan (12), pexiganan (10) and peptoid (15) were carried out 
according to literature procedures. Hinge region linkers were then synthesised and coupled 
to each of the tail peptides to generate a novel set of tail peptides + linkers. Concurrently, 
propargylamine was coupled to WT nisin rings AB (110). Click chemistry methodology was 
developed using model peptides and this work enabled the synthesis of six novel hybrid 
peptides (201, 202-206) which are assessed for biological activity in Chapter 5. Low yields 
for this work can be attributed to the difficulties of handling and purifying small scale 










5 In vitro Biological Testing 
 
As the pressure to produce new antimicrobials increases, so does the need for better 
screening methods that quantify biological activity, particularly, in vitro methods that 
provide accurate predictions for in vivo activity. Two of the most commonly used methods 
within the field of AMPs are agar well diffusion and broth dilution methods both of which 
will be discussed in this chapter. For a recent review on the full range of methods see 
Balouiri et al.228 Good agreement between the minimum inhibitory concentrations (MICs) 
obtained from using the different methods has been observed229,230 and a handful of 
different regulatory protocols exist in order to standardise MIC determination as much as 
possible, for example, the Clinical and Laboratory Standards Institute (CLSI) in the USA and 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST)231 in Europe. 
 
Agar well diffusion methods use nutrient agar plates innoculated with a defined number of 
bacteria that are spread over the entire agar surface.228 Wells are then punched into the 
agar and solutions of the antibiotic are spotted into the cavities prior to incubation. 
Alternatively, absorbent discs can be pre-soaked in an antibiotic solution and placed on top 
of the agar, alleviating the need for holes. Decreasing concentrations of antimicrobial are 
spotted into the wells or onto the discs and the MIC is determined when a “halo” of growth 
inhibition can no longer be observed. The size of the inhibition zone is attributed to the 
antimicrobial activity of the compound tested and the diameter can be used as a 
quantitative measurement of activity. 
 
For the broth dilution method, a liquid growth medium is used and the amount used can be 
varied depending on the scale required and the availability of equipment.228 On a larger 
scale, macro-dilution, around 2 mL of broth can be used and this can be carried out in 
falcon tubes. For a smaller scale, micro-dilution, up to 500 µL of broth can be used and this 
is usually carried out in microtitre plates. Typically, a range of concentrations of 
antimicrobial compound are generated by carrying out a two-fold serial dilution. The MIC is 
determined by the lowest concentration at which no turbidity or sediment (indicating 
bacterial growth) can be visibly observed. The optical density can also be measured as a 














Figure 5-1: Diagram of an agar plate with four wells (dark grey) and varying sizes of 
inhibition zones (white) (left); and a typical set up of a broth micro-dilution in a 96 well plate 
(right); each row can contain a different antimicrobial agent or a different strain of 
bacteria; shading indicates bacterial growth, for example, row B shows no inhibition of 
growth; column 11: growth control, column 12: sterility control 
 
Neither of these techniques provide information on the nature of inhibition - whether the 
antimicrobial is bactericidal (kills bacteria) or bacteriostatic (prevents growth) - and this is 
usually determined by further assays to produce a time-kill curve. 
 
5.1 Initial Testing - Agar Well Diffusion 
 
Assay work was performed by S. Mitchell and stock solutions of bacteria were prepared by 
Prof J. Ward. 
 
For the initial round of testing, the agar well diffusion method was used as this was simple 
to set up and a protocol was already in use within the laboratory. Four different strains of 
bacteria were tested. Two indicator strains of Gram positive bacteria, Micrococcus luteus 
and Bacillus subtilis and two strains of Gram negative bacteria, Escherichia coli and 
Pseudomonas aeruginosa. The first set of hybrids synthesised were the mastoparan 
analogues (203-205, Figure 5-2) and so these were used in initial testing. A number of 
controls were also used: Kanamycin, an antibiotic in clinical use; mastoparan (12); WT rings 
AB (93); full length WT nisin (27). 
 







Figure 5-2: Hybrid peptides tested using agar well diffusion 
 
All of the peptides and peptoids synthesised were cleaved in TFA and purified using a 
solvent system with 0.1% TFA and so it was assumed that all of the cationic residues exist 
as TFA salts. Due to the high number of cationic residues, the TFA content makes up a 
significant proportion of the isolated mass. It has previously been reported that the 
presence of TFA can inhibit bacterial growth in assays232 so to check if it would have an 
effect in the assays, a control solution of sodium trifluoroacetate was tested for 
antibacterial activity. It was made up to the same concentration as the sample with the 
highest concentration of TFA salt. No inhibitory activity was observed in agar well diffusion 
plates at the maximum amount tested, 25 µL of 0.4 mg mL-1.  
 
It was assumed that the hybrid peptides would have better activity against Gram positive 
bacteria, however, as mentioned in Chapter 1 the tail peptides have been shown to exhibit 
some antimicrobial activity against Gram negative bacteria. The mastoparan and pexiganan 
analogues were reported to have the most promising activity showing only a two-fold and 
four-fold increase in MIC against E. coli compared to B. subtilis respectively.21,86 
 
All peptides were made up to 1 mg mL-1 stock solutions in sterile water. An overnight 
culture of each bacteria strain was prepared by Prof. J. Ward and 100 µL of each were 
pipetted and spread onto plates of L-Agar. Four holes were punched into each plate and 25 
µL of peptide stock solution was spotted in each well. The plates were incubated for 48 




Inhibition zones were visible for all hybrid peptides and controls against M. luteus. Of the 
hybrids only AB-PEG3-mastoparan (204) showed slight inhibition of B. subtilis, with a small 





inhibition. Rings AB only showed inhibition against M. luteus. As expected, all peptides 
performed worse against the Gram negative bacteria with only Kanamycin showing any 

















    
AB-PEG3-Mastoparan (204)     
AB-C11-Mastoparan (205)     
Mastoparan (12)     
Nisin AB (93)     
Nisin (27)     
Kanamycin      
 
Table 5-1: Activity of hybrid peptides and controls determined using agar well diffusion 
: zone of inhibition visible, : no zone of inhibition visible 
Plates spotted with 25 µL of peptide and Kanamycin stock solutions made up to 1 mg mL-1 
 
5.3 MIC Determination - Broth Micro-dilution 
 
Assay work was performed by S. Mitchell. Preparation of stock solutions of bacteria and 
colony counts were performed by Prof J. Ward 
 
To determine the MIC of the hybrid peptides and to compare their activities more 
accurately the broth micro-dilution method was used as this consumed the minimum 
amount of peptide material. Due to limited amounts of peptides, further testing was also 
only carried out on M. luteus as this appeared to be the most sensitive strain of Gram 
positive bacteria.  
 
 
Figure 5-3: Hybrid peptides that were taken on for MIC determination 
 
The assays were carried out in 96-well plates using the broth micro-dilution method 





concentration of the assayed peptide that inhibits the visible growth of the microorganism 
tested. The optical density of the plates was also recorded.  
 
Polystyrene 96-well plates have been reported to inhibit the activity of cationic AMPs as it 
is believed the peptides bind to the negatively charged surface of the plastic.233 
Polypropylene plates were used for the assay to mitigate this effect. To aid solubility, 1% 
DMSO final volume was used throughout. 
 
The initial biological testing using agar well diffusion compared the peptides as a weight per 
volume concentrations but due to the differences in molecular weight and assumed TFA 
salt content it was decided that using a mole per volume concentration scale would give a 
clearer indication of the differences in activity. Controls of nisin (27), mastoparan (12), 
pexiganan (10), peptoid (15) and rings AB of nisin (93) were tested alongside the hybrids. 
 
All assays were performed in duplicate. 10 µL of an overnight stock of bacteria, as prepared 
by Prof. J. Ward, was used in each well. Colony counts performed by Prof. J. Ward on the 
overnight stock culture of bacteria gave a count of 1.07 × 107 cfu mL-1, however, the final 
concentration in each well is diluted by a factor of 25 and so the initial concentration of 
bacteria in each well was estimated at 4.28 × 105 cfu mL-1. Column 11 of the plates was 
used as a control for bacterial growth and this column contained only 10 µL of bacteria 
stock solution and 240 µL of broth. Column 12 of the plates was used as a control for 
sterility and contained 250 µL of broth. The plates were incubated for 20 hours at 37 °C 
with shaking after which the broth with any bacterial growth from each well was re-
suspended and transferred to a transparent polystyrene plate to measure the optical 
density.  
 
Initial broth-microdilution assays using the control peptides suggested the MICs would fall 
below 12 µM and so this was used as the initial concentration from which a two-fold serial 
dilution was carried out using the method suggested by Hancock and co-workers.233 Initial 
assays also suggested that the choice of growth medium was important. LB broth was 
initially used as growth medium for the overnight stocks of bacteria and this gave good 
growth of bacteria as indicated by a cloudy solution. However, when LB broth was used in 
the broth-microdilution assays, poor growth of the bacteria was visible with an optical 
density of around 0.2 for the growth control column and wells where growth inhibition was 
not expected. Oxoid Nutrient Broth No 2 was instead used for overnight culture medium 





with an optical density around 0.4 in the growth control column and wells where growth 
inhibition was not expected. Oxoid Nutrient Broth No 2 with 1% DMSO was then used for 




As expected, nisin (27) showed greater activity than any of the hybrids or linear peptides. 
All but one of the hybrids (205) were shown to have greater activity than rings AB 
suggesting that pore forming activity was restored to the lipid II binding motif (Figure 5-4). 
However, as none of the hybrids performed better than their tail component controls it is 
not conclusive that their activity is conferred by a lipid II dependant mechanism. It could be 
that the linear peptides are behaving as they would do in isolation and the AB rings are not 
disturbing that activity significantly. Further experiments using lipid II spiked LUVs, such as 
those used by  Breukink and co-workers,186 are required to probe the mechanism.  
 
Notably, the alkyl, C11 linked hybrids (205) and (206) exhibited the worst activity compared 
with the PEG4-lysine linked hybrids (201) and (203). The best of which (201) matched the 
activity of its tail peptide, pexiganan (10). The poorer activities may be because the alkyl 
linker disrupts the ability of the mastoparan and the peptoid tails to form a helix or possibly 
due to reduced solubility. The C11 linked hybrids also have the shortest tails of 14 residues 
and 12 monomers respectively. In comparison, the best performing hybrid (201) which has 
the longest peptide tail of 22 residues. It may be that the longer peptide tails can span the 
bacterial membrane better and form more effective pores. The hybrid (201) also has the 
highest number of cationic residues and is the least hydrophobic compared to the other 
hybrids as estimated by HPLC retention time however there is not enough evidence 







































Figure 5-4: Photographs of microdilution assay; each row contains decreasing concentration 
of peptide left to right; x = 12 µM; clear wells indicate bacterial growth inhibition, cloudy 















Nisin (27) 0.0234 5 28.0 
Pexiganan (10) 0.750 9 22.9 
Mastoparan (12) 1.50 3 25.9 
Peptoid (15) 1.50 4 30.7 
AB (93) >12.0 1 28.2 
AB-Lys-PEG4-Pexiganan (201) 0.750 11 24.9 
AB-Lys-PEG4-Mastoparan (203) 3.00 5 26.2 
AB-C11-Mastoparan (205) >12.0 4 31.0 
AB-C11-Peptoid (206) 6.00 5 32.8 
 
Table 5-2: MICs of hybrid peptides against M. luteus determined by broth micro-dilution 
assays; number of cationic residues or monomers (Arg, His, Lys or NLys) shown; HPLC 
retention time acquired using standard conditions as described in Chapter 7.3 
 
Although the MIC of AB-C11-mastoparan (204) did not show visible inhibition of M. luteus, 
when the optical density was taken the highest concentration of peptide does appear to 
show some decrease in optical density and it could be assumed that the MIC will fall within 
a fourfold increase in concentration (Figure 5-5).  
 
 
Figure 5-5: Graph showing optical density vs concentration of peptide of broth 





5.5 Summary of in vitro Testing 
 
Three out of the four hybrids (201, 203, 206) were shown to have good activity against 
M. luteus, in the low µM range, likely due to their membrane destabilising, pore forming 
ability. It was inconclusive whether this occurred through a lipid II binding mechanism and 
further testing needs to be carried out to establish this.  
 
The next stage of assessing the biological activity of the hybrid peptides should also involve 
assessment of activity against more clinically relevant strains of bacteria for example 







































6 Conclusions and Future Work 
 
The aim of this project was to prepare simplified mimics of nisin with improved drug-like 
properties and an accessible synthetic route. To preserve the selectivity and activity of nisin 
it was necessary to design mimics with conserved AB ring moieties. By extending SPPS 
methodology previously developed within the group, the AB ring moiety of nisin was 
simplified by replacing unstable dehydro residues and substituting methyl lanthionine for 
lanthionine to give two novel ring AB analogues. 
 
To enable the SPPS of ring AB analogues it was first necessary to synthesise (Teoc/TMSE, 
Fmoc) lanthionine (60). This was initially carried out on a small scale using a published 
procedure. Adjustments to reaction conditions and purification procedures were made to 
facilitate scaling up of this route. The overall yield was significantly improved and time 
taken for synthesis was reduced, enabling the synthesis of lanthionine (60) on a medium 
scale. A short investigation was also carried out into whether cheaper starting materials 
could be used. This was successful, reducing the number of steps to (60) and avoiding two 
hazardous reactions.  
 
With lanthionine (60) in hand the synthesis of simplified analogues of rings AB was then 
attempted. Three analogues were then designed in which Dha2 and Dhb5 were substituted 
with more stable residues: the biosynthetic precursors, threonine and serine to give (129); 
the saturated alkyl counterparts aminobutyric acid and alanine to give (130); 
α-aminoisobutyric acid (Aib), a known α-helix inducer and stabiliser to give (131).  
 
Initially, a novel ring B analogue (138) was synthesised to check the SPPS methodology. A 
considerable amount of optimisation of this methodology was required for the synthesis of 
novel Thr/Ser analogue (129) which was successfully synthesised using double couplings, 
microwave conditions and a commercially available pseudoproline residue. Novel Abu/Ala 
analogue (130) was also synthesised successfully using the optimised methodology with 
both double coupling and microwave conditions. The use of Hmb amino acids was 
investigated in both analogues was not found to help synthesis. The synthesis of Aib/Aib 
analogue (131) was also attempted but was unsuccessful and time constraints meant this 
was not probed further. WT rings AB were obtained using a literature procedure for the 






With two ring AB analogues and WT rings AB in hand, hybrid peptides were designed. The 
design centred around removing unstable dehydro residues and synthetically challenging 
lanthionine residues. The C-terminus of nisin was replaced with simpler, linear, pore 
forming peptides, mastoparan (12), pexiganan (10) and a peptoid (15) which could be 
synthesised by SPPS. Three different hinge region mimics were designed and incorporated 
into the SPPS of the pore forming, tail peptides and peptoid to give a set of seven novel tail 
+ hinge region peptides and peptoids. In addition, mastoparan (12), pexiganan (10) and 
peptoid (15) were synthesised as controls. 
 
Click chemistry methodology was then developed with a set of truncated model peptides. 
WT rings AB were alkylated with propargylamine to give (110) and click chemistry was used 
to couple this fragment with the tails + hinge region linkers to produce six novel hybrid 
peptides (201, 203-206). Three of these (203-205) were taken on for initial biological 
testing using the agar well diffusion method and they were shown to have activity against a 
Gram positive indicator bacteria Micrococcus luteus. A further four hybrids (201, 203, 205, 
206) were taken on for further biological evaluation and a micro-dilution assay was 
developed to allow for MIC determination using minimal amount of peptide material. The 
hybrids were shown to have promising biological activity with MICs ranging from 0.75-12 
µM, similar to the control tail peptides.  
 
To build on this work, the synthesis of the hybrid peptides should be scaled up to give multi 
milligram quantities of the full set of target hybrids with both the longer Lys(N3)-PEG4 
linkers and the shorter N3-PEG3 linkers. As the alkyl hinge region mimics, hybrids (205) and 
(206) were found to exhibit the poorest biological activity in the MIC assays and it would be 
reasonable not to include these in any further work. With greater quantities of hybrid 
peptides, it would then be desirable to screen for biological activity against a wider set of 
microbes including clinically relevant strains of MRSA and VRE. To test their drug-like 
properties, assays to test their stability and toxicity should be carried out. 
 
Further optimisation of the hybrid peptide design would be pertinent to investigate (Figure 
6-1). Possible modifications include shortening the hinge region further by using a 
diethylene glycol unit as the basis of a linker (207) or removing it altogether by clicking tail 
peptides directly to alkylated rings AB via 2-azidoaetic acid (208) Incorporation of the 
optimised hinge regions discussed in Chapter 1.3.8 would also be interesting to investigate 





of ring AB analogues is optimised further, full length analogues could be synthesised solely 
by SPPS and optimised hinge regions could be easily incorporated into the design (210). To 
further probe the role of ring C in the biological activity of nisin, a set of analogues that 
incorporate rings ABC could be synthesised. Rings ABC could be isolated using a 
chymotrypsin digest183 of WT nisin (211) or synthesised using SPPS (212). 
 
With analogues that are found to have good biological activity it may be useful to perform 
truncations to both the C-terminus and N-terminus of the tail peptides or peptoids to 
determine the minimum length necessary for activity.  
 
 






With the most promising hybrids further work would need to be carried out to elucidate 
their mechanism of action using LUVs encapsulating a fluorescent marker, both 
incorporating lipid II and without, to determine the extent of pore formation and lipid II 
binding.186 These hybrids could also be evaluated for their selectivity, using haemolysis 
assays and their toxicity, using mammalian cell toxicity studies. Serum stability assays could 
help to predict if the simplified structures would be more stable in vivo. 
 
Returning to the work carried out on ring AB analogues, the synthesis of the two novel 
analogues (129) and (130) should be scaled up to provide enough material for LUV, lipid II 
binding studies to assess the impact of the substitutions on binding to lipid II. A comparison 
of their NMR solution structures may also shed some light on this. If these results are 
promising the next step would be to incorporate the analogues into the best of the hybrid 
peptide design. 
 
With the developed SPPS methodology and a further understanding of the hybrid peptides 
in place this work could be extended in a number of ways such as continuing the work of 
Zhou et al.166 in attaching Gram negative active peptides to ring AB moieties or using ring 
AB moieties to improve selectivity of cell penetrating peptides that are known to have 

















7.1 General  
 
Reagents were purchased from chemical suppliers and were used as received without 
further purification. Custom, large scale synthesis of Fmoc-Cys-OtBu was carried out by 
Oxygen Healthcare, Cambridge, UK, which is part of Piramal Enterprises Ltd, Mumbai, India. 
Dry DMF, THF and CH2Cl2 were purchased as anhydrous solvents in Sureseal bottles from 
Sigma-Aldrich Co. Ltd. Brine refers to a saturated solution of sodium chloride in water and 
sodium bicarbonate refers to a saturated solution of sodium hydrogen carbonate in water. 
Ether refers to diethyl ether and petrol to petroleum ether fractions boiling between 40 
and 60 °C. All water used was either distilled using an Elga Purelab Option R7 water purifier 
or used directly from a bottle of HPLC-grade water. All reactions were carried out in closed 
systems under Argon. 
 
Thin layer chromatography (TLC) was performed on aluminium backed Sigma-Aldrich TLC 
plates with F254 fluorescent indicator. Developed plates were air dried and analysed under a 
UV light or by staining with the appropriate indicator. Normal phase flash column 
chromatography was carried out using silica gel (43-60 µm) supplied by Merck. Optical 
rotations were recorded using a Perkin Elmer 343 polarimeter and are reported in 
10−1 deg cm2 g−1. 
 
LRMS refers to low resolution mass spectrometry and HRMS refers to high resolution mass 
spectrometry. LRMS was performed on a Waters Acquity UPLC coupled to a SQD mass 
spectrometer using HPLC grade water and acetonitrile (both with 0.1% formic acid) as the 
solvents. HRMS electrospray ionization was determined using Waters LCT Premier XE 
instrumentation and Mass Lynx software.  
 
NMR (1H and 13 C) was performed on 300, 500 and 600 MHz AMX Bruker Spectrometers (as 
stated). The chemical shifts (δ) were given in units of ppm relative to tetramethylsilane 
(TMS), where δ(TMS) = 0 ppm. Data processing was carried out using ACD/NMR Academic 
Edition, Advanced Chemistry Development, Inc. For 1H NMR, the multiplicity used for 
assignment is indicated by the following abbreviations: s = singlet, d = doublet, t = triplet, q 
= quadruplet, qn = quintet, m = multiplet, br = broad, app. d. = apparent doublet and the 
coupling constants (J) were measured in Hertz (Hz). 13C NMR have been assigned using 





Spectrometers. Deuterated chloroform (CDCl3), dimethylsulfoxide (d6-DMSO) and methanol 
(CD3OD) were used as solvents (as stated) for all NMR analysis.   
 




Boc-Ser(Bn)-OH (112) (15.1 g, 48.8 mmol) and DMAP (1.19 g, 9.76 mmol) were dissolved in 
THF and the reaction mixture was cooled to -10 °C using a bath of sodium chloride and ice. 
TMSEOH (14.0 mL, 97.6 mmol) and DCC (13.1 g, 63.5 mmol) were added slowly. The 
reaction was warmed to room temperature and left stirring overnight. After this time the 
reaction mixture was concentrated in vacuo and the crude residue was dissolved in ethyl 
acetate (500 mL) and washed with NaHCO3 (500 mL) and brine (200 mL). The organic layer 
was dried over MgSO4, concentrated in vacuo and purified using flash column 
chromatography (10-30% ethyl acetate in petrol) to give (113) as an off white solid (16.6 g, 
83%). 
 
NMR: δH (600 MHz, CD3OD) 0.05 (9H, s, Si(CH3)3), 0.96-1.0 (2H, m, CH2Si(CH3)3), 1.46 (9H, s, 
C(CH3)3), 3.66-3.68 (1H, m, ArCH2OCH2), 3.85-3.87 (1H, m, 1 x ArCH2OCH2), 4.20-4.23 (2H, 
m, CH2CH2Si(CH3)3), 4.38-4.30 (1H, m, 1 x ArCH2OCH2CH), 4.47 (1H, d, J = 12.0 Hz, 1 x 
ArCH2OCH2), 4.54 (1H, d, J = 12.0 Hz, 1 x ArCH2OCH2), 5.39 (1H, d, J = 8.5 Hz, NH), 7.25-7.33 
(5H, m, Ar). 
 
δc (150 MHz, CD3OD) -1.6 (C6), 17.3 (C5), 28.3 (C9), 54.1 (C2), 63.9 (C4), 70.0 (C1), 73.2 
(C10), 79.9 (C8), 127.6, (CAr) 128.5 (CAr), 129.4 (CAr), 137.6 (C11), 155.5 (C3), 170.8 (C7). 
NMR data is in agreement with the literature.188  
 
LRMS: (ES+) [C20H34NO5Si]+ calculated = 396.2; found m/z = 418.2 [M+Na]+ 
 
[α]20D = - 8.2 (c = 10 mg mL-1, CHCl3) 








Pd/C (10%, 0.50 g) was added to a solution of Boc-D-Ser(Bn)-OTMSE (113) (4.00 g, 9.77 
mmol) in ethanol (100 mL) and the flask was placed under a hydrogen atmosphere for 24 h. 
After this time, the reaction was filtered over a bed of celite and the solvent was removed 
in vacuo.  
 
The crude product was treated with a solution of TFA (5 mL) and CH2Cl2 (5 mL) and left to 
stir for 2 h. After this time, the reaction was concentrated in vacuo and excess toluene was 
added and removed in vacuo. This was repeated twice and was followed by CH2Cl2. Flash 
column chromatography was used to purify the residue (2-5% MeOH in CH2Cl2) to give 
(114) as a colourless oil (1.73 g, 86%).  
 
NMR: δH (600 MHz, CD3OD) 0.06 (9H, s, Si(CH2)3), 0.97-1.10 (2H, m, CH2Si(CH3)3), 3.91-4.06 
(3H, m, CHCH2OH), 4.31-4.36 (2H, m, CO2CH2CH2Si(CH3)3). 
 
δc (150 MHz, CD3OD) -1.5 (C6), 18.4 (C5), 56.3 (C2), 60.8 (C4), 66.2 (C1), 169.2 (C3).  
NMR data is in agreement with the literature.188 
 
LRMS: (ES+) [C8H20NO3Si]+ calculated = 206.1; found m/z = 228.0 [M+Na]+ 
 
[α]20D = - 34.2 (c = 7.5 mg mL-1, MeOH)  




Trimethyl silyl chloride (18.7 mL, 147 mmol) was added to D-serine (127) (5.00 g, 47.6 
mmol) in anhydrous CH2Cl2. The reaction mixture was heated at reflux for 40 min and then 
left to cool to room temperature. Triethylamine (20.6 mL, 147 mmol) was diluted in CH2Cl2 
and added dropwise to the reaction mixture. The reaction was again heated at reflux for a 
further hour after which it was cooled to 0 °C. Anhydrous methanol (1.93 mL, 47.6 mmol) 





portion of triethylamine was added (6.63 mL, 47.6 mmol) and then triphenylmethyl 
chloride (13.2 g, 47.6 mmol) was added portion-wise and the reaction was left to stir 
overnight. Methanol and triethylamine were added until all solids had dissolved and the 
reaction mixture was concentrated in vacuo. The crude residue was dissolved in ethyl 
acetate and washed with 5% citric acid (2 x 500 mL). The organic layers were dried over 
MgSO4 and concentrated in vacuo. Flash column chromatography was used to purify the 
crude material (0-15% MeOH in CH2Cl2) to give (128) as an off-white powder (6.30 g, 38%). 
 
δH (600 MHz, CD3OD) 3.02-3.05 (1 H, m, 1 x CHCH2OH), 3.26-3.32 (2H, m, CHCH2OH & 1 x 
CHCH2OH),3.55 (1H, br s, NH), 7.21(3H, t, J = 7.0 Hz, Ar), 7.26 (6H, m, J = 7.0 Hz, Ar), 7.50 
(6H, d, J = 7.0 Hz, Ar). 
 
δc (150 MHz, CD3OD) 58.6 (C2), 62.6 (C1), 71.9 (C4), 127.4 (CAr), 128.5 (CAr), 128.6 (CAr), 
144.7 (CAr), 174.3 (C3). 
NMR data is in agreement with literature.234  
 
LRMS: (ES-) [C22H20NO3]- calculated: 346.1; found m/z = 346.3 [M-H]-, 693.3 [2M-H]- 
 





Method 1 - from H-Ser-OTMSE (114) 
Triethylamine (2.88 mL, 20.5 mmol) was added to a solution of H-Ser-OTMSE (114) (2.10 g, 
10.3 mmol) in DMF (200 mL) and the reaction mixture was cooled to 0 °C. To this, trityl 
chloride (2.58 g, 9.24 mmol) was added and the flask was warmed to room temperature. 
After 24 h, the mixture was washed with water (2 x 200 mL) and extracted with CH2Cl2 (2 x 
200 mL) and flash column chromatography was used to purify the residue (0-1% MeOH in 








Method 2 (from Trt-D-Ser-OH) (128) 
Trt-D-Ser-OH (128) (5.00 g, 14.4 mmol) and 2-(trimethylsilyl)ethanol (22.7 mL, 158 mmol) 
were dissolved in CH2Cl2 (5 mL) and the reaction mixture was cooled to 0 °C. DMAP (7.04 g, 
57.6 mmol) and EDCI (3.31 g, 17.3 mmol) were added to the reaction mixture which was 
then allowed to warm to room temperature and stirred for 24 h. After this time, excess 
CH2Cl2 (100 mL) was added and the reaction mixture was washed aqueous citric acid 
solution (5% w/v, 150 mL) and brine (150 mL). The organic layer was dried over MgSO4 and 
the solvent was removed in vacuo. The crude residue was purified by flash column 
chromatography (0-1% MeOH in CH2Cl2) to give (115) as a colourless oil (4.45g, 69%). 
 
NMR: δH (600 MHz, CDCl3) 0.01 (9H, s, Si(CH3)3), 0.76-0.81 (2H, m, CH2Si(CH3)3), 3.49-3.54 
(2H, m, CHCH2OH), 3.67-3.70 (2H, m, CO2CH2CH2Si(CH3)3), 3.76-3.80 (1H, m, TrtNHCHCH2), 
7.18-7.21 (3H, m, Ar), 7.25-7.31 (6H, m, Ar), 7.48-7.50 (6H, m, Ar).  
 
δc (150 MHz, CDCl3) -1.6 (C6), 17.0 (C5), 57.8 (C2), 63.4 (C4), 64.8 (C1), 70.0 (C7), 126.6 
(CAr), 127.2 (CAr), 127.9 (CAr), 128.7 (CAr), 145.6 (CAr), 173.6 (C3).  
NMR data is in agreement with the literature.188 
 
LRMS: (ES+) [C28H36NO3Si]+ calculated = 462.7; found m/z = 485.7 [M+Na]+ 
 
2-(Trimethylsilyl)ethyl (S)-3-iodo-2-(tritylamino)propanoate (116)188 
 
 
The protected serine (115) (1.20 g, 2.81 mmol) and PPh3 (1.10 g, 4.21 mmol) were dissolved 
in anhydrous CH2Cl2 (3 mL) at room temperature and left stirring for ten minutes. The 
reaction mixture was then cooled to -10 °C and DEAD (77.0 µL, 4.21 mmol) was added 
dropwise. After another five minutes MeI (26.0 µL, 4.21 mmol) was added and the reaction 
mixture was left stirring at -10 °C for 3 h. The reaction mixture was purified directly by flash 
column chromatography (10-25% ethyl acetate in hexane) to give the iodinated compound 






NMR: δH (600 MHz, CDCl3) 0.01 (9H, s, SiCH3)3, 0.77-0.87 (2H, m, CH2Si(CH3)3), 2.91 (1H, d, J 
= 9.0 Hz, NH), 3.21 (1H, dd, J = 7.0, 9.5 Hz, TrtNHCHCH2I), 3.33 (1H, dd, J = 3.0, 9.5 Hz, 
TrtNHCHCH2I), 3.34-3.46 (1H, m, TrtNHCHCH2I), 3.7 (1H, td, J = 6.0, 11.5 Hz, CO2CH2CH2Si), 
3.82 (1H, td, J = 6.0, 11.5 Hz, CO2CH2CH2Si), 7.19-7.24 (3H, m, Ar), 7.28-7.30 (6H, m, Ar), 
7.51-7.52 (6H, m, Ar).  
 
δC (150 MHz, CDCl3) -1.6 (C6), 10.2 (C1), 17.2 (C5), 56.1 (C2), 63.6 (C4), 71.1 (C7), 126.6 
(CAr), 128.0 (CAr), 128.7 (CAr), 145.7 (CAr), 172.4 (C3). 
NMR data is in agreement with the literature.188  
 
LRMS: (ES+) [C27H33INO2Si]+ calculated = 558.1; found m/z = 580.0 [M+Na]+ 
 
[α]20D = -5.8 (c = 6.6 mg mL-1, CHCl3) 
[lit188 [α]20D = -8.1 (c = 5.2 mg mL-1, CHCl3)] 
 
(Fmoc-Cys-OH)2  (120)235 
 
 
Method 1 from (Fmoc-Cys-OtBu)2 (118) 
(Fmoc-Cys-OtBu)2 (10.0 g, 12.6 mmol) was dissolved in 10 mL TFA and 10 mL CH2Cl2. After 3 
h the solvent was removed in vacuo to give (120) as an off white solid (11.5 g, 99%). 
 
Method 2 from L-Cystine (117) 
Sodium hydroxide (3.33 g, 83.2 mmol) was dissolved in 100 mL of water. THF (100 mL) was 
added and the mixture was cooled to 0 °C before the addition of cystine (5.00 g, 20.8 
mmol). The reaction mixture was left overnight and after this time the THF was removed in 
vacuo and the reaction mixture was acidified with 1.0 M HCl. The white precipitate could 
then be collected by filtration and the solid was re-suspended in ethyl acetate and left in 
the fridge overnight. The precipitate was again filtered and washed with portions of cold 
ethyl acetate to give an off white solid (120) (10.3 g, 52%). 
 
NMR: δH (600 MHz, CD3OD) 3.02 (2H, dd, J = 14.0, 9.5 Hz, CHCH2S), 3.28 (2H, m, CHCH2S), 





9.5, 4.5 Hz, CHCH2S), 7.27 (4H, t, J = 7.5 Hz, Ar), 7.33-7.37 (4H, m, Ar), 7.65 (4H, d, J = 7.5 Hz, 
Ar), 7.75-7.76 (4H, m, Ar). 
 
δc (150 MHz, CD3OD) 41.1 (C1), 48.3 (C6), 54.7 (C3), 68.2 (C5), 126.3 (CAr), 121.0 (CAr), 
126.6 CAr) 128.9 (CAr), 142.6 (CAr), 145.4 (CAr), 158.5 (C4), 174.0 (C3). 
NMR data is in agreement with the literature.235  
 
LRMS: (ES-) [C36H31N2O8S2]- calculated = 683.2; found m/z = 683.2 [M-H]- 
 
[α]25D = -65.4 (c = 9.0 mg mL-1, MeOH)  
[lit189 [α]25D = -79.6 (c = 8.9 mg mL-1, MeOH)]  
 
(Fmoc-Cys-OTce)2 (121)195  
 
 
(Fmoc-Cys-OH)2 (120) (5.00 g 7.30 mmol) and p-toluenesulfonic acid (3.33 g, 190 mmol) 
were dissolved in benzene (250 mL). 2,2,2-Trichloroethanol (2.62 g, 17.5 mmol) was added. 
The reaction was stirred at 110 °C under reflux for 24 h with a Dean-Stark trap attached. 
After this time the reaction was cooled to 0 °C and any unreacted acid was removed by 
filtration. The solvent was removed in vacuo and the crude residue was dissolved in 
chloroform (200 mL), washed with water (200 mL) and brine (200 mL). Flash column 
chromatography was used to give the title compound (121) as a white solid (6.02 g, 87%).  
 
NMR: δH (600 MHz, CDCl3) 3.14-3.31 (4H, m, CHCH2S), 4.19-4.23 (2H, m, 2 x CHCH2Fmoc), 
4.41-4.57 (4H, m, 2 x CHCH2Fmoc), 4.72-4.85 (6H, m, CH2Cl3 & CHCH2S), 5.74-5.80 (2H, m, 
NH), 7.30-7.32 (4H, m, Ar), 7.39-7.49 (4H, m, Ar), 7.56-7.64 (4H, m Ar), 7.75-7.80 (4H, m, 
Ar).  
 
δC (150 MHz, CDCl3) 40.7 (C1), 47.0 (C7), 53.3 (C2), 67.4 (C6), 74.8 (C4), 94.1 (C5), 120.0 
(CAr), 125.0 (CAr), 127.1 (CAr), 127.8 (CAr), 141.3 (CAr), 143.5 (CAr), 155.7 (C8), 168.9 (C3).  






LRMS: (ES+) [C40H35Cl6N2O8S2]+ calculated = 945.0; found m/z = 948.68 [M+H]+ 
 
Fmoc-Cys-OTce (122)195  
 
Method 1  
Triphenylphosphine (521 mg, 2.18 mmol), 2-mercaptoethanol (185 mg, 2.37 mmol) and 
water (89.0 µg, 4.95 mmol) were added to (Fmoc-Cys-OTce)2 (451 mg, 495 µmol) in THF 
(100 mL). The reaction was stirred at 50 °C for 5 h. After this time the reaction mixture was 
concentrated in vacuo and flash column chromatography (9% ethyl acetate in hexane) was 




Protected cystine (107) (3.79 g, 4.00 mmol) was dissolved in CH2Cl2 (250 mL). DTT (740 mg, 
4.79 mmol) and then triethylamine (670 µL, 4.79 mmol) were added and the reaction was 
left to stir for 4 h. After this time excess CH2Cl2 (250 mL) was added and the reaction 
mixture was washed with sodium bicarbonate (2 x 200 mL), water (2 x 200 mL) and brine (1 
x 200 mL). The organic layer was dried over MgSO4 and concentrated in vacuo to give (122) 
as a white solid (3.49 g, 92%). 
 
NMR:  δH (600 MHz, CDCl3) 1.47 (1H, t, J = 9.0 Hz, SH), 3.02-3.07 (1H, m, CHCH2S), 3.14-3.18 
(1H, m, CHCH2S), 4.25 (1H, t, J = 7.0 Hz, CHCH2Fmoc), 4.46 (2H, d, J = 7.0 Hz, CHCH2Fmoc), 
4.74 (1H, d, J = 12.0 Hz, CH2CCl3), 4.83-4.85 9 (1H, m, CHCH2S), 4.94 (1H, d, J = 12.0 Hz, 
CH2CCl3), 5.71 (1H, d, J = 7.5 Hz, NH), 7.33-7.35 (2H, m, Ar), 7.43 (2H, t, J = 7.5 Hz, Ar), 7.62 
(2H, d, J = 7.0 Hz, Ar), 7.79 (2H, d, J = 8.0 Hz, Ar).  
 
δC  (150 MHz, CDCl3) 27.0 (C1), 47.1 (C8), 55.1 (C2), 67.3 (C7), 74.6 (C4), 94.2 (C5), 120.1 
(CAr), 125.0 (CAr), 127.1 (CAr), 127.8 (CAr), 141.3 (CAr), 143.5 (CAr) 143.7 (CAr), 155.6 (C6), 





NMR data is in agreement with the literature.195  
 
LRMS: (ES+) [C20H19Cl3NO4S]+ calculated = 474.0; found m/z = 475.9 [M+H]+ 
 
2,2,2-Trichloroethyl N-(((9H-fluoren-9-yl)methoxy)carbonyl)-S-((S)-3-oxo-3-(2-
(trimethylsilyl)ethoxy)-2-(tritylamino)propyl)-L-cysteinate (123)188  
 
The protected cysteine (122) (831 mg, 1.82 mmol) and 2-(trimethylsilyl)ethyl 
(S)-3-iodo-2-(tritylamino)propanoate (116) (1.01 g, 1.82 mmol) were dissolved in DMF (100 
mL) and the reaction mixture was cooled to 0 °C. Caesium chloride (592 mg, 1.82 mmol) 
was added and the reaction mixture was left stirring at 0 °C for 3 h. After this time, excess 
ethyl acetate was added and the mixture was washed with citric acid (100 mL) and water (2 
x 500 mL). The combined organic layers were concentrated in vacuo and the residue was 
purified using flash column chromatography (5% ethyl acetate in hexane) to give the 
coupled product (123) as a clear oil (922 mg, 56%). 
 
 NMR: δH (600 MHz, CDCl3) 0.01 (9H, s, Si(CH3)3), 0.72-0.83 (2H, m, CH2Si(CH3)3), 2.75 (1H, 
dd, J = 7.5, 13.5 Hz, Hβ A side), 2.92 (1H, dd, J = 4.5, 13.5 Hz, Hβ A side), 3.02 (1H, dd, J = 6.5, 
14.0 Hz, Hβ B side), 3.15 (1H, dd, J = 4.5, 14.0, Hβ B side), 3.51-3.53 (1H, m, Hα A side), 3.61 
(1H, td, J = 5.5, 11.5 Hz, 1 x CO2CH2CH2Si), 3.76 (1H, td, J = 5.5, 11.5, 1 x CO2CH2CH2Si ), 4.25 
(1H, t, J = 7.0 Hz, CHFmoc), 4.38-4.44 (2H, m, CH2Fmoc), 4.72 (1H, d, J = 12.0 Hz, 1 x 
CH2CCl3), 4.75-4.78 (1H, m, Hα B side), 4.85 (1H, d, J = 12.0 Hz, 1 x CH2CCl3), 5.72 (1H, d, J = 
8.5 Hz, NHFmoc), 7.19 (3H, t, J = 7.0 Hz, Ar), 7.26-7.28 (5H, m, Ar), 7.30-7.34 (3H, m, Ar), 
7.4-7.43 (2H, m, Ar), 7.5 (6H, d, J = 7.5 Hz, Ar), 7.62-7.65 (2H, m, Ar), 7.78 (2H, d, J = 7.5 Hz, 






δC (150 MHz, CDCl3) -1.6 (C7), 17.0 (C6), 34.6 (C8), 37.6 (C1), 47.0 (C15), 53.6 (C9), 56.3 (C2), 
63.4 (C5), 67.4 (C14), 71.2 (C3), 74.6 (C11), 94.3 (C12), 120.0 (CAr), 125.2 (CAr), 126.6 (CAr), 
127.1 (CAr), 127.7 (CAr), 127.9 (CAr), 128.7 (CAr), 129.7 (CAr), 141.3 (CAr), 143.7 CAr), 
145.7 (CAr), 155.8 (C13), 169.3 (C10), 173.6 (C4).  
NMR data is in agreement with the literature.188  
 




13-oate (124)188  
 
The coupled lanthionine (123) (1.16 g, 1.19 mmol) was dissolved in CH2Cl2 (40 mL) and TFA 
(4.1 mL) and TIPS (1 mL) were added. The reaction was left stirring at room for 3 h. After 
this time, excess chloroform was added and the organic layer was washed with sodium 
bicarbonate (2 x 200 mL) and brine (200 mL). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The crude residue was dissolved in 1,4-dioxane (180 mL) 
which was followed by addition of DMAP (145 mg, 1.19 mmol) and 
1-[2-(trimethylsilyl)ethoxycarbonyloxy]pyrrolidine-2,5-dione (1.53 g, 5.90 mmol). The 
reaction was left to stir at room temperature overnight. Excess chloroform was added and 
the organic layer was washed with brine (200 mL) and then dried over MgSO4, 
concentrated in vacuo and purified by flash column chromatography (10-25% ethyl acetate 
in hexane) to give the title product (124) as a clear oil (566 mg, 58%).  
 
NMR: δH (600 MHz, CDCl3) 0.02 (18H, app. d, Si(CH3)3), 0.98-1.01 (4H, m, CH2Si(CH3)3), 2.95-
2.96 (1H, m, Hβ B side), 3.06-3.15 (3H, m, 1 x Hβ B side, 2 x Hβ A side), 4.16-4.26 (5H, m, 
CHFmoc, CH2CH2Si), 4.38-4.44 (2H, m, CH2Fmoc), 4.57 (1H, s, Hα A side), 4.77-4.79 (2H, m, 





7.33 (2H, t, J = 7.5 Hz, Ar), 7.41 (2H, t, J = 7.5, Ar), 7.63-7.65 (2H, m, Ar), 7.77 (2H, d, J = 7.5, 
Ar).  
 
δC (150 MHz, CDCl3) -1.6,-1.5 (C6, C10), 17.4, 17.6 (C5, C9), 35.3, 36.1 (C1,C11) 47.0, (C18) 
50.9 (C2), 53.8 (C12), 63.8, 64.6 (C4, C8), 67.7 (C17), 74.6 (C14), 94.2 (C15), 120.0 (CAr), 
125.1 (CAr), 125.2 (CAr), 127.1 (CAr), 127.8 (CAr), 141.3 (CAr), 143.6 (CAr), 143.7 (CAr), 
156.2 (C16), 168.8 (C3), 169.0 (C7) 170.6 (C13).  
NMR data is in agreement with the literature.188 
 








Zinc dust (450 mg, 6.89 mmol) was added slowly to a solution of the protected lanthionine 
(124) (565 mg, 689 µmol) in THF (100 mL). NH4OAc solution (1.0 M, 5 mL) was then added 
and the reaction was left to stir under nitrogen overnight. After this time the reaction was 
filtered and concentrated in vacuo. The residue was then dissolved in excess chloroform 
and washed with brine (200 mL). The organic layer was dried over MgSO4 and concentrated 
in vacuo to give a crude residue that was purified by flash column chromatography (2, 5% 
MeOH in CH2Cl2) to give the protected lanthionine (60) (298 mg, 66%).  
 
NMR: δH (600 MHz, CDCl3) 0.00 (18H, app. d, Si(CH3)3), 0.88-0.93 (4H, m, CH2Si(CH3)3), 2.93-
2.98 (3H, m, 2 x Hβ B side, 1x Hβ A side), 3.11-3.16 (1H, m, Hβ A side), 4.04-4.14 (4H, m, 2x 
CH2CH2Si, ), 4.19-4.21 (2H, m, CH2Fmoc), 4.32-4.41 (3H, m, Hα A side, Hα B side, CHFmoc), 
7.25 (2H, t, J = 7.5 Hz, Ar), 7.33 (2H, t, J = 7.5, Ar), 7.64 (2H, d, J = 7.0 Hz, Ar), 7.73 (2H, d, J = 






δC (150 MHz, CDCl3) -1.3,-1.24 (C6, 10), 18.3, 18.7 (C5, 9), 35.5 (C11), 36.7 (C1), 48.5 (C16), 
55.8, 57.2 (C2, 12), 64.5, 65.0 (C4, 8), 68.4 (C15), 94.2 (CAr), 121.1 (CAr), 126.5 (CAr), 126.6 
(CAr), 128.3 (CAr), 128.4 (CAr), 128.9 (CAr), 142.6 (CAr), 145.4 (CAr), 158.6 (C14), 158.8 
(C3), 172.8 (C7), 178.6 (C13). 
NMR data is in agreement with the literature.188 
 
LRMS: (ES)- [C32H45N2O8SSi2]- calculated = 673.2; found m/z = 673.4 [M-H]-. 
 
[α]25D = +3.6 (c = 10 mg mL-1, MeOH)  
 
7.3 Experimental for Peptide Synthesis  
7.3.1 General Methods  
 
Peptides were synthesised using an automated peptide synthesiser or by hand, manually. 
In both cases synthesis was carried out in 5 mL syringes with frits, purchased from 
Multisyntech GmbH. Microwave couplings and click chemistry were carried out using a 
Personal Chemistry Smith Creator Microwave Assisted Organic Synthesizer loaded with 
either 0.5, 2 or 5 mL reaction vials as purchased from Biotage. HPLC grade DMF purchased 
from Sigma Aldrich was used as the primary solvent throughout peptide synthesis. Peptides 
were centrifuged using an Eppendorf Centrifuge 5810 R and were lyophilised using an 
VirTis Benchtop Pro freeze dryer. 
 
Hmb-protected amino acids and Fmoc-Ile-Ser[ψ(Me,Me)pro]-OH were purchased from Merck. 
 
Method 1: Automated Peptide Synthesis 
 
Peptides were synthesised on a MultiSynTech Syro Peptide Synthesiser (model MP-60). The 
peptide synthesiser contains an agitation block which held 5 mL syringes with frits 
connected to a vacuum pump to remove solvents. Pre-loaded Rink amide resins (100-200 
mesh) purchased from Merck KGaA were used in all cases of automated peptide synthesis. 
The total volume of all reagents in each step was 1.5 mL and all reagents were dissolved in 
HPLC grade DMF. 
 
Fmoc Deprotection: A solution of piperidine in DMF (40% v/v, 1.5 mL) was added to the 





sec every minute for a total of 3 min. The reagents were removed by vacuum filtration and 
the resin was washed with DMF (6 x 1.5 mL). A second portion of piperidine in DMF (40% 
v/v, 0.75 mL) was added to the syringe followed by DMF (0.75 mL) to give a final solution of 
20% v/v of piperidine in DMF. The mixture was agitated for 20 sec every minute for a total 
of 10 min. The reagents were removed by vacuum filtration and the resin washed with 
DMF (6 x 1.5 mL) 
 
Amino Acid Coupling: Fmoc protected amino acid (4 eq.), HBTU (4 eq.) and DIPEA (4 eq.) 
were added to the reaction syringe. The mixture was agitated for 20 sec every minute for a 
total of 40 min. The reagents were removed by vacuum filtration and the resin was washed 
with DMF (4 x 1.5 mL).  
 
Method 2: Manual Peptide Synthesis 
 
Manual peptide synthesis was carried out using an IKA KS130 basic platform shaker to 
agitate the solutions. Reactions were carried out in 5 mL syringes with frits which were 
evacuated by hand after every reaction or wash. Amino acid reagent weights and 
concentrations were calculated based on quantity and loading of the resin and were added 
to the syringe by hand. All standard amino acids were pre-activated with the coupling 
reagents and base before being added to the resin. The total volume of all reagents in each 
step was 1.5 mL and all reagents were dissolved in HPLC grade DMF unless otherwise 
stated. 
 
Fmoc Deprotection: A solution of piperidine in DMF (40% v/v, 1.5 mL) was added to the 
syringe containing an N-terminal Fmoc-protected peptide. The mixture was agitated for a 
total of 3 min. The reagents were removed by vacuum filtration and the resin was washed 
with DMF (6 x 1.5 mL). A second portion of piperidine in DMF (40% v/v, 0.75 mL) was added 
to the syringe followed by DMF (0.75 mL) to give a final solution of 20% v/v of piperidine in 
DMF. The mixture was agitated for a total of 10 min. The reagents were removed by 
vacuum filtration and the resin washed with DMF (6 x 1.5 mL) 
 
Standard Amino Acid Coupling: Fmoc-protected amino acids (4 eq.), HOAt (5 eq.), PyAOP (5 
eq.) and DIPEA (10 eq.) were dissolved in DMF (1.5 mL) and added to the reaction syringe. 
The mixture was agitated for a total of 1 h and the reagents were then removed by 
filtration and the resin washed with DMF (5 x 1.5 mL). If double coupling was carried out 






Teoc/TMSE Deprotection: 1 mL of TBAF (1.0 M, THF) and 1 mL of DMF were added to the 
reaction syringe. The mixture was agitated for 1 h. After this time the reagents were 
removed by filtration and the resin washed with DMF (5 x 1.5 mL).  
 
Lanthionine Coupling: Lanthionine (60) (3 eq.), HOAt (5 eq.), PyAOP (5 eq.) and DIPEA (10 
eq.) were dissolved in DMF (4 mL) and added the reaction syringe. The resin and reagents 
were then transferred to a microwave vial which was irradiated for 5 min at 60 °C and then 
left to stir at room temperature for a further 1 h. The resin and reagents were transferred 
back to the reaction syringe and the resin was washed with DMF (5 x 1.5 mL). 
 
On-resin Cyclisation: HOAt (5 eq.), PyAOP (5 eq.) and DIPEA (10 eq.) were dissolved in DMF 
(4 mL) and added to the reaction syringe. The resin and reagents were then transferred to a 
microwave vial which was irradiated for 5 min at 60 °C and then left to stir at room 
temperature for a further 1 h. The resin and reagents were transferred back to the reaction 
syringe and the resin was washed with DMF 5 x (1.5 mL). 
 
Hmb-Protected Amino Acid Coupling: Hmb-protected amino acid (5 eq.). HBTU (5 eq.) and 
DIPEA (10 eq.) were dissolved in DMF (1.5 mL) and added to the reaction syringe. The 
mixture was agitated for a total of 1 h and the reagents were then removed by filtration 
and the resin washed with DMF (5 x 1.5 mL). If double coupling was carried out the process 
was then repeated. 
 
Symmetrical Anhydride coupling: The resin was first washed with CH2Cl2 (5 x 1.5 mL). The 
required symmetric anhydride (10 eq.) was dissolved in CH2Cl2 (1.5 mL) and added to the 
reaction syringe. The mixture was agitated for a total of 1 h and the reagents were then 
removed by filtration and the resin washed with DMF (5 x 1.5 mL). If double coupling was 
carried out the process was then repeated. 
 
Method 3: Automated Peptoid Synthesis 
 
Peptoids were synthesised in a similar manner to peptides using an automated peptide 
synthesiser as before. In addition to DMF, reagent grade NMP purchased from Sigma 
Aldrich was also used. The synthesiser was reprogrammed to add the non-amino acid 
reagents and both NMP and DMF were used as solvents. Bromoacetic acid was used as a 
1.2 M solution in DMF and boc-butanediamine and MBA were both used as 1 M solutions 






Fmoc Deprotection of Resin: The Fmoc deprotection protocol for automated peptide 
synthesis was used. 
 
Bromoacetic Acid Coupling: Bromoacetic acid (20 eq.) and DIC (25 eq.) were added to the 
reaction syringe and the mixture was agitated for 20 sec every minute for a total of 1 h. The 
reagents were removed by vacuum filtration and the resin was washed with DMF (3 x 1.5 
mL) and NMP (3 x 1.5 mL). 
 
Amine Coupling: The required amine (25 eq.) was added to the reaction syringe and the 
mixture was agitated for 20 sec every minute for a total of 1 h. The reagents were removed 
by vacuum filtration and the resin was washed with NMP (3 x 1.5 mL) and DMF (3 x 1.5 mL). 
 
Cleavage and Purification 
 
Cleavage and purification procedures were the same for both peptides and peptoids made 
manually and those made using the peptide synthesiser.  
 
Cleavage from the Resin: Peptides and peptoids were washed with DMF (5 x 1.5 mL), CH2Cl2 
(5 x 1.5 mL), methanol (5 x 1.5 mL) and diethyl ether (5 x 1.5 mL) and dried in desiccator for 
30 min. A solution of 96.5% TFA, 2.5% water and 1% TIPS (1 mL) was added to the reaction 
syringe and the mixture was agitated for 40 min on the platform shaker. The cleavage 
solution was removed by filtration and the filtrate was transferred to a 15 mL Falcon tube 
containing 13 mL of diethyl ether to give a milky white precipitate. Another aliquot (1 mL) 
of the cleavage solution was added to the reaction syringe and the mixture was agitated for 
a further 20 min on the platform shaker. The cleavage solution was again removed by 
filtration and transferred to the same Falcon tube. The Falcon tube was centrifuged for 10 
min at 4000 rpm at 0 °C after which the diethyl ether was carefully decanted. This process 
was repeated with a further 2 aliquots of fresh diethyl ether (13 mL) after which the 
peptide was re-dissolved in water and lyophilised. 
 
HPLC Purification: Peptides and peptoids were analysed and purified via reverse phase 
HPLC using a Dionex system with a PDA-100 photodiode array detector, a model ASI-100 
automated sample injector and Chromeleon Software version 2.0. Preparative purification 
was performed using an ACE 5 C8-300 column (150 x 10 mm), a Dr Maisch Reprosil Gold 
200 C8 (150 x 10 mm) or a Phenomenex Onyx monolithic C18 column (100 x 3 mm) with UV 





such. The mobile phase is quoted as a percentage of solvent B (acetonitrile with 0.1% TFA) 
in solvent A (water with 0.1% TFA). The fractions containing the correct peak were 




HPLC Analysis: All purified peptides except Thr/Ser Analogue (129) were analysed using a 
using the same Dionex system as used for purification. An ACE 5 C18-AR analytical column 
(150 x 4.6 mm) was used with a flow rate of 1.0 mL min-1 and a linear gradient of 5-95% 
over 60 min (A = water, 0.1% TFA and B = acetonitrile, 0.1% TFA) and with UV detection at 
214 and 254 nm unless otherwise stated. Thr/Ser Analogue (129) was analysed on an 
Agilent Technologies 1260 Infinity system using the same solvent system as above with 
detection at 215 nm. 
 
MS analysis: LRMS analysis was performed using the instrument described in Chapter 7.1. 
HRMS analysis for all peptides apart from ring B analogue (138) were performed on a Xevo 
G2-XS QTof with ESI source attached to a Water Acquity UPLC (Class I) system using LCMS 
grade water and acetonitrile both with 0.1% formic acid as an additive. Ring B analogue 
(138) was analysed using the Waters LCT Premier XE instrument as described in Chapter 
7.1. 
 
7.4 Experimental for Synthesis and Preparation of Ring AB Analogues of 
Nisin  
 
Synthesis of Ring AB Analogues 
 
All ring AB analogues were synthesised manually (Method 2, General Methods) using a 










Ring B Analogue (138) 
 
 
The resin (100 mg) was added to a reaction syringe, washed with DMF (4 x 1.5 mL) and left 
to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc group was removed using the 
standard Fmoc deprotection step as described in General Methods above. Lanthionine (60) 
(36.4 mg, 3 eq.), PyAOP (46.9 mg, 5 eq.), HOAt (12.3 mg, 5 eq.) and DIPEA (31.4 µL, 10 eq.) 
were dissolved in DMF and added to the reaction syringe. The coupling proceeded as 
described in General Methods. Subsequent Fmoc deprotections and amino acid couplings 
were carried out as described in General Methods using the amounts listed below. Double 
couplings were used for all amino acid couplings except lanthionine for which microwave 
irradiation was used. 
Amino Acid Mass (mg) 
Lanthionine (60) 36.4 
Fmoc-Gly-OH 26.8 x 2 
Fmoc-Pro-OH 30.4 x 2 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was first purified using a gradient of 5-40% over 
30 mins at 2 mL min-1 using a Dr Maisch, Reprosil Gold 200 C8 semi-preparative column. A 
second purification was carried out using the same conditions to give purified (138), 

















HRMS: (ES+) [C19H33N6O6S]+ calculated = 473.2177; found m/z = 473.2196 [M+H]+ 
 
 
Analytical HPLC: flow rate of 1.0 mL min-1 and a linear gradient of 5-47.5% over 30 min 
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General Procedure for the Synthesis of Amino Acid Symmetrical Anhydrides 
 
The required Fmoc protected amino acid was dissolved in anhydrous CH2Cl2. DCC (0.5 eq.) 
was added and the reaction left to stir at room temperature for 2 h. After this time, the 
reaction mixture was filtered and the solvent removed in vacuo. The symmetrical 
anhydride was used without further purification. 
 
Thr/Ser Analogue (129) 
 
 
 Red indicates use of pseudoproline  
 
Method 1 - No Nα-alkylated amino acids - Unsuccessful 
The resin (50 mg) was added to a reaction syringe, washed with DMF (4 x 1.5 mL) and left 
to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc group was removed using the 
standard Fmoc deprotection step as described in General Methods above. Lanthionine (60) 
(18.2 mg, 3 eq.), PyAOP (23.5 mg, 5 eq.), HOAt (6.13 mg, 5 eq.) and DIPEA (15.7 µL, 10 eq.) 
were dissolved in DMF and added to the reaction syringe. The coupling proceeded as 
described in General Methods. Subsequent Fmoc deprotections and amino acid couplings 
were carried out as described in General Methods using the amounts listed below. Double 
couplings were used for all amino acid couplings except lanthionine for which microwave 
irradiation was used. 
Amino Acid Mass (mg) 
Lanthionine 18.2 
Fmoc-Gly-OH 13.4 x 2 
Fmoc-Pro-OH 15.2 x 2 
Second Lanthionine 18.2 
Fmoc-Leu-OH 15.9 x 2 
Fmoc-Ser(tBu)-OH 17.3 x 2 
Fmoc-Ile-OH 15.9 x 2 
Fmoc-Thr(tBu)-OH 17.9 x 2 






The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. A peak for the target compound was not observed in the 
crude LCMS analysis. 
 
Method 2 - Use of Hmb-Leu - Unsuccessful 
The resin (50 mg) was added to a reaction syringe, washed with DMF (4 x 1.5 mL) and left 
to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc group was removed using the 
standard Fmoc deprotection step as described in General Methods above. Lanthionine (60) 
(18.2 mg, 3 eq.), PyAOP (23.5 mg, 5 eq.), HOAt (6.13 mg, 5 eq.) and DIPEA (15.7 µL, 10 eq.) 
were dissolved in DMF and added to the reaction syringe. The coupling proceeded as 
described in General Methods. Subsequent Fmoc deprotections and amino acid couplings 
were carried out as described in General Methods using the amounts listed below. Double 
couplings were used for all amino acid couplings except lanthionine for which microwave 
irradiation was used. 
 
Amino Acid Mass (mg) 
Lanthionine 18.2 
Fmoc-Gly-OH 13.4 x 2 
Fmoc-Pro-OH 15.2 x 2 
Second Lanthionine 18.2 
Fmoc-(Fmoc-Hmb)Leu-OH 32.0 x 2 
(Fmoc-Ser(tBu)-O)2 68.7 x 2 
Fmoc-Ile-OH 15.9 x 2 
Fmoc-Thr(tBu)-OH 17.9 x 2 
Fmoc-Ile-OH  15.9 x 2 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. A peak for the target compound was not observed in the 
crude LCMS analysis. 
 
Method 3 - Use of pseudoproline - Successful 
The resin (100 mg) was added to a reaction syringe, washed with DMF (4 x 1.5 mL) and left 
to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc group was removed using the 
standard Fmoc deprotection step as described in General Methods above Lanthionine (60) 
(36.8 mg, 3 eq.), PyAOP (46.9 mg, 5 eq.), HOAt (12.3 mg, 5 eq.) and DIPEA (31.4 µL, 10 eq.) 
were dissolved in DMF and added to the reaction syringe. The coupling proceeded as 
described in General Methods. Subsequent Fmoc deprotections and amino acid couplings 





couplings were used for all amino acid couplings except lanthionine for which microwave 
irradiation was used. The pseudoproline amino acid (43.3 mg, 5 eq.) was installed with 
standard amino acid coupling protocol. 
Amino Acid Mass (mg) 
Lanthionine 36.4 
Fmoc-Gly-OH 26.8 x 2 
Fmoc-Pro-OH 30.4 x 2 
Second Lanthionine 36.4 
Fmoc-Leu-OH 31.8 x 2 
Fmoc-Ile-Ser[ψ(Me,Me)pro]-OH 43.3 x 2 
Fmoc-Thr(tBu)-OH 35.8 x 2 
Fmoc-Ile-OH 31.8 x 2 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The pseudoproline protected peptide (158) was carried 
forward crude. 
 












Pseudoproline Deprotection (129) 
 
 
Crude AB analogue (158) (27 mg) was transferred to a 2 mL glass vial and cooled to 0 °C on 
ice. Triflic acid (300 µL) was added slowly. The vial was agitated every minute for 10 sec for 
a total of 5 min. The reaction mixture was added dropwise to a Falcon tube with dry ether 
(10 mL) at 0 °C. The Falcon tube was centrifuged for 10 min at 4000 rpm at 0 °C after which 
the diethyl ether was carefully decanted. This process was repeated with a further 2 
aliquots of fresh diethyl ether (13 mL) after which the peptide was re-dissolved in water 
and lyophilised as described in General Methods. Purification took place using a gradient of 
5-40% over 30 mins at 4 mL min-1 using a Phenomenex Onyx monolithic C18 column. 










Analytical HPLC: flow rate of 1.0 mL min-1 and a linear gradient of 5-95% over 15 min using 
an Reprosil Gold 200 C8, 5 µm, 250 x 4.6 mm analytical column. Rt: 7.69 min. 
 
 
Preliminary NMR work carried out by Dickman suggests this is one peptide.204  
12 uM
m/z
























Abu/Ala Analogue (130) 
 
Method 1 - No Nα-alkylated amino acids - Successful 
The resin (50 mg) was added to a reaction syringe, washed with DMF (4 x 1.5 mL) and left 
to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc group was removed using the 
standard Fmoc deprotection step as described in General Methods above. Lanthionine (60) 
(18.2 mg, 3 eq.), PyAOP (23.5 mg, 5 eq.), HOAt (6.13 mg, 5 eq.) and DIPEA (15.7 µL, 10 eq.) 
were dissolved in DMF and added to the reaction syringe. The coupling proceeded as 
described in General Methods. Subsequent Fmoc deprotections and amino acid couplings 
were carried out as described in General Methods using the amounts listed below. Double 
couplings were used for all amino acid couplings except lanthionine for which microwave 
irradiation was used. 
Amino Acid Mass (mg) 
Lanthionine 18.2 
Fmoc-Gly-OH 13.4 x 2 
Fmoc-Pro-OH 15.2 x 2 
Second Lanthionine 18.2 
Fmoc-Leu-OH 15.9 x 2 
Fmoc-Ala-OH 14.0 x 2 
Fmoc-Ile-OH 15.9 x 2 
Fmoc-Abu-OH 14.6 x 2 
Fmoc-Ile-OH 15.9 x 2 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was first purified using a gradient of 5-40% over 
30 mins at 4 mL min-1 using a Phenomenex Onyx monolithic C18 column. A second 
purification was carried out using the same conditions to give (130) 300 µg, 1% yield. 
 








Analytical HPLC: flow rate of 4.0 mL min-1 and a linear gradient of 5-20% over 20 min using 



























Method 2 – Use of Hmb-Ala - Unsuccessful 
The resin (50 mg) was added to a reaction syringe, washed with DMF (4 x 1.5 mL) and left 
to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc group was removed using the 
standard Fmoc deprotection step as described in General Methods above. Lanthionine (60) 
(18.2 mg, 3 eq.), PyAOP (23.5 mg, 5 eq.), HOAt (6.13 mg, 5 eq.) and DIPEA (15.7 µL, 10 eq.) 
were dissolved in DMF and added to the reaction syringe. The coupling proceeded as 
described in General Methods. Subsequent Fmoc deprotections and amino acid couplings 
were carried out as described in General Methods using the amounts listed below. Double 
couplings were used for all amino acid couplings except lanthionine for which microwave 
irradiation was used. 
Amino Acid Mass (mg) 
Lanthionine 18.2 
Fmoc-Gly-OH 13.4 x 2 
Fmoc-Pro-OH 15.2 x 2 
Second Lanthionine 18.2 
Fmoc-Leu-OH 15.9 x 2 
Fmoc-(Fmoc-Hmb)-Ala-OH 30.1 x 2 
(Fmoc-Ile-O)2 63.3 x 2 
Fmoc-Abu-OH 14.6 x 2 
Fmoc-Ile-OH 15.9 x 2 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. A peak for the target compound was not observed in the 
crude LCMS analysis. 
 
Method 3 - Use of Hmb-Leu - Unsuccessful 
The resin (50 mg) was added to a reaction syringe, washed with DMF (4 x 1.5 mL) and left 
to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc group was removed using the 
standard Fmoc deprotection step as described in General Methods above. Lanthionine (60) 
(18.2 mg, 3 eq.), PyAOP (23.5 mg, 5 eq.), HOAt (6.13 mg, 5 eq.) and DIPEA (15.7 µL, 10 eq.) 
were dissolved in DMF and added to the reaction syringe. The coupling proceeded as 
described in General Methods. Subsequent Fmoc deprotections and amino acid couplings 
were carried out as described in General Methods using the amounts listed below. Double 
couplings were used for all amino acid couplings except lanthionine for which microwave 







Amino Acid Mass (mg) 
Lanthionine 18.2 
Fmoc-Gly-OH 13.4 x 2 
Fmoc-Pro-OH 15.2 x 2 
Second Lanthionine 18.2 
Fmoc-(Fmoc-Hmb)-Leu-OH 32.0 x 2 
(Fmoc-Ala-O)2 55.7 x 2 
Fmoc-Ile-OH 15.9 x 2 
Fmoc-Abu-OH 14.6 x 2 
Fmoc-Ile-OH 15.9 x 2 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. A peak for the target compound was not observed in the 
crude LCMS analysis. 
 
Aib Analogue (131) 
 
The resin (50 mg) was added to a reaction syringe, washed with DMF (4 x 1.5 mL) and left 
to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc group was removed using the 
standard Fmoc deprotection step as described in General Methods above. Lanthionine (60) 
(18.2 mg, 3 eq.), PyAOP (23.5 mg, 5 eq.), HOAt (6.13 mg, 5 eq.) and DIPEA (15.7 µL, 10 eq.) 
were dissolved in DMF and added to the reaction syringe. The coupling proceeded as 
described in General Methods. Subsequent Fmoc deprotections and amino acid couplings 
were carried out as described in General Methods using the amounts listed below. Double 
couplings were used for all amino acid couplings except lanthionine for which microwave 
irradiation was used. 
Amino Acid Mass (mg) 
Lanthionine 18.2 
Fmoc-Gly-OH 13.4 x 2 
Fmoc-Pro-OH 15.2 x 2 
Second Lanthionine 18.2 
Fmoc-Leu-OH 15.9 x 2 
Fmoc-Aib-OH 14.6 x 2 
Fmoc-Ile-OH 15.9 x 2 
Fmoc-Aib-OH 14.6 x 2 






The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. A peak for the target compound was not observed in the 
crude LCMS analysis.  
 
Recovery of Lanthionine (60) 
 
The evacuated coupling solution was washed with a large excess of a solution of 5% citric 
acid and extracted with CH2Cl2. The resulting residue was purified by flash column 
chromatography (0-10% MeOH in CH2Cl2) to give clean lanthionine (60) 7.3 mg, 60% yield. 
Occasionally small amounts of DIPEA were still present after column chromatography and 
another washing with citric acid was required. 
 
Enrichment of WT Nisin (27) 
 
The commercially purchased nisin (25 g) was suspended in H2O (600 mL) and stirred for 15 
mins at room temperature. CH2Cl2 (500 mL) was added to give an emulsion which was 
transferred to falcon tubes and centrifuged for 15 min at 2500 rpm and 4 °C. A solid 
“pellet” was formed at the interface between H2O and CH2Cl2 which was collected by 
filtration and dried at room temperature under reduced pressure. The solid was re-
dissolved in H2O (350 mL) and filtered through a bed of celite. The filtrate was concentrated 




















LRMS: (ES+) [C141H229O41N38S7]+ calculated = 3334.5047; found m/z = 667.0 [M+5H]5+, 833.5 
[M+4H]4+, 1111.2 [M+3H]3+ 
 
 








Digest of WT Nisin (93)180 
 
Enriched nisin (600 mg) was dissolved in 250 mL Tris acetate buffer (25 mmol NaOAc, 5 
mmol Tris acetate, 5 mmol CaCl2, adjusted to pH 7 with acetic acid). The solution was 
cooled on ice for 15 mins, trypsin (50 mg) was added and the reaction mixture was stirred 
at room temperature for 15 mins. After this time the reaction vessel was transferred to an 
incubator where it was agitated at 30 °C for 16 h. Another 50 mg of trypsin was added and 
the digestion was left for a further 24 h. After this time the reaction mixture was acidified 
with 1M HCl to a pH of 4 and then the reaction mixture was concentrated in vacuo. The 
resulting residue was lyophilised to give a brown fluffy powder. This was then purified 
directly using a gradient of 5-40% B using an ACE C8 150 x 10 mm semi-preparative column 
at 4 mL min-1 to give purified nisin (1-12) (93) (23.2 mg, 11%). 
 











7.5 Experimental for Hybrid Peptides 
7.5.1 Hinge Region Linkers 
 
Tetraethylene glycol p-toluenesulfonate (185)236 
 
A solution of NaOH (800 mg, 20.0 mmol) in water (5 mL) was added to a reaction vessel 
containing triethylene glycol (184) (15.32 g, 102 mmol) dissolved in THF (10 mL). The 
reaction mixture was cooled to 0 °C. 4-Toluenesolfunyl chloride (2.4 g 12.6 mmol) in THF 
(16 mL) was added dropwise and the reaction mixture was left stirring at 0 °C for 2 h. After 
this time, the reaction mixture was poured onto ice and extracted with CH2Cl2 (2 x 200 mL). 
The combined organic layers were washed with water (2 x 300 mL) and then dried over 
MgSO4 and concentrated in vacuo to give the title product (185) as a clear oil (3.12 g, 81% 
yield).  
 
NMR: δH (600 MHz, CDCl3) 2.46 (3H, s, CH3), 3.58-3.59 (2H, m, CH2), 3.62 (4H, s, 2 x CH2), 
3.70-3.73 (4H, m, 2 x CH2), 4.17-4.19 (2H, m, CH2OS), 7.35 (2H, d, J = 8.5, 2 x Ar), 7.81 (2H, d, 





NMR is in agreement with the literature236 
 
LRMS: (ES+) m/z = 305.4 [M+H]+ 
 
 2-(2-(2-Azidoethoxy)ethoxy)ethan-1-ol (186)237 
 
 
NaN3 (1.42 g, 21.8 mmol) was added to a solution of tetraethylene 
glycol p-toluenesulfonate (185) (1.5 g, 4.93 mmol) in anhydrous DMF (50 mL). The reaction 
mixture was heated to 70 °C and left stirring overnight. After this time the solvent was 
removed in vacuo and the remaining residue was dissolved in CH2Cl2 and then washed with 
water (200 mL) and brine (200 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo to give azide (186) as a clear oil (790 mg, 91% yield). 
 
NMR: δH (600 MHz, CDCl3) 3.40-3.42 (2H, m, CH2N3), 3.62-3.64 (2H, m, CH2), 3.67-3.70 (6H, 
m, 3 x CH2). 
 
δc (150 MHz, CDCl3) 50.6 (C1), 61.7 (C6), 70.0 (C2), 70.3 (C3), 70.6 (C5), 72.4 (C4) 
NMR is in agreement with the literature237 
 
LRMS: (ES+) m/z = 351.2 [2M+H]+ 
 
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)acetic acid (187) 238 
 
 
Azide (186) (348 mg, 1.98 mmol) was dissolved in THF (30 mL) and the reaction vessel was 
charged with Argon and cooled to 0 °C. A solution of NaH 60% in oil dispersion (317 mg, 
7.93 mmol) in THF (5 mL) was added dropwise to the reaction mixture and it was left 
stirring for 40 minutes at 0 °C. After this time, a solution of bromoacetic acid (433 mg, 3.12 
mmol) in THF (3 mL) was added dropwise to the reaction mixture and it was then left 
stirring at room temperature. After 3 h the THF was removed in vacuo and the reaction 
residue was dissolved in CH2Cl2 and water was added to quench any excess NaH. After 30 





pH 2 using 1.0 M HCl. The aqueous phase was the extracted with CH2Cl2 (3 x 100 mL) and 
the combined organic layers were dried over MgSO4 and concentrated in vacuo to give acid 
x as a clear oil to give acid (187) as a clear oil (247 mg, 53%). 
 
NMR: δH (600 MHz, CDCl3) 3.36-3.39 (2H, m, CH2), 3.64-3.75 (10H, m, 5 x CH2), 4.16 (2H, s, 
CH2CO2H) 8.99 (1H, bs, CO2H). 
NMR is in agreement with the literature.238 
 
LRMS: (ES-) m/z = 232.3 [M-H]- 
 




NaN3 (1.10 g 16.8 mmol) was added to a solution of 11-bromoundecanoic acid (1.00 g, 3.77 
mmol) in DMF (20 mL) and the reaction mixture was left to stir overnight at room 
temperature. After this time, the reaction mixture was diluted with KHSO4 (1M, 50 mL) and 
extracted with hexane (2 x 200 mL). The combined organic layers were dried over MgSO4 
and concentrated in vacuo to give acid (189) as a white, fluffy powder (651 mg, 76% yield). 
 
NMR: δH (600 MHz, CDCl3) 1.27-1.36 (12H, m, 6 x CH2), 1.57-1.66 (4H, m, 2 x CH2), 2.35 (2H, 
t, J = 7.5, CH2CO2H), 3.26 (2H, t, J = 7.0, CH2N3).  
 
δc (150 MHz, CDCl3) 24.6 (C3), 26.7 (C9), 28.8, 29.0, 29.1, 29.1, 29.3, 29.4, 34.0 (C (C2), 51.5 
(C11), 180.1 (C1) 
NMR is in agreement with the literature.239 
 
LRMS: (ES-) m/z = 226.2 [M-H]- 
 
7.5.2 Hybrid Peptides  
 
All SPPS for tail peptides and peptoids was carried out on Rink amide MBHA resin unless 
otherwise stated. Model peptides were synthesised manually and full length peptides were 







Model Compounds for Model Click Reactions 
 
Model Propargylamine Coupling to Model Rings AB (198) 
 
 
Preloaded Fmoc-Lys(Boc)-Wang resin (50 mg, 0.70 mmol g-1) was added to a reaction 
syringe, washed with DMF (4 x 1.5 mL) and left to swell for 20 min in 1.5 mL DMF. After this 
time, the Fmoc group was removed using the standard Fmoc deprotection step as 
described in General Methods above. Subsequent amino acid couplings and Fmoc 
deprotections were carried out as described in General Methods using the amounts listed 
below. Double couplings were used for all amino acids. 
 
Amino Acid Mass (mg) 
Fmoc-Met-OH 65.0  




The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods to give a crude yield of 15.0 mg.  
 
LRMS: (ES+) m/z = 432.5 [M+H]+ 
 
Crude peptide (5.00 mg, 11.6 µmol) was dissolved in anhydrous DMF (50 µL) and 
propargylamine (37.0 µL, 580 µmol), BOP (10.0 mg, 23.2 µmol), and DIPEA (8.00 µL, 46.3 
µmol) were added to the reaction mixture. This mixture was left agitating for 20 min after 
which time it was quenched with buffer (1 mL, 0.1% TFA in water), filtered and purified 
directly using reverse phase HPLC over a gradient of 5-60% at 3 mL min-1 using a Reprosil 
Gold 200 C8 semi-preparative column, Rt = 12.4 min, to give (198) (3.00 mg, 55% yield). 
 










Truncated Pexiganan Analogue (199) 
 
 
Preloaded Fmoc-Phe-Wang resin (50 mg, 0.61 mmol g-1) was added to a reaction syringe, 
washed with DMF (4 x 1.5 mL) and left to swell for 20 min in 1.5 mL DMF. After this time, 
the Fmoc group was removed as described in General Methods above. Subsequent amino 
acid couplings and Fmoc deprotections were carried out as described in General Methods 
using the amounts listed below. 
 
 
Amino Acid Mass (mg) 
Fmoc-Lys(Boc)-OH 71.5 x 2 
Fmoc-Gly-OH 45.3 x 2 
Fmoc-Ile-OH 53.9 x 2 
Fmoc-Gly-OH 45.3 x 2 
Fmoc-Lys(N3)-OH 60.1 x 2 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. (183) (15.2 mg, 74% yield). The peptide was used without 
further purification. 
 
LRMS: (ES+) m/z = 338.5 [M+2H]+ 675.8 [M+H]+ 
 
Model Click Chemistry (200) 
 
 
Alkyne (198) dissolved in 62.5 µL of DMF and azide (183) dissolved in 62.5 µL of water and 
added to a 250 µL microwave vial.  Stock solutions of CuSO4.5H2O (4.20 mg, 500 µL water) 
and NaAsc (6.70 mg, 500 µL water) were made up. From each of the stock solutions 50.0 µL 
was taken and added to the microwave vial. The reaction mixture was then irradiated for 
20 min at 80 °C. After this time, the reaction mixture was quenched with buffer (3 mL, 0.1% 





mL min-1 over 35 min using a Reprosil Gold 200 C8 semi-preparative column, Rt = 14.9 min, 
but the product (200) was not isolated. 
 
LRMS: (ES+) m/z = 572.3 [M+2H]+ 
 




Purified WT rings AB (93) (5.00 mg, 4.35 µmol) was dissolved in anhydrous DMF (7.00 µL). 
Propargylamine (15.0 µL, 234 µmol) followed by BOP (4.00 mg, 9.04 µmol) and DIPEA (4.00 
µL, 23.0 µmol) were added. The reaction mixture was left stirring for 20 min after which 
time it was quenched with buffer (3 mL, 1% TFA in water), filtered and purified directly. The 
crude mixture was purified using a gradient of 5-40% over 30 min at 4 mL min-1 using a C18 






















LRMS: (ES+) [C54H87N14O12S2]+ calculated = 1187.6064; found m/z = 594.2 [M+2H]2+ 
 











The Rink amide resin (50 mg, 0.7 mmol g-1) was added to a reaction syringe, washed with 
DMF (4 x 1.5 mL) and left to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc 
group was removed using the standard Fmoc deprotection step as described in General 
Methods above. Subsequent amino acid couplings and Fmoc deprotections were carried 
out as described in General Methods with stock solutions of amino acids as listed below. 
 
Amino Acid Mass (mg) Vol. DMF (mL) 
Fmoc-Ala-OH 120 1.24 
Fmoc-Phe-OH 218 1.76 
Fmoc-Gly-OH 168 1.82 
Fmoc-Ile-OH 136 1.22 
Fmoc-Lys(Boc)-OH 764 4.97 
Fmoc-Leu-OH 136 1.22 
Fmoc-Val-OH 71.0 0.655 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-40% over 30 
min at 4 mL min-1 using a C18 semi-preparative column. The residue was purified a second 

















LRMS: (ES+) calculated [C122H210N32O22]+ = 2475.6292; found m/z = 826.6 [M+3H]3+, 620.2 
[M+4H]4+, 496.2 [M+5H]5+, 420.4 [M+5H+K]6+, 413.7 [M+6H]6+, 360.7 [M+6H+K]7+ 
 
 











SPPS was carried out as described for pexiganan (10). Prior to cleavage Fmoc-PEG4-OH 
(179) was coupled using standard amino acid coupling protocol as described in General 
Methods. Fmoc deprotection was carried out as described in General Methods. Fmoc-
Lys(N3)-OH (181) was then coupled to the N-terminus using the standard amino acid 
coupling protocol and Fmoc deprotection was carried out as described in General Methods.  
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-40% over 30 
min at 4 mL min-1 using a C18 semi-preparative column. The residue was purified a second 






















HRMS: (ES+) calculated [C139H242N37O28]+ = 2877.8645; found: m/z = 720.4740 [M+4H]4+, 
576.5814 [M+5H]5+, 480.6530 [M+6H]6+ 
 
 
Analytical HPLC: Standard conditions as described in General Methods. Rt = 23.79 min.  
 
m/z
























N3-PEG3-Pexiganan (191)  
 
 
SPPS was carried out as described for pexiganan (10). Prior to cleavage N3-PEG3-CO2H (187) 
was coupled using standard amino acid coupling protocol as described in General Methods.  
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-45% over 30 
min at 5 mL min-1 using a C18 semi-preparative column to give (191) (3.1 mg, 4%). 
 
LRMS: (ES+) calculated C130H223N35O26 = 2691.7276; found m/z = 674.1 [M+4H]4+, 539.5 













SPPS was carried out as described for pexiganan (10). Prior to cleavage 11-azidoundecanoic 
acid (189) was coupled using standard amino acid coupling protocol as described in General 
Methods.  
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-45% over 30 
min at 5 mL min-1 using a C18 semi-preparative column to give (193) (2.90 mg, 3%). 
 
HRMS: (ES+) calculated [C133H229N35O23]+ = 2685.7898; found: m/z = 1343.8999 [M+2H]2+ 




















































The Rink amide resin (50 mg, 0.7 mmol g-1) was added to a reaction syringe, washed with 
DMF (4 x 1.5 mL) and left to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc 
group was removed using the standard Fmoc deprotection step as described in General 
Methods above. Subsequent amino acid couplings and Fmoc deprotections were carried 
out as described in General Methods with stock solutions of amino acids as listed below. 
Double couplings were used for all amino acid couplings. 
 
Amino Acid Mass (mg) Vol. DMF (mL) 
Fmoc-Ala-OH 231 2.38 
Fmoc-Asp(OtBu)-OH 205 2.31 
Fmoc-Ile-OH 262 2.35 
Fmoc-Lys-OH 514 3.35 
Fmoc-Leu-OH 388 3.46 
Fmoc-Gln-OH 236 1.16 






The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-40% over 30 
min at 4 mL min-1 using a C18 semi-preparative column. The residue was purified a second 
time using the same conditions to give mastoparan (12) (4.1 mg, 5% yield). 
 

























SPPS was carried out as described for mastoparan (12). Prior to cleavage Fmoc-PEG4-OH 
(179) was coupled using standard amino acid coupling protocol as described in General 
Methods. Fmoc deprotection was carried out as described in General Methods. 
Fmoc-Lys(N3)-OH (181) was then coupled to the N-terminus using the standard amino acid 
coupling protocol and Fmoc deprotection was carried out as described in General Methods.  
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-40% over 30 
min at 4 mL min-1 using a C18 semi-preparative column. The residue was purified a second 






HRMS: (ES+) [C95H164N25O25]+ calculated = 2055.2325; found: m/z = 1028.6212 [M+2H]2+, 
686.0886 [M+3H]3+, 514.8204 [M+4H]4+ 
 
 
Analytical HPLC: Standard conditions as described in General Methods. Rt = 28.03 min.  
 
m/z







































SPPS was carried out as described for mastoparan (10). Prior to cleavage N3-PEG3-CO2H 
(187) was coupled using standard amino acid coupling protocol as described in General 
Methods. Fmoc deprotection was carried out as described in General Methods.  
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-40% over 30 
min at 4 mL min-1 using a C18 semi-preparative column. The residue was purified a second 
time using the same conditions to give (192) (8.0 mg, 9% yield). 
 







































SPPS was carried out as described for mastoparan (10). Prior to cleavage 11-
azidoundecanoic acid (189) was coupled using standard amino acid coupling protocol as 
described in General Methods. Fmoc deprotection was carried out as described in General 
Methods.  
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-40% over 30 
min at 4 mL min-1 using a C18 semi-preparative column. The residue was purified a second 













Analytical HPLC: Standard conditions as described in General Methods. Rf = 36.65 min. 
 
m/z





























The Rink amide resin (50 mg, 0.7 mmol g-1) was added to a reaction syringe, washed with 
DMF (4 x 1.5 mL) and left to swell for 20 min in 1.5 mL DMF. After this time, the Fmoc 
group was removed using the standard Fmoc deprotection step as described in General 
Methods above. The resin bound amine was then bromoacetylated with the addition of 1.2 
M bromoacetic acid in DMF (584 µL) and neat DIC (135 µL) and the coupling was carried 
out as described in General Methods. Bromide substitution was then carried out with the 
addition of 1 M MBA (875 µL) and the coupling was carried out as described in General 
Methods. These two reactions were repeated followed by a third bromoacetylation and the 
addition of 1 M bocbutanediamine in NMP (891 µL). The coupling was carried out as 
described in General Methods. The peptoid chain was built up using this submonomer 
approach with stock solutions of the reagents as listed below. 
 
Reagent Mass (g) Solvent Volume (mL) 
Bromoacetic acid 1.67 DMF 10.0 
DIC 2.04 neat 2.50 
Boc-butanediamine 0.941 NMP 5.00 
MBA 1.21 NMP 10.0 
 
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-60% over 30 
min at 5 mL min-1 using a C18 semi-preparative column. The peptoid was purified a second 
























Peptoid synthesis was carried out as described for pexiganan. Prior to cleavage 
11-azidoundecanoic acid (189) was coupled using standard amino acid coupling protocol as 
described in General Methods.  
 
The peptide was cleaved under standard conditions, washed with ether and lyophilised as 
described in General Methods. The peptide was purified using a gradient of 5-60% over 30 
min at 5 mL min-1 using a C18 semi-preparative column. The peptoid was purified a second 























HRMS: (ES+) [C115H159N20O13]+ calculated = 2028.2390; found m/z = 1015.1232 [M+2H]2+, 
677.0892 [M+3H]3+, 508.0722 [M+4H]4+ 
 
 
Analytical HPLC: Standard conditions as described in General Methods. Rt = 39.41 min. 
 
m/z










































Alkyne (110) (1.00 mg, 710 nmol) dissolved in 50 µL of DMF and azide (183) (2.8 mg, 710 
nmol) dissolved in 50 µL of water were transferred to a 250 µL microwave vial. Stock 
solutions of CuSO4.H2O (42.0 mg, 5.00 mL water) and NaAsc (67.0 mg, 5.00 mL water) and 
TBTA (2.20 mg, 500 µL DMF) were made up and 50.0 µL was taken from each and added to 
the reaction vial. The reaction mixture was then irradiated for 20 min at 80 °C. After this 
time, the reaction mixture was quenched with buffer (3 mL, 0.1% TFA in water), filtered 
and purified directly using reverse phase HPLC over a gradient of 5-40% over 30 min at 
4 mL min-1 using a C18 semi-preparative column. The peptide was purified a second time 






















HRMS: (ES+) [C193H328N51O40S2]+ calculated = 4064.4636; found m/z = 1017.3734 [M+4H]4+, 
814.1019 [M+5H]5+, 678.5875 [M+6H]6+, 581.7919 [M+7H]7+, 509.1930 [M+8H]8+ 
 
 
Analytical HPLC: Standard conditions as described in General Methods. Rt = 29.92 min. 
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Alkyne (110) (1.00 mg, 710 nmol) dissolved in 50 µL of DMF and azide (193) (2.56 mg, 710 
nmol) dissolved in 50 µL of water were transferred to a 250 µL microwave vial. Stock 
solutions of CuSO4.H2O (42.0 mg, 5.00 mL water) and NaAsc (67.0 mg, 5.00 mL water) and 
TBTA (2.20 mg, 500 µL DMF) were made up and 50.0 µL was taken from each and added to 
the reaction vial. The reaction mixture was then irradiated for 20 min at 80 °C. After this 
time, the reaction mixture was quenched with buffer (3 mL, 0.1% TFA in water), filtered 
and purified directly using reverse phase HPLC over a gradient of 5-40% over 30 min at 






Alkyne (110) (1.00 mg, 710 nmol) dissolved in 50 µL of DMF and azide (191) (2.30 mg, 710 
nmol) dissolved in 50 µL of water were transferred to a 250 µL microwave vial. Stock 
solutions of CuSO4.H2O (42.0 mg, 5.00 mL water) and NaAsc (67.0 mg, 5.00 mL water) were 
made up and 50.0 µL was taken from each and added to the reaction vial. The reaction 
mixture was then irradiated for 20 min at 80 °C. After this time, the reaction mixture was 
quenched with buffer (3 mL, 0.1% TFA in water), filtered and purified directly using reverse 
phase HPLC over a gradient of 5-40% over 30 min at 4 mL min-1 using a C18 semi-









Method 1 - Unsuccessful 
Alkyne (110) (1.00 mg, 710 nmol) dissolved in 50 µL of DMF and azide (190) (2.37 mg, 710 
nmol) dissolved in 50 µL of water were transferred to a 250 µL microwave vial. Stock 
solutions of CuSO4.H2O (42.0 mg, 5.00 mL water) and NaAsc (67.0 mg, 5.00 mL water) were 
made up and 50.0 µL was taken from each and added to the reaction vial. The reaction 
mixture was then irradiated for 20 min at 80 °C. After this time, the reaction mixture was 
quenched with buffer (3 mL, 0.1% TFA in water), filtered and purified directly using reverse 
phase HPLC over a gradient of 5-40% over 30 min at 4 mL min-1 using a C18 semi-
preparative column. No product was observed. 
 
Method 2 - Successful 
Alkyne (110) (1.00 mg, 710 nmol) dissolved in 50 µL of DMF and azide (190) (2.37 mg, 710 
nmol) dissolved in 50 µL of water were transferred to a 250 µL microwave vial. Stock 
solutions of CuSO4.H2O (42.0 mg, 5.00 mL water) and NaAsc (67.0 mg, 5.00 mL water) and 
TBTA (2.20 mg, 500 µL DMF) were made up and 50.0 µL was taken from each and added to 
the reaction vial. The reaction mixture was then irradiated for 20 min at 80 °C. After this 
time, the reaction mixture was quenched with buffer (3 mL, 0.1% TFA in water), filtered 
and purified directly using reverse phase HPLC over a gradient of 5-40% over 30 min at 
4 mL min-1 using a C18 semi-preparative column. The peptide was purified a second time 











HRMS: (ES+) [C149H250N39O37S2]+ calculated = 3241.8316; found m/z = 1081.9500 [M+3H]3+, 
811.7181 [M+4H]4+, 649.3778 [M+5H]5+ 
 
Analytical HPLC: Standard conditions as described in General Methods. Rt = 28.20 min. 
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Alkyne (110) (1.00 mg, 710 nmol) dissolved in 50 µL of DMF and azide (192) (1.57 mg, 710 
nmol) dissolved in 50 µL of water were transferred to a 250 µL microwave vial. Stock 
solutions of CuSO4.H2O (42.0 mg, 5.00 mL water) and NaAsc (67.0 mg, 5.00 mL water) and 
TBTA (2.20 mg, 500 µL DMF) were made up and 50.0 µL was taken from each and added to 
the reaction vial. The reaction mixture was then irradiated for 20 min at 80 °C. After this 
time, the reaction mixture was quenched with buffer (3 mL, 0.1% TFA in water), filtered 
and purified directly using reverse phase HPLC over a gradient of 5-40% over 30 min at 
4 mL min-1 using a C18 semi-preparative column. The peptide was purified a second time 






















LRMS: (ES+) [C140H232N37O35S2]+ calculated = 3055.6948; found m/z = 1019.9 [M+3]3+, 765.1 








Alkyne (110) (1.00 mg, 710 nmol) dissolved in 50 µL of DMF and azide (194) (1.57 mg, 710 
nmol) dissolved in 50 µL of water were transferred to a 250 µL microwave vial. Stock 
solutions of CuSO4.H2O (42.0 mg, 5.00 mL water) and NaAsc (67.0 mg, 5.00 mL water) and 
TBTA (2.20 mg, 500 µL DMF) were made up and 50.0 µL was taken from each and added to 





time, the reaction mixture was quenched with buffer (3 mL, 0.1% TFA in water), filtered 
and purified directly using reverse phase HPLC over a gradient of 5-50% over 40 min at 
5 mL min-1 using a C18 semi-preparative column. The peptide was purified a second time to 
give clicked product (205) (200 µg, 8% yield). 
 
HRMS: (ES+) [C143H238N37O32S2]+ calculated = 3049.7570; found m/z = 1017.5908 [M+3H]3+, 






















































Alkyne (110) (1.00 mg, 710 nmol) dissolved in 50 µL of DMF and azide (195) (1.76 mg, 710 
nmol) dissolved in 50 µL of water were transferred to a 250 µL microwave vial. Stock 
solutions of CuSO4.H2O (42.0 mg, 5.00 mL water) and NaAsc (67.0 mg, 5.00 mL water) and 
TBTA (2.20 mg, 500 µL DMF) were made up and 50.0 µL was taken from each and added to 
the reaction vial. The reaction mixture was then irradiated for 20 min at 80 °C. After this 
time, the reaction mixture was quenched with buffer (3 mL, 0.1% TFA in water), filtered 
and purified directly using reverse phase HPLC over a gradient of 5-60% over 30 min at 
5 mL min-1 using a C18 semi-preparative column. The peptide was purified a second time 






HRMS: (ES+) [C169H245N34O25S2]+ calculated = 3214.8381; found m/z = 1072.9497 [M+3H]3+, 





















































7.6 Experimental for in vitro Biology  
7.6.1 General Methods  
 
In vitro work was carried out under sterile conditions in a category 2 safety hood. Oxoid 
Nutrient Broth No 2 was used purchased from ThermoFisher Scientific as a dehydrated 
powder and was made up as a solution according to the manufacturer’s instructions. 
OD600 readings of bacteria stock solutions were taken using a Nanodrop 2000c 
Spectophotometer. Polypropylene and polystyrene 96-well plates were purchased from 
Greiner Bio One. Aeraseal Sterile gas permeable seals were purchased from Excel Scientific. 
96-Well plates were incubated overnight in Eppendorf Thermomixer comfort/C incubators. 
OD625 readings of 96-well plates were measured using a Tecan infinite M200 Pro plate 
reader with i-control 1.11 software.  
 
7.6.2 Well Diffusion Method 
 
All compounds to be tested were made up to a concentration of 1 mg mL-1 in sterile water 





inoculated with 100 µL of an overnight culture of either Micrococcus luteus, Bacillus 
subtilis, Escherichia coli or Pseudomonas aeruginosa and spread evenly across the surface 
of the plate. The overnight cultures of bacteria were grown at 37 °C in Oxoid Nutrient Broth 
No. 2 with shaking. Four wells of 8 mm diameter were punched into each plate. 25 µL of 
the stock solution was spotted into a well for each strain of bacteria. Plates were incubated 
for 48 h at 37 °C except for those inoculated with M. luteus which were incubated at 30 °C. 
Later work with M. luteus was carried out at 37 °C. After 48 h, antibacterial activity was 
evaluated by the appearance of a zone of inhibition. 
 
7.6.3 Broth Micro-dilution Method 
 
Overnight stocks of bacteria were prepared by Prof John Ward. Bacteria were streaked out 
onto nutrient agar plates and single colonies taken from these to plates to grow overnight 
in 5 ml Nutrient broth No.2 (Oxoid) with shaking at 37 °C. The absorbance of the bacterial 
cultures were measured at 600 nm and diluted by a factor of 10 with nutrient broth to give 
an OD of 0.118. Routinely 10 µL of this dilution was used in the micro titre plates to test the 
antimicrobial activity of the compounds. 
 
Oxoid Nutrient Broth No 2 was used with 1% DMSO to aid solubilisation. All compounds to 
be tested were made up to 0.60 mM stock solutions in sterile water with 1% DMSO. To 
ensure peptides were fully dissolved stock solutions were placed in a bath sonicator for 30 
s. 10 µL of peptide stock solution was added to 90 µL of nutrient broth with 1% DMSO. This 
was then transferred to the first column of a 96-well polypropylene plate. A two-fold serial 
dilution was carried out as described by Hancock and co-workers:233 50 µL of nutrient broth 
was added to columns 2-10. 50 µL was taken from column 1 and added to column 2 and 
mixed well by pipetting up and down 8 times. 50 µL was taken from column 2 and added to 
column 3 and again mixed well. This process was repeated through to column 10. The 50 µL 
taken from 10 was discarded. 250 µL of nutrient broth was added to the sterility control 
column, 12, and 240 µL was added to the growth control column, 11. 
 
10 µL of an overnight stock of bacteria adjusted to have an OD 0.817 (of a 1 in 10 dilution) 
was added to each well except from the final column which was reserved as a sterility 
control containing only nutrient broth. A further portion of Oxoid Nutrient Broth No 2 was 
added to make each well up to 250 µL total volume. A gas permeable adhesive seal was 





bacteria were re-suspended and transferred to clear, flat-bottomed, polystyrene 96-well 
plates and the OD was measured. The MIC is defined as the lowest concentration of the 
antimicrobial agent that inhibits visible growth of the tested isolate as observed with the 
unaided eye. The error of the MIC results is estimated as one half of the interval between 
the MIC dilution and the next lowest concentration (i.e. the highest concentration that 
resulted in growth of bacteria).  
 
Colony counts were carried out by Prof John Ward. The viable cell numbers were calculated 
by using a dilution series of the overnight culture to a final of 10-7 and plating 100 μL 
aliquots of the 10-6 and 10-7 dilutions on nutrient agar plates (2 per dilution) and incubating 
overnight. The viable cell count in the original overnight culture was calculated from the 
numbers of colonies on these plates x the amount plated x the dilution factor and 
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